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Abstract
The corpus luteum is one of the most intriguing and understudied endocrine glands in the
human body. Understanding the mechanisms behind corpora lutea development, function
and regression will enhance many major unresolved issues in human reproduction, with
important consequences on infertility, miscarriage and contraception. Formed at the end-
stage of folliculogenesis, the corpus luteum has the important role of being the interface
between pregnancy and menstruation. This transition involves the terminally differentiated
granulosa- and theca-lutein cells along with endothelial, fibroblast and immune cells to form
the most steroidogenically active tissue in the body. In a non-conception cycle the corpus
luteum will experience high cell turnover, intense remodelling and structural and functional
demise within a 14-day period, succinctly followed by the initiation of a new cycle.
Alternatively, during maternal recognition of pregnancy, the corpus luteum will continue to
secrete vast quantities of steroid hormones under the trophic stimulation of conceptus
derived-human chorionic gonadotrophin (hCG), subsequently maintaining structural and
functional integrity. Therefore the luteal lifespan is regulated by massive tissue and vascular
remodelling that is induced and regulated by gonadotrophins (luteinising hormone (LH) and
hCG) which elicit disparate changes in the number and function of cells that do not express
hCG/LH receptors. For example, luteolysis in women is associated with an up-regulation of
the expression and activity of matrix metalloproteinase-2 (MMP-2) which is inhibited by
hCG during maternal recognition of pregnancy. As the primary source of MMP-2 is
fibroblasts that do not express LH/hCG receptors, the scope of this thesis was to investigate
the regulation of MMP-2 by dissecting out potential paracrine signalling molecules.
Women with regular cycles having hysterectomy for non-malignant conditions and women
undergoing oocyte retrieval for assisted conception were used in the current study. Novel
primary cultures and co-cultures of luteinised granulosa cells and fibroblast-like cells
allowed the mechanistic in vivo interactions of the corpus luteum to be mimicked with an in
vitro system. Herein, activin A is identified as a regulated molecule that may promote tissue
remodelling during luteolysis. Activin A is secreted by luteal steroidogenic cells and at
physiological concentrations it up regulates MMP-2 activity and expression in luteal
fibroblast-like cells. HCG can inhibit activin A action through several mechanisms
including up-regulating activin inhibitors, inhibin A and follistatin.
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If activin A is a paracrine molecule with potential roles in luteolysis, Cortisol is a paracrine
molecule with possible roles in luteal rescue. The corpus luteum expresses glucocorticoid
receptors and the Cortisol metabolising enzymes lip hydroxysteroid dehydrogenase type 1
(11 piISDl) and type 2 (11PHSD2). Both in vitro and in vivo, hCG promotes 11(3HSD1
expression and facilitates the local generation of Cortisol. Cortisol at physiological
concentrations inhibits local MMP-2 expression to inhibit the tissue remodelling associated
with luteolysis. During luteolysis activin and hCG have opposing effects and the same is
true during luteinisation. HCG promotes a luteinised granulosa cell phenotype, whilst
activin A promotes a more follicular phenotype by up-regulating granulosa cells markers
such as follicle-stimulating hormone (FSH) receptor, 11 [1HSD2 and blocking hCG up-
regulation of steroidogenic acute regulatory protein (StAR), 3p hydroxysteroid
dehydrogenase (3|3HSD) and 11PHSD1. Activin A appears to be an anti-luteal molecule in
nature. Activin A is not the only activin produced by the corpus luteum, activin B is also a
luteal cell product and its secretion is regulated in a similar manner to activin A with similar
endocrine effects. As activin has a fundamental role at beginning and end of the luteal
phase, it has the potential to be a major regulatory molecule in women. Indeed it can
regulate its own activity in the absence of hCG by self promoting its own expression and
down regulating its own inhibitors.
Collectively these results suggest that activin is an excellent anti-luteal molecule whose
paracrine actions are to remove or potentially inhibit luteal tissue formation, and moreover to
facilitate human luteolysis. However, the biological actions of activin A are inhibited during
maternal recognition of pregnancy by the endocrine actions of conceptus-derived hCG that
has marked and disparate changes on surrounding cell types that do not expression the
LH/hCG receptor. Consequently, luteolysis is prevented, such that luteal fibroblast-like
MMP-2 is inhibited as hCG-derived Cortisol supports promotes the maternal recognition of
pregnancy.
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Chapter 1 Literature Review 1
1 Literature review
The ovary is one of the most dynamic organs in the human body, experiencing extensive
tissue remodelling each month in a cyclic manner. Within the ovary is the most
steroidogenic gland in the body, the corpus luteum. Formed at the end-stage of
folliculogenesis from the dominant follicle, the corpus luteum is of fundamental
importance in reproductive biology. It has the principal role of preparing the uterine
environment for implantation of a conceptus by secreting vast quantities of steroid
hormones. In the absence of conception, the functional lifespan of the corpus luteum is
approximately 14 days, after which it will undergo the process of luteolysis. This process
involves demise of the gland whereby there is a loss of structural (tissue) and functional
(hormone synthesis) integrity that consequently leads to endometrial shedding. During a
conception cycle however, the structural and functional integrity of the corpus luteum is
maintained in the presence of an implanting conceptus which secretes logarithmically
increasing amounts of hCG. Consequently, luteolysis is inhibited and the corpus luteum
will maintain the role of principle steroid production until the luteo-placental shift.
Understanding the molecular mechanisms behind processes such as luteolysis and luteal
rescue during maternal recognition of pregnancy provides valuable insights toward
reproductive promotion and prevention. This thesis aims to dissect out possible
molecular pathways in corpus luteum physiology in order to further understand the
changes in multiple cells types, angiogenesis, proliferation and cell death that is both
unique yet predictable. Therefore, as well as increasing knowledge about the corpus
luteum itself, these studies can facilitate the understanding of basic mechanisms involved
in normal and dysregulated fundamental tissue processes. Examples of important
physiological and pathological processes include integral remodelling events such as
wound repair and tumourigenesis.
Formation of the corpus luteum can only occur after successful folliculogenesis.
Therefore the review of the current literature will begin with follicle formation involving
the regulation of gonadotrophins, follicle selection and feedback, consequently leading to
the oestrogenic dominant follicle that undergoes the process of ovulation to form the
focus of the current thesis, the corpus luteum.
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1.1 The ovary
The ovaries are paired intra-abdominal organs that have the principal roles of producing
(i) the female gamete, the ovum and (ii) and sex steroid hormones, notably oestrogen and
progesterone. Each month, the ovary undergoes changes that are tightly orchestrated by
growth factors, gonadotrophins and sex steroids in a cyclic manner. The ovarian cycle
represents the growth and regression of follicles from a primordial status to post-
ovulatory corpora lutea (Figure 1.1), with ovulation occurring approximately every 28
days in woman. Although the ovulatory process generally occurs once a month, the
process of folliculogenesis (the activation and development of a primordial follicle





Figure 1.1 Schematic diagram of the ovary demonstrating the various follicle and cell
types. Folliculogenesis begins with the most primitive follicle, the primordial which
undergoes various stages of development under the influence of growth factors,
gonadotrophins and steroid hormones to mature into a pre-ovulatory follicle that is
capable of ovulation. The resulting follicular cells undergo luteinisation to form the
steroidogenically active corpus luteum that has the integral role of maintaining early
pregnancy.
(Porth, 2004)
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1.1.1 Germ cells
Unlike the male whereby new germ cells are produced throughout life, a female is born
with (human, mouse) or acquires shortly thereafter (rat, pig) a finite number of germ
cells. Early studies suggest that the peak number of germ cells is observed at the time of
mitotic to meiotic transition, which in the human is around 20 weeks of gestation with the
number of primary oocytes reaching a maximum of 6-7 million (Baker, 1971) (Figure
1.2). By birth however, this number has markedly declined to 1-2 million and by the time
of puberty Gougeon estimated it to have further fallen to a mere 400,000 (Gougeon,
1986). Of the original 6-7 million germ cells that were originally produced in the pair of
fetal ovaries, only about 400 will reach ovulatory status, therefore in women more than
99% of ovarian follicles will undergo atresia in postnatal life (Baker, 1971; Hsueh et al.,
1994).
Figure 1.2 In the human all primordial follicles are formed in the fetus between 6 and 9
months gestation. There is a marked loss of oocytes during this period and consequently
the number of primordial follicles decreases due to apoptosis and follicle recruitment.
Follicle loss continues throughout reproductive life until very few, if any, are present after
menopause.
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It is worth noting that during the past three years considerable amount of controversy has
arisen regarding the dogma on a 'finite' germ cell pool in women. Studies thus far have
concentrated on mouse models beginning with the initial study from Johnson et al.,
whereby it was reported that the existence of germline stem cells and therefore follicular
renewal may exist in the postnatal mouse ovary (Johnson et al., 2004). As expected, this
contrast in doctrine raised significant controversy and was subsequently followed by
letters of criticism (Telfer et al., 2005) and follow up studies (Eggan et al., 2006; Kerr et
al., 2006) including one from the initial laboratory (Johnson et al., 2005). Consequently,
no further conclusions regarding this matter have been published of late and, until more
work is focussed upon this issue, the 'finite germ cell population' theory in a female
gonad remains.
1.1.2 The ovarian cycle
The ovarian cycle may be split up into three components, the pre-ovulatory follicular
development, ovulation and the functional life span of the corpus luteum (Hillier, 1994b).
Each of these functional stages are characterised and directed by defined key proteins in
which transgenic knockout mouse models have proved to be of great importance (Matzuk
and Lamb, 2002). The next few sections will review folliculogenesis (gonadotrophin-
independent and gonadotrophin-dependent) and ovulation before discussing the
functional lifespan of the corpus luteum.








Figure 1.3 A functional model of follicular growth and atresia that describes the
gonadotrophin-independent and gonadotrophin-dependent events. The quiescent
primordial follicle pool experiences little atresia and activated follicles move into the
growth phase to become committed follicles. Once the follicle forms an antral cavity it
becomes gonadotrophin-responsive and will eventually become gonadotrophin-
dependent. High rates of atresia are evident at this stage and in the absence of
gonadotrophic support follicle development will cease. In the presence of high FSH
concentrations the dominant follicle will express LH receptors and in response to a LH
stimulatory surge this follicle will undergo ovulation.
(Scaramuzzi et al., 1993)
1.1.2.1 Folliculogenesis
The process of folliculogenesis involves the co-ordinated growth and development of
primordial follicles through to a dominant follicle capable of ovulation. This can be
further classed into either gonadotrophin-independent or gonadotrophin-dependent events
(Figure 1.3). Early follicle development involves the activation of primordial follicles
into the growth phases. Anatomically, primordial follicles consist of an oocyte partially
or fully surrounded by squamous pre-granulosa cells (Figure 1.4). Once in the growing
pool, the transition of a primordial into a primary follicle is associated with moderate
oocyte growth and morphological transformation of previously flattened squamous
granulosa cells into cuboidal cells (Hirshfield, 1991). Although the primordial follicles
are formed during fetal life, they may remain dormant within the ovaries for as long as 40
years (Zeleznik and Pohl, 2006). Transcription factors such NOBOX (Rajkovic et al.,
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2004), Foxl2 (Schmidt et al., 2003)and Foxo3a (Castrillon et al., 2003) have been shown
to be critical for early follicle formation in transgenic mice and mutations in Foxl2 and
NOBOX have been linked to premature ovarian failure in women (Gersak et al., 2004;
Pangas and Rajkovie, 2006). Consequently, the aforementioned mouse gene knockout
studies, coupled with many others (Matzuk and Lamb, 2002; Rajkovic and Matzuk, 2002)
have provided new insights into factors that may be involved in recruitment of follicles
into the growing pool.
The transition of the primordial follicle to a primary follicle marks its entry into the
growth phase. Morphologically this transition is characterised by a transformation of
squamous pregranulosa cells into a more cuboidal phenotype and this is accompanied by
the formation of a zona pellucida (ZP) matrix. The ZP is a non-cellular membrane
composed of three glycoproteins (ZP1, ZP2 and ZP3) (Harris et al., 1994) that forms
between the primary oocyte and granulosa cells. This matrix provides an effective means
for selective transfer of nutrients to and from the oocyte (Centola, 1999) and a selective
barrier to polyspermy at fertilisation after ovulation.
More recently, many investigators have taken to studying oocyte-specific proteins which
have been found to be imperative for successful folliculogenesis. An example of an
oocyte-specific gene which is essential for follicular development is growth
differentiation factor 9 (GDF9). This factor is expressed in oocytes beginning
approximately at birth and continuing through the late antral stage in adults (Dube et al.,
1998; Elvin et al., 1999b; Rajkovic et al., 2004). One of the critical roles of GDF9
appears to be post-primary follicle development. Homozygous mice for the GDF9
deletion arrest at the primary follicle stage with a single layer of granulosa cells, do not
develop a thecal layer, and have defects in oocyte meiotic competence and growth (Dong
et al., 1996). Furthermore sheep homozygous for GDF9 mutations are sterile due to
premature ovarian failure (McNatty et al., 2006) suggesting that this gene is critical in
both mono- and polyovular species.
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Figure 1.4 Morphological classification of folliculogenesis. These images are taken from
the mouse ovary, however the general morphology is the same as the human with the
exception of the size of the follicles; a, Primordial follicles consists of an oocyte (o)
either partially or fully surrounded by a layer of squamous pregranulosa cells (arrow). As
these follicles enter the growth phase the transformation of squamous granulosa cells into
cuboidal granulosa cell (arrowhead) is morphologically evident, b, The primary follicle is
composed of a single layer of cuboidal granulosa cells (arrow) whilst c, a secondary
follicle is continuing to acquire more layers of granulosa cells, d, As the follicle acquires
many layers of granulosa cells the emergence of an antral cavity (arrow) is evident, e, A
fully formed antral follicle possesses a fully formed fluid filled cavity (arrow). At this
stage the antral follicle is gonadotrophin-dependent and will experience atresia if
'threshold' FSH levels are not sufficient, f, The pre-ovulatory follicle is the largest type
and a clear distinction can be made between the cumulus granulosa cells (arrowhead) and
the mural granulosa cells on the follicle wall. Scale bars a-b=20pm, c=50pm, d-
e= 100pm, f=200pm
(Myers et al., 2004)
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As the granulosa cells begin to proliferate, form multiple layers and the oocyte enlarges,
the primary follicle undergoes the progression to a secondary/pre-antral follicle.
Development of a secondary follicle is also associated with the recruitment of an
additional outermost cellular layer that surrounds the highly dividing granulosa cell
layers. These cells are termed theca cells and are derived from the inter-follicular stromal
tissue. The theca cell layer comprises the two outermost layers of the secondary follicle.
The theca interna layer is comprised of elongated endocrine cells and is approximately 3-
5 cells thick. This layer is highly vascularised and lies immediately adjacent to the basal
lamina that separates the theca and granulosa cells. Adjacent to the theca interna layer is
an outermost layer of non-steroidogenic theca cells (theca externa) that are loosely
organised between the theca interna and inter-follicular stroma (Magoffin, 2005).
Unlike granulosa cells, not a lot is known about theca cells, however they have been
reported to have differentiated from the unspecialised mesenchymal ovarian stroma
(Magoffin, 2005). Interestingly, the granulosa cells are believed to play a key role in the
differentiation of theca cells. Unidentified small molecular weight proteins secreted from
granulosa have been confirmed to stimulate theca cell differentiation, under the control of
FSH (Magoffin and Magarelli, 1995). It is generally assumed that such precursor cells
are capable of proliferation and differentiation and consequently have properties common
to that of stem cells (Magoffin, 2005), however more research in this area is warranted.
Absolutely imperative for the survival of a multilayered follicle is an extensive network
of communication portholes known as gap junctions (Hirshfield, 1991). Formed from
intercellular membrane channels, gap junctions serve the importance of allowing
nutrients, inorganic ions, second messengers and small metabolites transfer from cell to
cell. This serves an important role, particularly as the multilayered follicle contains an
oocyte surrounded by many layers of avascular granulosa cells. Much ovarian research
has focussed upon the importance of gap junctions with a family of proteins called
connexins receiving a lot of attention. Connexins are intercellular channel-forming
membrane proteins that elicit cell-to-cell communication. They have been shown to be
absolutely imperative for follicular development to the pre-antral stage. Of particular
relevance for ovarian cellular communication has been the discovery of connexins 37 (Cx
37) and 43 (Cx 43) (Albertini et al., 2001). Studies using mice null for either Cx 37
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(oocyte-granulosa cells junctions) or Cx 43 (granulosa-granulosa cell junctions) have
provided clear evidence that these types of gap junctions are indeed essential for follicular
development beyond the pre-antral stage (Ackert et al., 2001; Simon et al., 1997). As the
pre-antral follicle acquires six to seven layers of granulosa cells, a fluid filled antral
cavity (filled with nutrients, electrolyte, water, growth factors and steroid hormones) is
generated within the granulosa cell layers and marks the formation of an antral follicle.
Based on measurements of mitotic indices and granulosa cell doubling times, the growth
of a follicle to the antral stage is estimated to take at least 85 days in women (Gougeon,
1986).
As the antral cavity begins to develop the follicle acquires gonadotrophin responsiveness
and it is at this stage of development that most follicles will undergo the process of
atresia, with the remaining only surviving with sufficient gonadotrophic support. For this
reason, any early antral follicles before the onset of puberty will subsequently undergo
atresia as blood concentrations of follicle-stimulating hormone (FSH) do not rise
sufficiently to sustain their development (Hillier, 1994a). However after puberty as each
menstrual cycle begins, FSH concentrations rise beyond the critical threshold and
consequently follicles are recruited for pre-ovulatory development. Key studies utilising
hypophysectomised and pre-pubertal monkey ovaries have elegantly shown that
gonadotrophic stimulation is essential for follicular development past the early antral
stage (Knobil et al., 1959; Peters, 1992). These early studies coupled with the many more
modern transgenic mouse models of gonadotrophin deficiency clearly demonstrate that in
the absence of either FSH/luteinizing hormone (LH) ligand or receptor, folliculogenesis is
compromised and infertility results (Abel et al., 2000; Danilovich et al., 2000; Dierich et
al., 1998; Kumar et al., 1997; Lei et al., 2001; Zhang et al., 2001). Therefore
developmental competence of ovarian follicles after antral cavity formation is known to
be a gonadotrophin-dependent event.
The stimulation of granulosa cells by FSH results in important co-ordinated changes in
the activation of numerous genes whose products are responsible for the acquisition of
steroidogenic capacity and their ability to respond to LH (Hillier, 1991a). One of the
hallmarks of ovarian follicle development is the acquisition of aromatase cytochrome P-
450 (P450arOm) and its encoded protein which results in the ability of the follicle to
produce oestrogen as described in section 1.1.3. During each cycle one follicle assumes
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dominance, secretes oestrogen and ovulates, whilst the others become atretic (Gougeon,
1986; Hillier, 1994a; Hillier et al., 1994) (Figure 1.3). This selection of the dominant
follicle is a result of the developmental changes in FSH and LH responsiveness which
leads to gonadotrophic control of ovarian steroid secretion.
1.1.3 Gonadotrophic control of ovarian steroid secretion
Described by Eli Adashi as the 'master gland' of steroid production in reproductive
biology, the ovary is indeed an extremely steroidogenically active endocrine gland.
Mature granulosa cells are the cellular source of the two most important ovarian steroids,
oestradiol and progesterone. Whilst the production of progesterone is possible by single
cell components alone (ie. theca cells and granulosa-lutein cells), the biosynthesis of
oestrogen requires the co-operation between granulosa cells and the adjacent thecal cells
(Adashi, 1994). Proposed by Falck in 1959 and later confirmed by Ryan and Petro the
two-cell, two-gonadotrophin theory provides evidence that the thecal interstitial cells are
the producers of C19 androgens (Falck, 1959; Ryan and Petro, 1966). The androgens can
then cross the basal lamina to diffuse into the granulosa cells where they aromatised into
Cig oestrogens, which are essential for complete follicular growth and development
(Figure 1.5). Both the theca and granulosa cells are responsive to the gonadotrophins, LH
and FSH respectively. The delivery of LH to the theca cells leads to the synthesis and
secretion of androstenedione whilst in response to FSH, the P450arOm enzyme in the
granulosa cells will aromatase androstenedione to oestrone, which then is converted to
oestradiol by 17P hydroxysteroid dehydrogenase (17|3HSD).

















Figure 1.5 The two-cell, two-gonadotrophin concept of ovarian steroid secretion
demonstrates that follicular oestradiol synthesis is primarily under the influence of the
gonadotrophins. The dominant follicle is consists of an outermost theca externa (TE)
layer, an inner theca interna (TI) cell layer that produces androgens that cross the
basement membrane (BM) to enter the granulosa cell (GC) layer whereby they are
aromatised to oestrogens which are secreted into either the circulation or follicular fluid.
LHR- LH receptor, ATP- adenosine-triphosphate, AMP-adenosine-monophosphate,
FSHR- FSH receptor.
Oestrogen secreted by the pre-ovulatory follicle is vital to female reproductive
physiology, serving to prepare the reproductive tract for conception, suppressing FSH
pituitary release to minimise the likelihood of multiple dominant follicles, and to cause
the release of the mid-cycle LH surge from the pituitary gland to trigger ovulation
(Hillier, 1990; Hillier etal., 1994).
1.1.4 Follicle selection
Before successful ovulation can proceed, selection of the dominant follicle must occur.
In most species, including humans the development of large ovulatory sized follicles is
not a random process (Fortune, 1994). These follicles do not develop during the luteal
phases (as discussed in section 1.2), however a cohort of smaller follicles emerge during
the early follicular phase. In mono-ovulatory species such as women, only one of these
follicles will continue to grow during the late-follicular phase whilst the rest of the cohort
will regress (Fortune, 1994). This follicle is termed the 'dominant follicle' and grows
faster than the rest of the cohort by producing higher concentrations of oestrogens and
inhibin (Zeleznik and Pohl, 2006). The exact reasons why one follicle can emerge as
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dominant are not fully understood, however it strongly believed that one follicle becomes
more sensitive to FSH than the other (Fauser and Van Fleusden, 1997). The dominant
follicle will then proceed to produce ostrogens and inhibins in order to suppress FSH
released during the mid-follicular phase. Consequently, the other antral follicles become
deprived of FSH stimulation that is essential for survival and undergo apoptosis (Hillier,
1994a; Zeleznik and Pohl, 2006), leaving only the dominant follicle to experience
ovulation. Elegant monkey studies have shown that neutralisation of circulating
oestrogens in the follicular phase leads to maintained FSH levels in the circulation, thus
leading to the development ofmultiple pre-ovulatory follicles (Zeleznik and Pohl, 2006).
Figure 1.6 Pattern of gonadotrophic secretion across the ovarian cycle. Note the fall in
FSH during follicular selection (arrow)
1.1.5 Ovulation
Ovulation is a complex, inflammation-like, and LH-induced process that permits that
release of a fertilisable oocyte (Espey, 1980; Richards, 2005). The only follicles capable
of releasing an oocyte for fertilisation are those of a pre-ovulatory status. As described
above, both LH and FSH are required for sex steroid synthesis, however once the follicle
has reached a pre-ovulatory status FSH is thought to induce cell surface receptors for LH
on granulosa cells. Consequently in pre-ovulatory follicles LH can regulate both thecal
cell androgen production and granulosa cell androgen aromatisation. It has been
proposed that the acquisition of LH receptors may serve to protect the follicle from the
falling plasma FSH concentrations by providing the follicles with the ability to respond to
LH (Zeleznik and Pohl, 2006). Ovulation of the oocyte-cumulus complex is induced by
LH from the pituitary gland in response to increasing ovarian steroid synthesis from the
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pre-ovulatory follicle. This next stage of the ovarian cycle, ovulation can be split up into
three main components; oocyte reactivation, follicular rupture and luteinisation.
1.1.5.1 Oocyte reactivation
Oocytes undergo spontaneous maturation in response to the LH surge, which
consequently results in prophase-arrested oocytes making the transition from G2 phase of
the cell cycle to M phase. In addition removal of the oocyte from somatic cell contacts in
vitro results in spontaneous maturation (Dekel and Beers, 1978; Dekel and Beers, 1980).
This is thought to be a result of a decline in intracellular cyclic adenosine monophosphate
(cAMP) which the oocyte itself naturally contains very little. Maturation can therefore be
prevented by the addition of cAMP which is most likely derived from the granulosa cells.
Oocytes do not contain gonadotrophin receptors and therefore reactivation of the oocyte
in response to LH must depend upon signals from cells that do express the LH receptor.
Such LH responsive cells (ie granulosa cells) must signal to the oocyte in order to
maintain it in an arrested state. However in event of the LH surge, LH acts via the LH/
hCG receptor to increase intracellular cAMP concentration (which at such high
concentrations) target the granulosa cells and break down intercellular communications,
subsequently uncoupling the oocyte and resulting in a reduction in oocyte cAMP
(Albertini and Anderson, 1974). Once the oocyte re-enters the cell cycle it is no longer
arrested in diplotene stage of meiosis I. However, this does not last long and soon after it
will rearrest again at the metaphase II stage until fertilisation occurs.
1.1.5.2 Follicular rupture
Follicular rupture involves the extrusion of the cumulus-oocyte complex (COC). Like
resumption of meiotic competence, this stage is dependent upon the LH surge, however it
may well begin 5-6 days prior (Adashi, 1994). Rupture of the follicular wall and
extrusion of the COC is accompanied by a gentle, rather than an explosive expulsion of
the oocyte and antral fluid like initially thought (Adashi, 1994). Direct measurements
have indeed found that the pressure within the pre-ovulatory follicle is quite low and
rupture is not a result of high intrafollicular pressure (Adashi, 1994). Mechanisms of
follicular rupture are often compared to that of inflammation, as a direct result
vasodilation, vascular permeability, exudation, oedema and tissue remodelling (Espey,
1994). Gene profiling of mouse COC have revealed that many genes originally believed
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to be expressed exclusively in immune cells are indeed present in cumulus cells
(Richards, 2007).
Considerable work has gone into understanding mechanisms of follicular rupture and
many mouse models have shown that impairment of important genes can alter this
process. For example, mice null for the proteolytic enzyme ADAMTS1 (a disintegrin and
metalloproteinase with thrombospondin 1 motifs) demonstrate impaired ovulation which
is most likely associated with a lack of protease activity (Mittaz et al., 2004; Shindo et
al., 2000). A role for prostaglandins during follicular rupture also appears most likely. In
a variety of mammalian species, the prostaglandin synthetic enzyme cyclooxygenase
(COX) isoform 2 expression is up-regulated around the time of the pre-ovulatory surge.
Evidence exists to suggest that prostaglandins play an important role during follicular
rupture as monkeys administered with the COX inhibitor, indomethacin, into their
follicular fluid experience inhibition of follicular rupture (Duffy and Stouffer, 2002).
These findings are in parallel with a human study which suggests women on non-steroidal
anti-inflammatory drugs experience luteinised unruptured follicle syndrome (Mendonca
et al., 2000), clearly suggesting that prostaglandins play a role during follicular rupture.
Indeed, akin to inflammatory processes, protease activity is also associated with the
process of follicular rupture. Evidence of MMPs and their inhibitors suggests that as
follicles approach ovulation there is an increase protease activity (Hagglund et al., 1999;
Liu et al., 1998). As a result of the thinning follicular wall, the epithelial cells slough off,
follicle ruptures occurs and some 26-40 hours after the pre-ovulatory LH surge the COC
is extruded, the follicular wall collapses and the resulting cells give rise to the corpus
luteum.
1.1.5.3 Luteinisation
In concert with the release of the oocyte-cumulus complex, the LH ovulatory surge also
induces luteinisation of the resulting steroidogenic cells of the dominant follicle. Prior to
the LH surge, the granulosa cells of the follicle are limited to aromatisation of androgens
from adjacent theca cells as they do not possess the enzymes necessary for androgen
synthesis (Hillier et al., 1994). However, FSH-induced maturation of granulosa cells
coupled with the LH surge induces the expression of steroidogenic enzymes P450
cholesterol side-chain cleavage (P450scc) and 3(3HSD that are required for the secretion of
steroid hormones by the corpus luteum.
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Luteinisation can be mimicked by in vitro conditions. Indeed, granulosa cells will
spontaneously luteinise and produce progesterone when removed from the follicular
environment, even in the absence of LH (Hillier et al., 1981). Therefore it appears that
the follicular environment has an inhibitory effect upon the granulosa cells that can
provide a milieu to discourage luteinisation (Channing et al., 1980; Eppig et al., 1997;
Murphy, 2000). Inhibitor(s) of such magnitude have been reported to be present in
follicular fluid (Channing et al., 1978; Ledwitz-Rigby et al., 1977) or to come directly
from the oocyte itself (Brankin et al., 2003; Vanderhyden and Macdonald, 1998).
Therefore, it appears that the LH surge is able to remove such inhibitory factors, disrupt
connections between granulosa cells and the oocyte (for example, connexins) and/or
induce genes that facilitate luteinisation to transform these cells into the most
steroidogenically active cells in the body.
1.2 The corpus luteum
In the first detailed description of corpora lutea (1672), Reygneir de Graaf described
"globular bodies" in the ovary that formed in the place of ova and were associated with
the presence of a fetus in the uterus. We now know that the transformation of a dominant
follicle into the corpus luteum is one of the fundamental processes in reproductive
biology.
The corpus luteum has the important role of being the interface between menstruation
(non-conception cycle) and pregnancy (conception). In a non-conception cycle the
corpus luteum will experience a high rate of cell turnover, intense remodelling and
structural and functional demise within a 14-day period, succinctly followed by the
initiation of a new cycle. Alternatively, during maternal recognition of pregnancy, the
corpus luteum will continue to secrete vast quantities of steroid hormones under the
trophic stimulation of conceptus- derived hCG, subsequently maintaining structural and
functional integrity.
High steroidogenic output from the corpus luteum results in a reduction in ovarian
cyclicity during the luteal phase. As a consequence, follicles fail to develop beyond an
antral stage until luteal tissue has regressed (Zeleznik and Pohl, 2006). Such extremely
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high steroidogenic output of progesterone, oestrogen and inhibin A from the active corpus
luteum, are thought to exert negative feedback on the hypothalamic-pituitary axis by
suppressing the trophic support of FSH and LH that is integral for pre-ovulatory follicle
development (see section 1.1.2.1). Elegant studies have clearly demonstrated that
removal of the corpus luteum before the expected time of luteal regression results in the
prompt resumption of pre-ovulatory follicular development and ovulation approximately
14 days later (Baird el al., 1984; Nilsson et al., 1982). Such resumption of cyclicity is a
common feature of most mammalian species and in the absence of conception it is
important for the corpus luteum to be removed so that a new cycle can begin. This is
clearly evident in infra-primate species such as the laboratory rodent which do not have
long luteal phases and indeed require coital stimulation to produce fully functional
secretory corpora lutea. This mechanism allows high levels of fecundity as ovulation and
potential conception could occur every 4-5 days.
Unlike follicular development, corpora lutea development, function and subsequent
demise differ greatly between species. This makes large mono-ovulatory species (cows,
sheep) and the more manipulative poly-ovulatory species (rodents) very useful models of
human follicular function and dysfunction in the laboratory. However, in regards to
corpora lutea physiology, different functional mechanisms exist between species. Whilst
these differences in reproductive patterns are meaningful in terms of adaptation of species
to reproduce more efficiently under different environment and life patterns, comparative
biology of corpora lutea becomes increasingly complex. On the other hand, some aspects
of corpora lutea formation are similar between species for example corpora lutea
formation, angiogenesis and steroid synthesis. Therefore a careful understanding of
interspecies differences is integral when studying laboratory models in the context of
human corpora lutea function. The next few sections will consider aspects of corpora
lutea biology in regards to the focus of this thesis, the human corpus luteum, however
some comparative observations will be made.
1.2.1 Formation and function of the corpus luteum
The transformation of the post-ovulatory follicle into the corpus luteum is of fundamental
importance. In primates, both ovulation and corpora lutea formation are under
gonadotrophic control. After follicular rupture and expulsion of the ovum, extensive
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tissue and vascular remodelling is associated with the breakdown of the basement
membrane of the follicle wall that once separated the avascular granulosa cells of the
follicle from the theca interna layer (Luck and Zhao, 1995). The theca cell layer begins
to engorge with blood, becoming oedematous and invaginating between the granulosa
cell layers. This results in the follicle wall collapsing into folds characteristic of the
corpus luteum (Figure 1.7). Invasion of capillaries is evident and this most likely under
the influence of angiogenic and mitogenic factors (McCracken et al., 1999). Although
the control of corpora lutea function differs between speices, many key studies
investigating luteinisation and corpora lutea development have been generated from
rodent models. No evidence exists to suggest that these processes differ in the human
(Behrman et al., 1993), and therefore these studies remain useful in the context of human
corpora lutea function.
1.2.2 Cellular component of the corpus luteum
The corpus luteum is composed of many cells types making it a heterogenous tissue in
nature. This is evident in Figure 1.7 whereby the different compartments of the tissue can
be morphologically identified. Steroidogenic cells exist in two forms and are often
referred to as large and small luteal cells. Granulosa-lutein cells (large luteal cells) are of
granulosa cell origin and make up the bulk of the volume of the corpus luteum existing in
roughly a 2:1 ratio to the smaller theca-lutein cells. Both granulosa and thecal cells
undergo massive hypertrophy during luteinisation, with the granulosa cells experiencing
an eight-fold volume increase relative to their pre-ovulatory size (Murphy, 2000) to
become the largest steroidogenic cell in the body (Fawcett et al., 1969). Unlike many
other species, the granulosa and theca cells of the human corpus luteum do not intermix
and remain in separate clusters (Niswender and Nett, 1994) which is clearly evident in
Figure 1.7. Surprisingly however, the human corpus luteum contains more non-luteal
cells than luteal cells (Behrman et al., 1993). Endothelial cells for example make up a
substantial contribution of the cellular composition of corpus luteum. These cells are
located at blood vessels and capillaries and are the result of the intense angiogenesis
process that occurred post-luteinisation. Additionally, immune cells such as macrophages
are well characterised to the corpus luteum, and indeed have been shown to markedly
increase in number from the early to the late-luteal phase (Duncan et al., 1998b).
Structurally supporting cells such as fibroblasts and other components of the extracellular
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matrix (ECM) are also important and prominent cells type within the corpus luteum.
Fibroblasts are reported to make up a high proportion of the cells in the corpus luteum
(Behrman et al., 1993) and greatly increase in number during the late-luteal phase (Lei et
al., 1991). This may suggest that both macrophages and fibroblast cell types play integral
roles during luteolysis.
Figure 1.7 Masson's Trichrome stain of a human corpus luteum demonstrating the
histological structure of the steroidogenic gland. The central core (CC) of fibrin clot and
extravasated red blood cells once formed the antral cavity of the dominant follicle.
Surrounding the central clot are the folds of granulosa-lutein cells (GL) that comprise the
bulk of the corpus luteum. Smaller theca-lutein cells (TL), in separate clumps along with
fibrous connective tissue (blue stain) invaginate between the granulosa-lutein cells. A
stromal network of tissue (St) surrounds the steroidogenic cells to provide a structural
network which comprises blood vessels (BV), fibroblasts and extracellular matrix. Scale
bar=200 pm
1.3 Luteal steroidogenesis
The human corpus luteum is a remarkable steroidogenic gland that can produce 25-40 mg
of progesterone daily (Lippsett, 1978). In women the corpus luteum also secretes vast
quantities of androgens and oestrogens (Devoto et al., 2002) in addition to progesterone.
Hormone production in the corpus luteum is largely dependent upon the pituitary-derived
LH utilising a cAMP second messenger system similar to that described in section 1.1.3.
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1.3.1 Progesterone
Simultaneously crystallised and characterised by four independent groups, the discovery
of progesterone as a secreted 'luteal factor' came to light in experiments involving
pregnant rabbits. In these experiments the pregnant rabbits were subjected to either the
removal of their ovaries or treatment with luteal extracts which resulted in
abortion/resorption or survival of embryos respectively (Niswender et al., 2000). This
luteal extract factor became known as progesterone and was found to be the support
hormone of pregnancy.
Unlike follicular granulosa cells, whereby progesterone is not synthesised, the granulosa-
lutein cells of the corpus luteum have recently acquired, as a result of the pre-ovulatory
LH surge, the steroidogenic machinery to generate their own progesterone. This, coupled
with the newly formed vasculature provides the gland with its major source of circulating
cholesterol, and the corpus luteum now has the potential to secrete vast amounts of
progesterone. Although cholesterol can be synthesised de novo by the corpus luteum, it
is mainly obtained from circulating plasma lipoproteins. High- and low- density
lipoproteins (HDL and LDL) provide the corpus luteum with a cholesterol supply with
LDL the predominant source in the human ovary (Soto et al., 1984). The uptake of LDL
by luteal cells is quite an efficient process. It occurs by receptor mediated endocytosis,
with each LDL molecule containing roughly 2500 cholesterol molecules (Brown and
Goldstein, 1986). Due to its hydrophobic nature, cholesterol cannot freely diffuse within
the luteal cell and consequently requires sterol carrier proteins (SCP) to transport it from
the cytosol to the mitochondria. SCP facilitate the transport of cholesterol to the outer
mitochondrial membrane before being transferred to the inner mitochondrial membrane
via the aqueous intermembrane space. This step involves several proteins including StAR
(steroidogenic acute regulatory protein), the protein that is reported to be the rate limiting
step in the steroidogenic pathway (Stevens et al., 1993). Once transported into the matrix
of the mitochondria, P450scc cleaves the side chain of cholesterol to form pregnenolone.
Pregnenolone can then be transported to the closely associated smooth endoplasmic
reticulum where the enzyme 30HSD converts it to progesterone (Figure 1.8).









Figure 1.8 Steroidogenesis in the corpus luteum. The corpus luteum has the capacity to
produce androgen, oestrogen and progesterone. The pre-ovulatory LH surge induces
enzymatic changes such that the newly differentiated granulosa-lutein cells (GLC) can
continue to secrete oestrogen however they can now also synthesise large quantities of
progesterone due to the acquisition of 3(3HSD. The adjacent theca-lutein cell (TLC) layer
is no longer separated by a basement membrane and also contributes to the progesterone
output. The surrounding stromal layer (St) is evident in blue which stains positively for
collagen.
In all mammalian species, progesterone is the common secretory product of the corpus
luteum. In a cycle whereby conception occurs and successful implantation is achieved, a
viable corpus luteum is essential to ensure progesterone secretion is maintained. The
principle targets of progesterone are the reproductive tract and the hypothalamo-pituitary
axis. Well characterised for its role in the female reproductive tract, progesterone has the
important function of preparing the uterine environment for the initiation and
maintenance of pregnancy and suppression of the maternal immune response to fetal
antigens (Siiteri et al., 1977; Siiteri and Stites, 1982). In order for progesterone actions to
be mediated in the reproductive tract, exposure to oestrogens is a pre-requisite for
progesterone receptor induction (Ing and Tornesi, 1997; Kraus and Katzenellenbogen,
1993). Nuclear progesterone receptors are activated upon ligand interaction and can
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1.3.2 Other steroidal products
In addition to progesterone, the corpus luteum is also capable of producing androgens and
oestrogens (Retamales et al., 1994) (Figure 1.8). The exact role of oestrogen remains
questionable. For example, in some species oestradiol is known to be a luteotrophic factor
(ie rat, rabbit, pig), however the dependence of the corpus luteum on oestradiol for
support varies within these species (Niswender et al., 2000). In humans however,
addition of exogenous oestradiol has been shown to diminish progesterone synthesis by
inhibition of 3(1HSD in dispersed cultures of luteal cells (Vega et al., 1994). Therefore it
is possible that oestrogens have the opposite effect in the human corpus luteum and have
luteolytic properties. Further interventional studies are required to decipher a role for
oestrogen in the human corpus luteum. Regardless of the role of their role, oestradiol
receptors (ER) are indeed expressed in corpora lutea of women and primates, most
notably in the form of ERjl (Duffy et al., 2000; Saunders et al., 2000). In contrast to the
follicular granulosa cells, the corpus luteum does not appear to express the ERa isoform
(Chandrasekher et al., 1994; Iwai et al., 1990). Consistent with this observation,
transgenic mice null for each receptor isoform have clearly indicated that ERp rather than
ERa has a more predominant role in the corpus luteum (Couse et al., 1995; Couse et al.,
2005). Whether this observation extends to other species remains unknown, however due
to the nature of their localisation this is probably true for humans and primates. A role for
oestrogens in the corpus luteum cannot be ruled out and there may even be temporal and
spatial roles. This is clearly an area lacking in current research.
1.3.3 Non-steroidal regulators
It is well recognised the corpus luteum is not only the site of steroidal hormones but also
has the ability to produce and/or respond to many other factors that may act as local
(paracrine/autocrine) or endocrine signals (Stouffer, 2006). Prolactin, oxytocin, relaxin
and prostaglandins are common hormones considered in luteal physiology. Although the
role of some of these molecules in the human corpus luteum remains elusive, they have
more defined roles in corpora lutea of other species. Understanding the various
mechanisms of these factors may allow a more critical understanding of the human
corpus luteum. However, many species have evolved various mechanisms for controlling
their reproductive activities and consequently corpora lutea function that are different
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from that seen in human corpora lutea. This becomes clearly evident when discussing
luteotrophic or luteolytic factors.
In rodents, prolactin (PRL)-like hormones are essential luteotrophins, whereby mating
during the estrous stage of the cycle stimulates the cervix and activates a neuorendocrine
loop to result in the secretion of pituitary-derived prolactin. A week later however, this
prolactin secretion is taken over from the pituitary by the placenta and the pituitary is no
longer essential for maintenance of pregnancy (Stouffer, 2006). Consequently, the PRL
system is integral for promoting luteal structure-function in rodents. One of the key
mechanisms by which this system achieves this is by directly stimulating progesterone
production (Stouffer, 2006). A less convincing role for prolactin however exists in
human corpora lutea. Prolactin receptors have been localised to the ovary and corpus
luteum (Alila et al., 1987; McNeilly et al., 1980), however unlike the rodent most human
and other primate studies have found that exogenous prolactin does not appear to
influence progesterone production in dispersed luteal cells (Stouffer et al., 1980; Tan and
Biggs, 1983). Whether this is a result of the differences between species or an in vitro
versus an in vivo system remains unknown.
Another protein hormone known to regulate luteal lifespan is oxytocin. Unlike domestic
animals (such as cows, sheep, goats and pigs) whereby evidence suggest that oxytocin
plays a role in luteal regression at the end of a non-fertile cycle, there remains no concrete
role for oxytocin in the primate corpus luteum. Oxytocin is indeed expressed in the
human corpus luteum, albeit at much lower levels (1000-fold) (Ivell et al., 1997) than
found in other species, and receptor expression is also described (Einspanier et al., 1994;
Fuchs et al., 1990). Evidence in primates suggests that the LH surge promotes the
expression and production of oxytocin and its receptor in the luteinising cells of the
ovulatory follicle (Einspanier et al., 1997; Ivell et al., 1998) whilst others report that
oxytocin interrupts progesterone synthesis (Bendz, 1977; Richardson and Masson, 1985).
At least two studies however report that oxytocin infused in vivo to the corpus luteum
shortens the luteal phase in both rhesus monkeys (Auletta et al., 1984a; Auletta et al.,
1984b) and humans (Bennegard-Eden et al., 1995), suggesting that there may be a
potential paracrine role for oxytocin. Similarly, a lack of research exists also for a role
for relaxin in the human corpus luteum. In many species relaxin is considered to be a
hormone of pregnancy and parturition (Stouffer, 2006), however in the human limited
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studies failed to demonstrated a physiological role for the hormone. The protein and
mRNA have indeed been localised to steroidogenic cells of the corpus luteum (Stoelk et
al., 1991), however, like oxytocin, these levels are much lower than detected in other
species.
In non-primate species prostaglandin F20 (PGF2a) has clearly been shown to be a critical
regulator of the corpus luteum. Sheep, cow, pig, horse, rabbit and rat corpora lutea all
experience luteolysis in response to uterine PGF2a signal. This fundamental aspect of
corpora lutea biology was first reported by Loeb in 1923 who classically demonstrated
that hysterectomy in the cyclic guinea pig abolished cycles and caused persistence of
corpora lutea. Hysterectomy however has no effect on the length of ovarian lifespan or
corpus luteum in either primates or women, clearly demonstrating the uterine-derived
PGF2a is not of importance in higher species. This does not rule out a luteolytic role for
PGF2a in primates; however the source is clearly not of uterine origin. Additional
monkey studies have shown that PGF2a does have luteolytic tendencies, however the
evidence in women is less marked. Some studies have reported a fall in plasma
progesterone or shortening of cycles (Embrey et al., 1972) whereas others report no
effects (Jones and Wentz, 1972). Whilst in vitro studies with cultured granulosa cells in
the human do display inhibition of progesterone by PGF2a (Henderson and McNatty,
1977), further studies are essential to further dissect out a potential role for prostaglandins
in the corpus luteum ofwomen.
1.4 Luteolysis
In the absence of pregnancy, the corpus luteum has a finite lifespan of approximately 14
days and thereafter will undergo structural and functional demise, a process termed as
luteolysis. Luteolysis is absolutely obligatory for the next wave of folliculogenesis. The
concept of luteolysis has been well acknowledged for many decades, however many of
the regulatory mechanisms involved in the loss of function and involution of the gland are
incompletely understood (Davis and Rueda, 2002). Generally, luteolysis is often divided
into two distinct stages, functional and structural luteolysis. Functional luteolysis refers
to the increasing failure of progesterone synthesis and secretion whilst structural
luteolysis refers to the involution of the gland (Behrman et al., 1993). Although it is not
really understood if there are temporal and endocrinological distinctions between these
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stages of luteolysis in the human, it is easier to describe them as separate events.
Evidence does suggest however that, like the rat, functional and structural luteolysis may
be separate events in the human as small corpora lutea of previous cycles are still evident
within the ovary (Behrman et al., 1993). Therefore, for purpose of this literature review,
the term luteolysis will be sub-categorised into functional and structural luteolysis.
1.4.1 Functional luteolysis
Functional luteolysis is most commonly associated with the cessation of progesterone
steroid output. This is generally a result of the abrogation of LH action and consequently
the trophic mechanisms of support are interrupted. Surprisingly however, this is not a
result of LH withdrawal, as natural luteal regression is not associated with a decrease in
LH secretion; rather luteal responsiveness to LH is interrupted (Behrman et al., 1993).
This is also not due to LH receptor down regulation in the human at least, as mRNA
expression and in situ binding studies clearly demonstrate that there are no significant
changes in receptor expression throughout the lifespan of corpora lutea (Duncan et al.,
1996a). LH-induced progesterone synthesis declines in the presence of all other members
of the steroidogenic pathway such as StAR, P450scc and 3(!HSD (Duncan et al., 1999).
This suggests that the LH receptor undergoes some type of desensitisation or uncoupling
from second messenger systems (Segaloff and Ascoli, 1993), which would explain why
increasing doses of hCG are required to maintain progesterone production during
pregnancy (Duncan et al., 1996a). In contrast to human corpora lutea, rat corpora lutea
do however demonstrate a ligand-induced reduction in the number of LH receptors
(Hoffman et al., 1991). This however this may be an example of species specific
differences in the regulation of corpora lutea function.
1.4.2 Structural luteolysis
Grossly characterised by a massive decrease in size and weight, structural luteolysis
involves intense tissue remodelling of the corpus luteum that is associated with cell death,
an influx of immune cells and increased fibrotic tissue. Subsequently structural luteolysis
can be characterised by a loss and involution of the tissue (Behrman et al., 1993) which
goes on to form corpus albicans. After a few cycles the corpus albicans are eventually
completely reabsorbed and replaced by ovarian stroma. Therefore involution of luteal
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tissue involves incredible cell loss and major remodelling of the ECM. Dissolution of the
corpus luteum during luteolysis has been attributed to an increase in protease activity
during the late-luteal stages in many species. Furthermore, it is clearly evident that during
luteolysis there is a marked increase in macrophages (Duncan et al., 1998b) and
fibroblasts (Lei et al., 1991), both of which can secrete the proteolytic matrix
metalloproteinases (Duncan, 2000).
1.4.2.1 Matrix metalloproteinases
MMPs are a family of homologous zinc-dependent endopeptidases that play central roles
in many biological processes by degrading ECM and basement membrane components.
Ample evidence exists to suggest MMPs have integral roles in embryogenesis, normal
tissue remodelling, wound healing, cardiovascular diseases and cancer (Chakraborti et al.,
2003; Visse and Nagase, 2003). MMPs are highly active proteolytic enzymes which are
tightly controlled at several levels. Certain signalling pathways lead to the expression of
particular MMP genes and therefore the first level of control is the activation of mRNA
synthesis (Nagase and Woessner, 1999). Secondly, most MMPs are secreted as inactive
zymogens (proMMP) and therefore require activation of their proMMP form. Activation
of proMMPs in vivo occurs by tissue or plasma proteinases or opportunistic bacterial
proteinases (Nagase and Woessner, 1999). A third level of MMP regulation involves
endogenous inhibitors, namely a-macroglobulin and tissue inhibitors of matrix-
metalloproteinases (TEMPs). An example of the tight control of MMPs can be seen with
MMP-2, whereby activation requires both membrane-type 1 MMP (MT1-MMP) and
TIMP-2 bound to MT1-MMP (Strongin et al., 1995).
1.4.2.2 Inhibitors of matrix metalloproteinases
The major endogenous regulators of MMPs are the TIMP proteins, which bind to and
inhibit MMP action with a 1:1 stoichiometry. TIMPs in general are widely expressed and
although not always, they are frequently regulated in co-ordination with MMPs (Hulboy
et al., 1997). Currently four homologous TIMPs have been identified and all demonstrate
important regulatory roles not only in matrix turnover but also in cellular activities. A
second line of defence against MMPs is found in the serum in the form of a-
macroglobulin (Baker et al., 2002). This protein serves as a substrate for some TIMPs
and after cleavage a conformational change in the inhibitor occurs that can act to entrap
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and covalently bind the MMP to prevent cleavage of any other matrix molecules
(Woessner, 1991).
1.4.2.3 Remodelling in the corpus luteum
The role of MMPs in remodelling in the corpus luteum has been well characterised in
many species including humans. To date, over 20 different MMPs have been described
with the most commonly studied being MMP-1 (collagenase), MMP-2 (gelatinase A) and
MMP-9 (gelatinase B). MMPs are synthesised by connective tissue cells such as
fibroblasts, endothelial cells in newly formed vessels, and infiltrating cells such as
macrophages and neutrophils (Hulboy et al., 1997). Considerable tissue remodelling
occurs in the ovary, particularly during the processes of ovulation and luteolysis —
therefore much of the MMP activity occurs in parallel with important remodelling events
of the corpus luteum. Key studies looking at protease action in the human corpus luteum
have shown that although the TIMPs are produced in vast quantities their expression does
not consistently change over the luteal phase unlike that ofMMP activity which is clearly
regulated (Duncan, 2000). Further supporting a role for MMP regulation across the luteal
phase is the finding that MMPs and TIMPs have differential localisation in the corpus
luteum and consequently an excess of TIMPs does not necessarily fully inhibit MMP
activity (Duncan, 2000; Duncan et al., 1998a).
1.5 Maternal recognition of pregnancy in women
In a cycle where conception occurs, the corpus luteum is rescued from luteolysis and the
structural and functional integrity of the gland is maintained. Not surprisingly,
mechanisms of maternal recognition of pregnancy differ between species. A common
feature however, is the requirement of progesterone secretion necessary to maintain
gestation in its early stages (McCracken et al., 1999). In all species, progesterone is
initially produced by the corpus luteum, generally in response to LH. However, the
placenta also produces progesterone in some species (sheep, horse, human) and in these
species the placenta will become the predominant source of progesterone. This change in
the source of progesterone is known as the luteo-placental shift. In other species (goat,
pig, rabbit, mouse) the corpus luteum will continue as the sole source of progesterone
throughout pregnancy and as a result the initiation of labour coupled with a uterine
luteolytic signal appears to be the trigger for luteal regression (McCracken et al., 1999).
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In the human however, the focus of this thesis, logarithmically increasing concentrations
of hCG are secreted from the developing syncytiotrophoblast and will continue to
progressively rise during early pregnancy until peak levels are reached at seven to nine
weeks (Kletzky et al., 1985). Thereafter, hCG concentrations will decline as the placenta
assumes the principal role of progesterone secretion.
HCG is a member of the glycoprotein hormone family that also includes the structurally
related LH, FSH and thyroid stimulating hormone (TSH). All of these glycoproteins
consist of an identical a-subunit that is non-covalently bound to a P-subunit that confers
their hormone specificity. Both hCG and LH are thought to share a common receptor that
belongs to the family of G protein-coupled receptors (GPCRs). Although some
controversy does exist on whether hCG may have its own receptor (Gromoll et al., 2000),
no such gene has been identified to date. Human LHp and hCGp demonstrate 85%
homology in the first 114 amino acids, however hCGp is unique from the other
glycoprotein p subunits because of its 24-31 amino acid extension at the C-terminus.
Additionally, unlike LH subunits, the subunits of hCG contain terminal sialic acid
residues that are not sulphated which markedly influence the size and charge of the
molecule subsequently resulting in hCG having a greater half-life and bioactivity
compared to that of LH (Stouffer, 2006).
How hCG achieves luteal rescue is one of the major questions emerging regarding luteal
physiology. Whilst the obvious answer is that it is maintaining physiological progesterone
concentration via interactions with the LH/hCG receptor, it is also becoming increasingly
evident that hCG is having marked effects on cell types that do not express this receptor
(Duncan, 2000). A clear example of this is evident in relation to MMP-2, which is
localised to the stromal-fibroblast areas of the human corpus luteum, yet is regulated by
hCG which can only act upon the steroidogenic cells expressing their receptor (Duncan et
al., 1998a). Studies are now emerging with this hypothesis in mind, aiming to understand
the potential paracrine interactions that may exist between the different cell types
(Duncan et al., 2005b). Two emerging paracrine factors in luteal biology which are
discussed in this thesis are activins and glucocorticoids.
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1.6 Activins and Inhibins
Originally discovered for their opposing roles in pituitary-derived FSH modulation
activin, inhibin and follistatin have been in the forefront of reproductive research for the
past 20 years. Named according to the role each dimeric glycoprotein had upon FSH
secretion, activin and inhibin are structurally similar but functionally diverse members of
the transforming growth factor -P (TGF-P) superfamily that is comprised of over 30
members (Lin et al., 2003). Follistatin is structurally unrelated to either activin or inhibin
but shares the antagonist-like properties of inhibin by irreversibly binding and
subsequently neutralising activin actions (discussed in section 1.6.4.2). Although
originally discovered in a reproductive context, the importance of the
activin/inhibin/follistatin system has been extrapolated to many other body systems such
as wound repair (Sulyok et al., 2004), inflammation (Jones et al., 2000a), fetal
development (Matzuk et al, 1995), cell proliferation and apoptosis (Hully et al., 1994).
The following paragraphs will review the nature and actions of activin, inhibin and
follistatin in regards to female reproduction, namely in the ovarian follicles and corpus
luteum.
1.6.1 Activin
After the initial purification of inhibin from porcine follicular fluid, another compound
was discovered which could positively modulate FSH release from pituitary
gonadotrophes in vitro (Ling et al., 1986; Vale et al., 1986). This compound was termed
activin and is now recognised as one of the most important growth factors produced both
locally and systemically in many tissue systems. Comprised of two mature inhibin [S
subunits, activins are dimeric proteins of approximately 25kDa. Multiple forms of
activins exist due to the various P subunit isoforms, all of which are encoded by different
genes. To date five isoforms of the P subunit have been cloned with PA and pB being the
best characterised. Activin A (PA:PA), the major focus of this thesis, and activin B
(PB:PB) are homodimers composed of two PA and two PB subunits respectively. Activin
AB (PA:PB) is a heterodimeric protein consisting of both a pA and PB subunit. The
homology between the PA and pB subunits is approximately 63% (Chang et al., 2001)
and the P subunit is highly conserved between species (mature pA is 100% conserved
between human, cow, rat and sheep; whilst mature PB differs by only one amino acid).
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This suggests important function and evolutionary pressure to maintain the molecular
integrity of inhibin family members (Vale et al., 1990).
The more recent discoveries involving the inhibin/activin p subunit family have been
termed PC, PD and PE and have been cloned from human liver (Hotten et al., 1995),
Xenopus laevis (Oda et al., 1995) and mouse liver (Fang et al., 1996) respectively.
Reproductive roles have been suggested for PC as the mRNA has been found by
Loveland and colleagues (Loveland et al., 1996) in the human ovary, placenta and testis.
This thesis will focus on activin A and to a lesser extent activin B.
Activin A is the major activin found in the circulation whilst activin B is reported to be
predominantly produced in the pituitary. A pituitary-ovarian axis model proposed by
Muttukrishna and colleges aims to demonstrate disparate roles of activin A and activin B
within the hypothalamic-pituitary gonadal (HPG) axis (Muttukrishna et al., 2004). This
model suggests that activin A acts more as an endocrine modulator of pituitary FSH
whilst activin B has more of an autocrine/paracrine role for pituitary derived FSH
secretion. The major source and principal site of PA, pB and follistatin expression in the
ovary are the follicular granulosa cells and the granulosa-lutein cells.
1.6.1.1 Extragonadal activin A
Extragonadal sources of activin A have been identified in non-ovarian sites including
bone marrow, human leukemia cells (Lockwood et al., 1996) and immune cells (Phillips
et al., 2005). When looking at the serum profiles of activin A, inhibin A, FSH/LH,
progesterone and oestradiol, it is evident that activin A is negatively correlated with the
other hormone profiles (Muttukrishna et al., 1996) (Figure 1.9). Whilst inhibin A and
steroidal hormones fall at the end of the luteal phase, activin A however is maximal,
suggestive that it may have a positive role in luteolysis. This source of activin A in the
circulation is probably not from the follicles as there is no difference in serum activin A
concentrations between women undergoing gonadotrophin-induced follicular
development compared to those in non-stimulated cycles (Knight et al., 1996).
Coincident with the rise in serum activin A during the late-luteal phase, the corpus luteum
maybe a possible source of the rising protein concentration or alternatively may just be a
paracrine target of its actions.
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Figure 1.9 Mean serum profiles of activin A, inhibin A, the gonadotropins and steroid
hormones over the ovarian cycle of five spontaneously cycling women. Unlike inhibin A,
FSH, LH, oestradiol or progesterone, activin A is maximal in the late-luteal phase
suggestive that it may play an important role in the luteolytic mechanism.
(Muttukrishna et al., 1996)
Chapter 1 Literature Review 31
1.6.2 Inhibin
Although first described in the seminal plasma of normal men, the heterodimeric protein
inhibin was first isolated and purified in bovine follicular fluid by scientists in
Melbourne, Australia (Robertson et al., 1985). The mature form of the inhibin protein is
approximately 32 kDa and is composed of an a subunit and [1 subunit as described above.
The two isoforms of inhibin that have been isolated from follicular fluid are inhibin A
(a:pA) and inhibin B (a:pB), which share the same a subunit but like the different activin
isoforms are encoded by different P subunit genes.
1.6.3 Activin receptors and intracellular signalling
Activins elicit their responses via extracellular reception and an intracellular signalling
system. The activin receptors were cloned and characterised in the early 1990s
(Zimmerman and Mathews, 1996) and like all members of the TGF-P superfamily use a
common mechanism to signal to the nucleus. Activin signalling events are initiated in
response to activin binding to its two types of transmembrane serine/threonine receptor
kinases, activin type II receptors (ActRII, ActRIIB) and activin type I receptor (activin
receptor-like kinase; ALK). Upon ligand binding, two of each receptor type are brought
together in order to form an activated stable receptor complex. Activin type II receptors
are the primary ligand binding proteins, and even in the absence of type I receptors they
have a very high affinity for the activin protein (Mathews and Vale, 1991). Once in the
activated receptor complex, the binding of the activin ligand results in the constitutively
active type II receptor phosphorylating the type I receptor and subsequently activating the
kinase domain (Attisano et al., 1996). Once activated, ALK4 can then phosphorylate the
cytoplasmic intracellular Smad (named after the sma genes and the human homologue of
Drosophila Mothers against decapentaplegic) signalling proteins which initiate a
signalling cascade that ultimately regulates gene transcription and expression.
The Smad proteins are a group of evolutionarily conserved proteins that act as mediators
of transcriptional activation by members of the TGF-P superfamily, including activins,
bone morphogenic proteins (BMPs) and GDF9. Members of the Smad family are divided
into three distinct classes. The receptor-activated Smads (R-Smads), the common-
mediated Smad (Co-Smad) and the inhibitory Smads (I-Smads). Essentially, once the R-
Smad (Smad 2 or 3 for the TGF-p/activin signalling pathway or Smad 1, 5 or 8 for the
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BMP pathway) has been phosphorylated by ALK4 it forms a complex with the co-Smad
(Smad 4, common to both TGF-p/activin and BMP signalling pathways) which is then
free to translocate from the cytoplasm into the nucleus to regulate target genes by DNA
binding and recruitment of transcriptional co-factors (Welt et al., 2002) (Figure 1.10).
Increased expression of the I-Smads (Smad 6 for BMP signalling and Smad 7 for TGF-
p/activin signalling pathway) however can inhibit activin signalling by two known
inhibitory mechanisms. To negatively regulate the signalling pathway, I-Smads can form
stable complexes with ALK4 to inhibit pathway-specific Smad phosphorylation and/or
they can compete with Smad 4 for binding to phosphorylated pathway-specific Smads,
preventing formation of transcriptionally active Smad complexes (Zimmerman and
Mathews, 2001). In addition to the I-Smads there are other intracellular modulators of
activin signalling, for example a protein named SARA (Smad anchor for receptor
activation) (Welt et al., 2002). SARA is capable of binding to unphosphorylated Smad 2
and modulating its access to type I activin receptor, thereby masking its nuclear
localisation signal and maintaining it in a cytoplamic distribution (Welt et al., 2002).
Conversely, upon receptor activation, SARA can also interact with the type I activin
receptor and facilitate Smad 2 phosphorylation, dissociate from the Smad, allowing it to
form a complex with Smad 4 and translocate into the nucleus.
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Figure 1.10 Schematic diagram of the activin receptor and intracellular Smad signalling
proteins. In the presence of an activin ligand activin receptor type II (ActRII) will recruit
and phosphorylate activin type I receptor (ALK4) forming an actively stable receptor
complex. ALK4 with the aid of SARA which stablises the complex, activates the SMAD
2/3 protein in the cytoplasm (blue) which is then able form a complex with the common
SMAD 4. This complex then translocates into the nucleus (yellow) to regulate target
genes. The inhibitory SMAD 7 can antagonise these responses primarily by associating
with the receptors and preventing SMAD 2/3 activation.
1.6.4 Inhibitors of activin action
One of the unique characteristics about activin and inhibin is that although they are
structurally very similar, functionally they are diverse. Although activin acts on more cell
types than inhibin, in cells where both proteins have biological effects, their actions are
always antagonistic (Vale et al., 1990). The proposed principal mechanism of action by
which inhibin exerts its antagonistic effects upon activin action is by interfering with
activin signal transduction. The next section describes the role of follistatin, inhibin and
the inhibin co-receptor P-glycan in mediating functional antagonism of activin signalling.
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1.6.4.1 Follistatin
Unlike activin or inhibin, follistatin is a monomeric protein that like inhibin, was initially
discovered for its ability to inhibit FSH activity. It was not until the late 1980s (DePaolo
et al., 1991) however until the physiological significance of follistatin was identified. It
became evident that follistatin was a high-affinity activin-binding protein that could
modulate the biological availability of activin at the target cell level (Kogawa et al., 1991;
Nakamura et al., 1990). Although follistatin binds to both activin and inhibin via their
common P subunits (two follistatin molecules for each activin p/p homodimer) it is
believed that only activin action is neutralised by the interaction (Shimonaka et al., 1991).
The dissociation rate of the activin-follistatin complex is so slow that the interaction
between the two proteins is rendered irreversible (Schneyer et al., 1994). As a result
follistatin inhibits activin by preventing it from binding to its own receptors.
Follistatin is encoded by a single gene, however alternative splicing of the mRNA gives
rise to two different precursor forms; follistatin 344 and follistatin 317 (Shimasaki et al.,
1988). From the two precursor forms, removal of the signal peptide results in mature
peptides of 315 and 288 amino acids respectively (Figure 1.11). Further forms of
follistatin can be cleaved at the carboxy-terminus by proteolytic enzymes, however the
two major forms, follistatin 315 and follistatin 288 will be discussed. Both forms of
follistatin are able to neutralise activin activity although it has been reported that
follistatin 288 has a higher affinity for activin than the 315-residue molecule (Hashimoto
et al., 2000). It is generally thought the follistatin 315 is the predominant follistatin in the
circulation (Schneyer et al., 1996), although measurable quantities of follistatin 288 are
detected in the serum (de Kretser et al., 2002; Evans et al., 1998). Most of the follistatin
in the circulation is bound, presumably to activin, although it can bind to other molecules
such as a2-macroglobin and factors with structural homology such as inhibin, BMP-4 and
BMP-7 (Phillips et al., 2001). This suggests that follistatin most likely acts as
neutralising agent and does not have any endocrine actions of its own (Khoury et al.,
1995).
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Figure 1.11 Schematic representation of the follistatin gene and the alternate splicing of
the six exons that generates two major forms of pre-proteins (344 and 317). Removal of
the signal peptide (S) leaves mature peptides of follistatin 315 and follistatin 288, whilst
the 315 form can be further cleaved by proteolytic enzymes (dashed line on exon 5) to
form a truncated form of follistatin 315 (approx. 300 amino acids) which is particularly
abundant in follicular fluid.
Adapted from (Phillips et al., 2001)
1.6.4.2 Inhibin and (3-glycan
So far, activin actions with two types of transmembrane serine/threonine receptor kinases
have been discussed. Although structurally related, the functional properties of inhibin
are very diverse in comparison to that of activin. Because of the structural properties of
inhibin can also bind to the type II activin receptors (particularly type IIB) via the
common ft subunit, with up to 40% competition for activin-binding (Lebrun and Vale,
1997; Robertson et al., 2000). However, unlike activin binding, the interaction of inhibin
and the activin type II receptor does not result in recruitment of the ALK receptor and
therefore signalling via the Smad cascade does not occur. This is thought to be due to the
lack of a second p subunit and although the a subunit is similar, it is unable to recruit the
ALK receptor and form a stable signalling complex (Robertson et al., 2000; Xu et al.,
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1995). As a result, inhibin binding to the activin receptor type II exerts antagonistic
actions as it prevents activin binding its own receptor. Therefore inhibin impedes activin
action at the level of the receptor.
The quest for an inhibin receptor has been an on going enigma for many research groups,
coupled with the fact that inhibins fail to antagonise activin in some tissue and cells, it
appears that additional components may well be required for inhibin action (Draper et al.,
1998; Hertan et al., 1999; Lebrun and Vale, 1997). Elegant studies in the Vale laboratory
at the Salk Institute have shown that the TGF-(3 III receptor P-glycan, can function as an
inhibin co-receptor with ActRII (Lewis et al., 2000). These studies clearly demonstrate
that P-glycan can function as an inhibin co-receptor by binding with high affinity to the
protein and enhancing the interaction in cell that co-express ActRII and P-glycan (Lewis
et al., 2000). Indeed, protein localisation studies using anti p-glycan antibodies have
shown positive staining in the oocyte, follicular granulosa and thecal cells and
steroidogenic cells of the corpus luteum (Drummond et al., 2002; Lewis et al., 2000; Liu
et al., 2003), all cells which have been reported to express activin receptors. It should be
noted that studies using rat tissue (Drummond et al., 2002; Lewis et al., 2000) described
positive staining in all stages of follicular development, whilst the human study (Liu et
al., 2003) reported primordial, primary, pre-antral and early antral follicles P-glycan
negative. Therefore in human ovarian tissue protein localisation of P-glycan is
predominant in the later follicle stages that coincide with activin inhibition or down-
regulation (Figure 1.12). Presumably this coincides with the developmental stages when
inhibin is also maximal and the sensitivity of inhibin binding to the activin receptors is
increased in order to impede activin action.
1.6.4.3 a-2 macroglobulin
Another extra-cellular binding protein with an affinity for activin is the plasma proteinase
inhibitor a2-macroglobulin (Niemuller et al., 1995). Like that of follistatin, a2-
macroglobulin can bind to activin and neutralise its bioactivity, however it does this with
a lower affinity than that of follistatin (Niemuller et al., 1995). As a2-macroglobulin is
found in the extracellular spaces and circulation in large quantities it has been proposed to
act as a high abundance, low-affinity binding partner for activin A (Phillips, 2000).
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Figure 1.12 The likely developmental-related changes ofactivin, inhibin and follistatin in
the human ovary. Collective studies suggest that smaller follicles are exposed to and
reliant on activin, however once the follicles acquire gonadotrophin responsiveness it
appears that activin action is down-regulated due to an increase in inhibitors such as
follistatin and the structurally related inhibin protein. This phenomenon appears to be
important as the dominant follicle undergoes the folliculo-luteal transition into the corpus
luteum, until in the late-luteal phase when activin levels begin to rise again.
Adapted from (Knight and Glister, 2001)
Although initially characterised for their ability to regulate FSH secretion, activins are
have been found to have a diverse range of functions and effects. They have been
characterised in a plethora of physiological systems and found to play integral roles in
many processes ranging from fetal development to the innate immune responses to
reproductive function. Within the ovary, activins are important regulatory molecules that
have a wide range of effects within female reproduction. Activins are also tightly
regulated at many levels. Inhibitors of activin action are present in the ovary along with
activin receptors and the signalling components of the intracellular Smad pathway. This
review of the literature has focused upon activins and considered the sex steroids
progesterone, testosterone and oestrogen; however another steroid worth consideration
are the glucocorticoids.
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1.7 Glucocorticoid synthesis and regulation
Synthesised in the zona fasciculata of the adrenal cortex in response to
adrenocorticotrophic hormone (ACTH), glucocorticoids are known to exert diverse
actions throughout the body. Produced from a cholesterol precursor in the same manner
as described in the 'two-cell, two-gonadotrophin' model of oestrogen synthesis (Figure
1.5), progesterone and 17a hydroxyprogesterone are converted to mineralocorticoids and
glucocorticoids via the 21 hydroxylase and 1 lphydroxylase enzymes (Figure 1.13). Most
studies confer that there is no 21 hydroxylase enzyme in the ovary, however a recent study
reports for the first time that this enzyme is indeed localised to the luteinised granulosa
cells from macaque and increases following an ovulatory synthesis (Fru et al., 2006).
Uphydroxylase 2
21 hydroxylase Uphydroxylase 1
11PHSD2
11PHSD1
Figure 1.13 A model of mineralocorticoid (aldosterone) and glucocorticoid
(cortisone/cortisol) synthesis. Progesterone and its metabolite 17a hydroxy progesterone
are catalysed to 11 -deoxycorticosterone and 11 -deoxycortisol respectively by
21 hydroxylase. The enzyme 1 lphydroxylase 1 is responsible for the conversion to
corticosterone and Cortisol whilst the lipHSD enzymes regulate metabolism between
Cortisol and cortisone.
Glucocorticoids (Cortisol and cortisone) have been documented to have an array of
physiological roles including regulation of carbohydrate and amino acid metabolism,
maintenance of blood pressure, and modulation of stress and inflammatory responses
(Munck and Naray-Fejes-Toth, 1992; Tomlinson et al., 2004). Cortisol is the
predominant circulating glucocorticoid in humans and is tightly controlled at various
molecular levels. The majority of circulating Cortisol (more than 90%) is bound to a
Cortisol binding protein (CBP) and other mechanisms such as 11PHSD2 enzyme exist in
Chapter 1 Literature Review 39
order to protect both the mineralocorticoid and glucocorticoid receptor (GR) from
excessive active Cortisol.
1.7.1 11 p hydroxysteroid dehydrogenase enzyme
At the tissue level, the lipHSD isoforms act to regulate the local bioavailability of
glucocorticoids. The lipHSD isoforms, namely I lpHSDl and 11PHSD2 are
biochemically distinct isoforms encoded by separate genes and share little homology
(<15%) in their primary sequence (Albiston et al., 1994; Michael et al., 2003). Both
isoforms are members of the short chain alcohol dehydrogenase superfamily that also
include other mammalian and bacterial HSD enzymes (Michael et al., 2003). Type 1
lipHSD functions as either has a dimer or tetramer to predominantly convert inactive
cortisone, by nicotinamide-adenine dinucleotide phosphate (NADPH)-dependent
reduction, into the active form of Cortisol (Figure 1.14). Although lipHSDl is
bidirectional and can subsequently inactivate glucocorticoids, this direction of conversion
is dependent upon the NADPH state of the cell, which in steroidogenic tissue such as the
ovary and testis is reported to favour lipHSDl activity (Michael et al., 2003). Type 2
lipHSD however is a nicotinamide-adenine dinucleotide (NAD+) dependent
unidirectional enzyme that works to inactivate glucocorticoids (Albiston et al., 1994).
This shuttle system of glucocorticoid activation/inactivation operates to control the access
of active glucocorticoids to GR.
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Figure 1.14 The 11(3HSD enzymes exist in two isoforms. Interconversion of Cortisol and
cortisone occurs by oxidation or reduction at carbon position 11. The 11(3HSD1 isoform
acts predominantly as an NADP(H)-dependent reductase to generate active Cortisol whilst
1 lpHSD2 is a high affinity NAD+ -dependent enzyme that catalyses the inactivation of
glucocorticoids. This is often referred to as the glucocorticoid shuttle as these enzymes
essentially catalyse glucocorticoid activation and inactivation.
(Michael et al., 2003)
1.7.2 The glucocorticoid receptor
Glucocorticoids elicit their responses via GR encoded by a 10 exon gene which is ligand
induced transcription factor, that is member of the nuclear receptor superfamily (Duma et
al., 2006). Inactive GR is located in the cell cytoplasm as a hetero-oligomeric complex
containing chaperone proteins such as heat shock proteins (HSP) and others. When the
glucocorticoid ligands bind, GR undergoes a conformational change such that the
chaperones dissociate and nuclear localisation sequences are revealed which enable
translocation of the ligand-receptor complex into the nucleus. The GR is highly
conserved throughout different species (Encio and Detera-Wadleigh, 1991) due to the
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profound influence of glucocorticoids upon development, differentiation and survival.
This is clearly evident in mice which due to a deletion of exon 2, are null for GR and
experience severe abnormalities and die within two hours of birth (Cole et al., 1995).
Alternative splicing of GR gives rise to two receptors, GRa and GR(1 (Hollenberg et al.,
1985). Most work reported on GR has involved the classical receptor, GRa. This
isoform is present is almost all human tissues and cells and functions as ligand-dependent
transcription factor. GR(1 however is expressed in many human tissues and cell but
usually at lower concentrations than GRa (Duma et al., 2006). In addition, unlike GRa
which as previously mentioned is present in either the cytoplasm or nucleus depending
upon ligand availability, GR(! is constitutively localised to the cell nucleus (Duma et al.,
2006). To date, no functional role for GRp has been identified in the ovary, however it
has been localised to fetal trophoblast cells (Gupta et al., 2003) suggesting that it may
potentially be present in other reproductive tissues. Most work investigating a putative
role for this isoform have found that GRP acts as a dominant negative inhibitor of GRa
mediated transcription and may be involved in the regulation of tissue-specific sensitivity
to glucocorticoids in several pathological conditions (Duma et al., 2006; Hammond,
2002; Shetterly et al., 2001). Further work needs to be carried out in order to identify
whether GRp may play a role in reproductive and indeed ovarian function.
1.7.3 Glucocorticoids in the ovary
Much evidence exists to suggest that glucocorticoids have role in the ovary and indeed
during corpora lutea formation. Regardless of whether the ovary itself can synthesise
glucocorticoids, it can most definitely regulate the local environment via the lipHSD
enzymes. The temporal and spatial expressions of both lipHSD isoforms have been
well documented in the ovary many species (Ricketts et al., 1998; Smith et al., 2000;
Tetsuka et al., 1997; Yong et al., 2000). It is well established that during the follicular
phase, in follicles that have not been exposed to the pre-ovulatory LH surge that
1 lpHSD2 is the predominant isoform (Tetsuka et al., 1997). This is an important concept
as too much Cortisol during the follicular phase is reported to disrupt FSH-stimulated
granulosa cell development/function (and presumably oestradiol production) (Hsueh and
Erickson, 1978), that would consequently inhibit successful folliculogenesis.
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After the pre-ovulatory surge there appears to be a switch in llfSHSD isoform, with
lipHSDl becoming the predominant form (Ricketts et al., 1998; Smith et al., 2000;
Tetsuka et al., 1997; Yong et al., 2000). Therefore, as pointed out by Michael et al., it
appears that the type of lipHSD expression (type 1 or type 2 isoform) is dependent upon
the differential state of the granulosa cell (Michael et al., 2003) and results in a net result
of increased Cortisol production as ovulation approaches. One of most characterised roles
of Cortisol in reproduction is during the ovulation process and the resulting folliculo-
luteal transition. This process has been likened to an inflammatory-like process as a
result of the acute haemodynamic, cellular and biochemical changes that occur at the site
of follicle rupture (Espey, 1980; Hillier and Tetsuka, 1998). Many key studies have
clearly shown that the repetitive damage from consecutive ovulations must be quickly
repaired in anticipation for the next ovulatory cycle, and locally produced glucocorticoids
are indeed involved (Gubbay et al., 2005; Rae et al., 2004a; Yong et al., 2002).
Therefore it is a well established that lipHSDl is the predominant isoform after the pre¬
ovulatory LH surge, suggesting that Cortisol levels are relatively high in the developing
corpus luteum. Andersen proposes in his 'free hormone hypothesis' that such high levels
of Cortisol may be vital to reduce or prevent unwanted inflammatory events from taking
place (Andersen, 2002). Much less work however has focused upon a functional role for
Cortisol beyond ovulation and corpora lutea formation, looking at functional role for
glucocorticoids over the functional lifespan of the corpus luteum. There is one exception
however from a study which looked at the pregnant rat corpus luteum. Although
governed by different luteolytic mechanisms than in women, this study elegantly
described a potential role for 11PHSD2 in the regressing corpus luteum (Waddell et al.,
1996).
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1.8 The general scope of this thesis
As discussed, the human corpus luteum is one of the most active endocrine glands in the
body. Not only does it experience extensive tissue and vascular remodelling in a transient
and predictable fashion, it has a steroidogenic output unparalleled to any other tissue.
This thesis reports work on the human corpus luteum utilising both observational and
interventional approaches. The careful collection and precise dating of human corpora
lutea from women in this study provide the opportunity to map the functional and
structural changes that occur over the normal luteal lifespan. Furthermore, unique to our
laboratory is the 'rescued' corpora lutea, which complement the normal luteal phase data.
Collection of rescued tissue from women given daily doubling doses of exogenous hCG
in the mid-luteal phase allows temporal and spatial aspects of maternal recognition of
pregnancy to be studied. This tissue has proved to be indeed an integral aspect of the
present study.
To fully complement the observational studies which utilised human corpora lutea, an
interventional model system was also used. This involved dispersed cultures of human
luteal cells in two distinct forms obtained from women undergoing IVF (in vitro
fertilization) assisted conception programmes. Steroidogenic cells in the form of
luteinised granulosa cells and stromal cells in the form of fibroblast-like cells were also
key tools in this thesis. This in vitro system allowed potential in vivo interactions to be
modelled and further confirmed with the observational human luteal phase material.
Although many investigators work on the corpus luteum, very few of these studies utilise
human models. Therefore careful interpretations of animal data are warranted when
applying findings to human relevance as species differences clearly exist. Furthermore,
this makes the literature sometimes less useful and applicable to the current study. This
thesis investigates paracrine and endocrine influences on human luteal cells in four
experimental chapters. Together, these findings employing both the in vivo and in vitro
models aim to give insights into some of the functional mechanisms that control the
human corpus luteum.
Fundamental to this thesis is the concept that hCG has effects upon cell types in the
corpus luteum that do not express the hCG/LH receptor. Therefore paracrine signalling
molecules must be involved. Chapter 3 sets the scene with the aim of investigating a role
Chapter 1 Literature Review 44
for activin A in the tissue remodelling that is associated with human luteolysis. It became
evident whilst investigating a role for activin A, the regulation of hCG upon activin A,
activin inhibitors and the activin signalling pathway, that hCG had disparate effects upon
other potential effector molecules. Consequently a role for the glucocorticoid Cortisol was
considered with the anticipation that the opposite effects upon tissue remodelling (or
indeed an opposing role) to that of activin A would be evident (Chapter 4). As an
emerging role for activin A was clearly evident during the luteolytic period in the corpus
luteum, it became apparent that activin A may indeed be an anti-luteal molecule that
would therefore have opposing effects to the luteotrophic hCG. This concept was
investigated in relation to many important genes involved in luteinisation and accordingly
forms the crux of Chapter 5. Finally, Chapter 6 explores a potential role for activin B in
the human corpus luteum in order to decipher if this less considered glycoprotein has a
paracrine role as fundamental to corpora lutea regulation as activin A appears today.
Herein this thesis provides novel data that, for the first time, clearly demonstrates that
activin A is an excellent candidate molecule as an important regulator of the human
corpus luteum; one of the major enigmas in human reproductive biology.
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2 General Materials and Methods
2.1 Collection of human material
2.1.1 Ethical Approval
The collection and use of corpora lutea used in this study was approved by the
Reproductive Medicine Sub-Committee of the South East Scotland Medical Ethics
Committee and reapproved by the common reproductive ethics committee (COREC) on
two further occasions. Informed consent was obtained from all patients and their
consultant gynaecologists. The recruitment of patients and the collection of tissue was
initiated and performed by Dr W. Colin Duncan during his Doctor of Medicine under the
supervision of Dr Peter Illingworth.
The Reproductive Medical Subcommittee and subsequently COREC separately approved
the collection of cells from patients undergoing assisted conception at Edinburgh Fertility
and Reproductive Endocrine Centre (EFREC). Informed consent was obtained from all
patients and their consultant gynaecologists, notably Dr K. Joo Thong.
2.1.2 Corpora lutea
Human corpora lutea collected over the past 12 years (Duncan et al., 2005b; Duncan et
al., 1998a) were enucleated at the time of surgery from women with regular menstrual
cycles undergoing hysterectomy for benign conditions and dated on the basis of the
urinary LH surge as described previously (Duncan, 2000; Duncan et al., 1996b). Briefly,
all the women in the study were on the waiting list for hysterectomy at the Royal
Infirmary of Edinburgh and were under the age of 45 years. Healthy women, with regular
menstrual cycles, who had not received any form of hormonal therapy in the last three
months, who did not have a history of infertility, and who were having open abdominal
hysterectomy for benign conditions, were identified.
2.1.2.1 Collection of human corpora lutea
Upon collection at operation, the corpus luteum was quartered to ensure that each quarter
contained all cellular elements. Two quarters were immediately frozen and stored at
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-70°C until RNA extraction was carried out. The remaining tissue was fixed in 10%
neutral buffered formalin for subsequent immunohistochemistry.
2.1.2.2 Dating of human corpora iutea
Women participating in the study were asked to collect urine samples during the days
leading up to their operation so that their normal hormone production could be assessed.
Of all the women who collected urines, 65% had a suitable corpus luteum collected at
surgery. Urine samples were used to measure LH concentrations and the LH surge was
defined as the date of peak urinary LH after standardisation for creatinine concentrations.
The corresponding corpus luteum was not classified into one of the defined stages (and
consequently not used for definitive studies) if there was no LH peak or there was more
than one disparate peak in the urinary samples.
2.1.2.3 Classification of human corpora lutea
Corpora lutea were classified into one of three defined stages. If collected one to five
days after the urinary LH peak (LH+1 to LH+5), corpora lutea were classed as early-
luteal; mid-luteal was days six to ten (LH+6 to LH+10); and late-luteal as days eleven to
fourteen (LH+11 to LH+14). Plasma progesterone concentrations were obtained from
patients and are depicted in Figure 2.1.
2.1.2.4 Addition of exogenous hCG to mimic 'luteal rescue' in patients
In order to research into the establishment of early pregnancy, a regime was set to
administer exogenous hCG to women in the mid-luteal stage of their cycle. Daily
intramuscular injections of hCG were given from LH+7 until operation (5-8 days) with
dosage beginning at 125 IU (LH+7) and doubled daily until 16,000 IU at LH+14.
2.1.2.5 Maintenance and re-establishment of archived human corpora
lutea
In the previous years (roughly 1995-1998) corpora lutea tissue has been readily available
for research purposes from women undergoing surgery for benign conditions. More
recently however, women are able to obtain medical and not surgical therapy for such
cases, and consequently the availability of tissue and indeed corpora lutea has become
scarce. As a result approximately only 4-5 corpora lutea have been collected in the
duration of the present study. During this time, tissue collection has been performed by
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technical staff in Prof Hamish Fraser's laboratory under the guidance/instructions of Dr
W. Colin Duncan. All recently collected tissue is treated in very similar conditions to
that of earlier studies (Duncan et al., 1996a; Duncan et al., 1996b) with the exception of a
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Figure 2.1 Schematic representation of plasma progesterone concentrations in carefully
dated human corpora lutea. Progesterone levels rapidly rise in the early-luteal phase
(LH+1 to LH+5), peak in the mid-luteal phase (LFI+6 to LH+10) and fall in the absence
of pregnancy hormone during the late-luteal stage (LH+11 to LH+14). However, after
luteal 'rescue' progesterone concentrations are maintained and increased from LH+11 to
LH+14.
(Duncan, 2000)
2.1.2.6 Derivation of primary cell culture from patients undergoing
assisted conception programmes
Primary cell culture material was obtained from women undergoing assisted conception
programmes in EFREC at the Royal Infirmary of Edinburgh. Follicular fluid was
collected from women undergoing transvaginal oocyte retrieval for in vitro fertilisation
procedures. Ovarian stimulation was achieved by a long-protocol stimulated cycle which
involved intranasal naferelin (Pharmacia Biotech, Milton Keynes, UK) to down-regulate
pituitary gonadotrophins, followed by daily purified gonadotrophins (Menopur, Ferring
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Pharmaceutical, Langley, UK) for ovarian stimulation. When at least three follicles
reached 18 mm in diameter, 10,000 IU hCG was administered and 35 h later transvaginal
oocyte collection was performed under sonographic guidance. After the removal of the
oocyte, follicular fluid was aspirated from the remaining follicles. Individual follicles
were not distinguished and all follicular fluid from the same patient was pooled. Samples
were stored at 4°C after operations until transfer to the laboratory on the same day.
2.1.3 Luteinised granulosa cells
Collected follicular fluid was carefully transferred into 50 ml centrifuge tubes and spun at
1500 rpm for 10 min. After supernatant was removed, the cellular layer was layered over
a 45% Percoll/serum-free culture medium mixture and centrifuged at 1200 rpm for 30
min in order to pellet blood cells. Luteinised granulosa cells were then visible in the
interface and were carefully pipetted from Percoll solution and placed in a clean 20 ml
centrifuge tube for subsequent washes with sterile phosphate buffered saline (PBS)
(Invitrogen, Paisley UK). Once the cells had lx 10 min wash and at least 3x 3 min
washes, they were resuspended in 1-2 ml (depending on size of pellet) of serum-free
culture medium and viable cells were counted on a haemocytometer using a trypan blue
(Sigma-Aldrich, Dorset UK) exclusion method. Twenty-four well cell culture plates were
precoated with 25 pi ofmatrigel (BD Biosciences, Bedford, MA) diluted 1:1 with serum-
free culture medium before cells were plated. Once the Matrigel had set, each well was
briefly washed with culture medium before plating approximately 100,000 viable cells
per well in 1 ml of serum-free media. Cell were incubated at 37°C in 5% C02 in air for
5-7 days or as otherwise described.
2.1.3.1 Manipulation of hCG in prolonged cultures of luteinised
granulosa cells
In order to mimic the luteal phase in primary cell culture, luteinised granulosa cells were
plated as described above (section 2.1.3) and grown for 12 days. Cells were stimulated
with low dose hCG (1 ng/ml) with LDL (50 mg/1) beginning on day 2 and this was
repeated every 2nd day until day 7 when treatments were replaced with maximal doses of
100 ng/ml hCG/LDL or LDL alone. Cells were analysed after seven days with hCG and
on day 12 in the presence or absence of hCG to mimic the progesterone secretion profile
of late-luteal and luteal rescue stages respectively (Duncan et al., 2005a).
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Figure 2.2 Phase-contrast image of luteinised granulosa cells in primary cell culture.
2.1.4 Fibroblast-like cells
To derive ovarian fibroblast-like cells, collected follicular fluid was carefully transferred
into 50 ml centrifuge tubes and centrifuged at 1500 rpm for 10 min as above. Supernatant
fluid was then removed and the cellular component was resuspended in 5 ml of 10% fetal
bovine serum (FBS) supplemented culture media before being carefully pipetted into a
plastic cell culture flask. Medium was changed weekly and cells were trypsinised
(Sigma) after 2 weeks in order to remove contaminating granulosa cells that were at the
end-stage of their life. Once fibroblast-like cells had reached confluence (Figure 2.3),
usually around 5-7 weeks, they were removed from the flasks using
trypsin/ethylendiaminetetraacetic acid (EDTA) solution and viable cells were counted on
a haemocytometer using a trypan blue exclusion method. Sixty-thousand cells per well
were then plated in 1 ml of FBS culture medium on 24-well plastic cell culture plates and
used for investigation as described in appropriate chapters.
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Figure 2.3 Phase contrast image of fibroblast-like cells in primary cell culture.
2.1.5 Tissue preservation
Upon collection of human corpora lutea, two quarters of the tissue were immediately
frozen and stored at -70 C until RNA extraction was carried out. The remaining tissue
was fixed in 10% neutral buffered formalin.
2.1.6 Tissue fixation
In order to preserve tissue and cell preparations in a life-like manner, fixatives were used
stabilize the morphology and protect them against the rigors of processing and staining
techniques. The fixative used for preparations described in this study was 10% neutral
buffered formalin.
2.1.6.1 Human corpora lutea
Human corpora lutea sections were fixed 10% neutral buffered formalin at the time of
collection and left in solution for 24 h. Tissue was then transferred to 70% ethanol and
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processed for 17.5 h in an automated Leica TP1050 processor (Leica Microsystems,
Milton Keynes, UK). Processed tissue was embedded by hand in liquid paraffin wax and
the cooled wax block was stored at room temperature until required.
2.1.7 Histological analysis of tissue
Gross histological analysis of tissue or cell morphology was performed on hematoxylin
and eosin stained sections. Sections were dewaxed as detailed in section 2.1.9.2 and
immersed in Harris's haematoxylin for 3-5 min which stains nuclei purple. Slides were
then briefly washed in water before being de-differentiated in 1% acid alcohol very
briefly and washed again in water. To allow cell nuclei to 'blue up' sections were placed
in Scott's tap water for up to 1 min before being immersed in Eosin for 30 s for
cytoplasmic staining. Slides were washed in tap water before dehydration and cover
slipping took place as described in section 2.1.9.8.
2.1.8 Protein analysis
2.1.9 Immunohistochemistry
In order for a stain or a particular protein to more readily seen with a microscope, an
antibody can be used to link a cellular antigen specifically to the protein. This technique
is known as immunohistochemistry in tissues and immunocytochemistry in cells. With
the abundance of a variety of offered antibodies and several detection methods available,
optimal conditions for immunohistochemical detection must be determined for individual
situations. Immunohistochemistry was performed as detailed below on sections of human
corpora lutea using standard detection protocols to highlight localisation of protein of
interest.
2.1.9.1 Sectioning
Fixed tissue was routinely processed to paraffin and subsequently embedded in wax
blocks. Prior to sectioning, blocks were chilled on ice to make them more rigid and
easier to cut into 5 pm sections using a Leica microtome (model RM 2135). Cut sections
were floated on a waterbath (Lamb RA, model E/65) pre-set at 45°C in order to flatten
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sections and remove any folds or creases before mounting on poly-L-lysine coated slides
(VWR, Lutterworth, Leics, UK). Sections were then placed in slide racks and dried
overnight in an oven set between 40-60°C.
2.1.9.2 Dewaxing and rehydrating
Sections were deparaffinised in Histoclear (National diagnostics, Hull, UK) at room
temperature for 5 min, x2. Tissue was then rehydrated by immersing in alcohols
beginning at 100% ethanol for 30 s x2, 95% for 30 s, 75% for 30 s before being washed
in tap water.
2.1.9.3 Antigen retrieval
In order to maximise the availability of the tissue antigen to interact with specific
antibodies an antigen retrieval method was employed. In some cases fixatives used to
preserve tissue integrity can mask proteins by over inducing cross-linkings of the tissue
and thus they are no longer recognised by their complimentary antibodies. To overcome
this problem, sections were immersed in a high temperature antigen retrieval method in
2L of citrate buffer, pH 6.0 in a domestic pressure cooker (Tefal, Clypso). Once boiling,
sections were placed into cooker for 5 min of full pressure and left to stand for
approximately 20 min before being cooled under running water.
2.1.9.4 Blocking
Non-specific binding is a common problem encountered during immunohistochemical
localisation. This is usually due to a primary or secondary antibody or other detection
reagents binding non-specifically to molecules other than the desired protein.
2.1.9.4.1 Endogenous peroxidase blocking
Horseradish peroxidase (HRP) amplication was used (see section 2.1.9.6) to catalyse a
colourmetric result for antibody detection and consequently endogenous peroxidase
activity needed to be blocked. Sections were immersed in 3% hydrogen peroxidase in
methanol (30% H202, VWR) for 30 min at room temperature on a rocker after antigen
retrieval. Sections were then washed in water for 5 min.
Chapter 2 General Materials and Methods 53
2.1.9.4.2 Endogenous biotin blocking
As biotin is a co-factor for a number of enzymes within the body and has wide tissue
distribution, blocking of endogenous biotin can be an important step when using
biotinylated secondary reagents (see section 2.1.9.6). Endogenous biotin can be
sequestered by the use of an avidin/biotin kit (Vector Laboratories, Orton Southgate,
UK). Avidin is incubated on sections for 15 min to bind any endogenous biotin and a
subsequent application of biotin for 15 min is added to fill any of the binding sites on the
avidin molecule.
2.1.9.4.3 Non-specific binding of secondary antibody blocking
In order prevent any non-specific binding of secondary antibodies, sections were
incubated in a dilute solution from the species' in which the secondary antibody was
raised in. In the majority of cases a goat or rabbit raised secondary antibody was used
and therefore goat or rabbit serum respectively was used. Animal serum (Diagnostics
Scotland, Edinburgh UK) was diluted 1 in 5 in PBS containing 5% bovine serum albumin
(BSA; Sigma). Sections were removed from water after peroxidase blocking and
carefully dried around tissue section to remove excess liquid. Blocking serum was added
to sections which were incubated in a humidity chamber at room temperature for
approximately 1 h.
2.1.9.5 Primary antibodies
After appropriate serum blocking, slides were gently tapped and carefully wiped around
tissue section to remove serum which was then replaced with a solution of primary
antibody. Primary antibodies were diluted in blocking serum at an optimised
concentration. Slides were incubated overnight in a humidity chamber at 4°C. Negative
control sections were incubated with blocking serum alone as the primary antibody was
omitted to confirm antibody specificity.
2.1.9.6 Secondary antibodies
Once the primary antibody was washed off, the appropriate secondary antibody was
incubated on section in order to amplify the detection of the primary antibody. Secondary
antibodies raised against a species-specific sequence on the primary antibody, labelled
with biotin were diluted 1 in 500 in blocking serum and incubated on sections at room
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temperature for 1 h in a humidity chamber. To amplify antibody signal, sections were
then washed and incubated for 1 h with avidin-biotin HRP complex (ABC-HRP; DAKO)
which takes advantage of the extremely high binding affinity that avidin and biotin have
for each another. ABC-HRP complex was made according to manufacturers' instructions
at least 30 min prior to use.
2.1.9.7 Antigen detection
To localise the desired antigen, liquid 3,3'-diaminobenzidine (DAB; DAKO,
Cambridgeshire UK) was used to generate a colourmetric result. DAB chromagen was
diluted in the provided buffer according to manufacturers' instructions just prior to use.
Once DAB staining was optimised in a positive control section, subsequent sections were
incubated in the reagent for the desired time. Generally this time varied from 30 s to 3
min depending on the primary antibody used. Sections were placed in distilled water in
order to stop the reaction and a colour was generated at the site of the original antigen,
therefore allowing its localisation within the tissue.
2.1.9.8 Hematoxylin & eosin counterstain and mount
Sections were lightly counterstained in Harris's hematoxylin in order to stain nuclear
tissue. Nuclei initially stain a purple colour until washed in water and immersed in
Scott's tap water for 1 min after which they will appear blue. In order to redehydrate the
tissue, sections were immersed in 70% ethanol for 20 s, 85% ethanol for 20 s, 95%
ethanol for 20 s and 100% ethanol for 20 s x2. To prepare sections for mounting they
were then immersed in HistoClear (National diagnostics) for 5 min and cleared in Xylene
for 5 min. Glass coverslips (VWR, Lutterworth, UK) were mounted on sections using the
solvent based glue, Pertex (Cell Path, Hemel Hempstead, UK). Slides were left to dry in
a fume hood until used for light microscopy.
2.1.9.9 Light microscopy
Images were captured using an Olympus Corp. Provis microscope (Olympus Corp.
Optical Co., London, UK) equipped with a Kodak DCS330 camera (Eastman Kodak Co.,
Rochester, NY), stored as a digital file and assembled using Photoshop CS2 (Adobe
Systems Inc. Mountain View, CA).
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2.1.10 Immunofluorescence
Another detection method, and one that allows co-localisation of more than one antigen,
is fluorescent immunohistochemistry. Sections were dewaxed, rehydrated and if
necessary antigen retrieved as previously described (section 2.1.9.3). Sections only
required peroxidase blocking if Tyramide Signal Application (TSA; Perkin-Elmer Life
Sciences, Boston, USA) enhancement was employed as this method involves the use of a
secondary antibody which is conjugated to HRP complex (section 2.1.10.2.3).
2.1.10.1 Primary antibody
After appropriate serum blocking, slides were gently tapped and carefully wiped around
tissue section to remove serum which was then replaced with a solution of primary
antibody. Primary antibodies were diluted in blocking serum at an optimised
concentration. Slides were incubated overnight in a humidity chamber at 4°C. Negative
control sections were incubated with blocking serum alone as the primary antibody was
omitted to confirm antibody specificity.
2.1.10.2 Secondary antibody
Sections were washed in PBS after primary antibody incubations and the appropriate
secondary antibody was added for 1 hr. Fluorescent chromagens are light sensitive and,
once added, slides were protected from the light to prevent bleaching of the signal.
2.1.10.2.1 Direct method
Dectection with an Alexa fluorescent dye was a single-step process whereby sections
could be incubated with the secondary antibody that is directly conjugated to a
fluorescent chromagen.
2.1.10.2.2 Indirect method
This method was a two-step process that allowed amplification of immunofluorescence
via a biotin labelled secondary antibody. Sections were incubated with a biotin labelled
secondary antibody that was raised against a species-specific sequence on the arm of the
primary antibody. The signal was amplified and detected using a fluorescently labelled
avidin or strepavidin complex which binds to the biotin of the previous antibody.
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2.1.10.2.3Tyramide enhancement method
The tyramide Cy3 (TSA plus cyanine 3 system; Perkin-Elmer Life Sciences) was used in
order to amplify a primary antibody signal diluted 1 in 50 in the supplied buffer. This
detection method significantly increases the sensitivity of the primary antibody without
increasing the resolution or background staining.
2.1.10.3 Counterstain and mount
For labelling of nucleic acids sections were incubated in either To-Pro 3 (Molecular
Probes, Invitrogen) as indicated in appropriate chapter. To-Pro results in nuclear-specific
stains of blue. After nuclear stain sections were washed in PBS and mounted in
Permafluor aqueous mounting media (Beckman Coulter, High Wycombe, UK).
2.1.10.4 Fluorescent Microscopy
Fluorescent images were captured using an LSM 510 Axiovert 100M confocal
microscope (Carl Zeiss Ltd., Welwyn Garden City, UK). Images were compiled using
Photoshop CS2 (Adobe Systems Inc.).
2.1.11 Gelatine Zymography
2.1.11.1 Freeze drying of collected cell culture medium
Cell culture medium was collected from serum-free cultures and subsequently frozen at
-20°C. Aliquots of 200 pi were subjected to freeze drying for 2-3 h until they resembled
a powder and then reconstituted in 20 pi of sterile dH20.
2.1.11.2 Preparation of polyacrylamide gels containing gelatine
Gelatine zymography was prepared and run with a BioRad mini PROTEAN 3 (BioRad,
Hercules, CA, USA). Sodium dodecyl sulfate (SDS) gels were prepared in two parts; a
resolving lower gel that contained 10 mg/ml gelatine (w/vol) and 0.1% SDS and a 0.1%
SDS upper stacking gel that contained the loading wells. Once the resolving gel was
poured between the glass apparatus, a thin layer of water saturated sec-butanol
(1:1vol/vol) was carefully overlayed to prevent bubbles and level up the top of the gel.
The resolving gel was then left to set at room temperature for 45 min before the stacking
gel was poured on and left to set at room temperature for 90 min.
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2.1.11.3 Gel Electrophoresis
One microlitre of reconstituted sample was added to sample buffer and gels were run in
lx SDS buffer at 100 V for 1.5 h. A molecular weight marker (Perfect Protein Marker,
Novagen, WI, USA) was used to identify protein size and an internal control was used in
every zymography performed to ensure gel compatibility. Gels were then incubated in
2.5% Triton X-100 for 45 min after electrophoretic protein separation washed in tris-
buffered saline (TBS) wash buffer and incubated overnight at 37°C in digestion buffer to
facilitate enzymatic activity.
2.1.11.4 Identification of gelatinase activity
Once digestion incubation was complete, gels were briefly washed and immersed in a
acetic acid/methanol solution containing 0.5% (wt/vol) Coomassie brilliant blue for 1 h.
Gels were then detained using the same solution minus the Coomassie dye for 30 min or
as long as it took for the white bands to appear which reflect the MMP-2 activity. Gels
were stored in water until analysed by transmission densitometry (G-700 densitometre;




RNA was extracted using two different methods throughout this study. Tri-Reagent
(Sigma) RNA extraction methods were employed for archival corpora lutea that had been
extracted before the current study. Additionally, RNA extracted from primary cell
culture in Chapter 3 also extracted using Tri-Reagent. Alternatively, RNA extractions
performed in all remaining chapters and from archival frozen corpora lutea was extracted
using RNA Mini extraction kits (Qiagen, Crawley, UK).
2.1.13.1 RNA extraction using Tri-Reagent
Total RNA was extracted from 0.2-0.5g frozen corpora lutea samples or cultured primary
cell using Tri-Reagent according to manufacturers' instructions. For every 1 ml of Tri-
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Reagent, 200 pi of chloroform was added to sample, shaken vigorously and let to stand at
room temperature for 5 min. Samples were centrifuged at 13,000 rpm at 4°C for 20 min
so that the top layer containing the RNA portion could be carefully removed and placed
in a clean tube containing 500 pi isopropanol. Samples were gently mixed and left on ice
at 4°C for 1 h and centrifuged at 13,000 rpm at 4°C for 15 min. With a pellet now
visible, isopropanol was carefully removed and replaced with 500 pi of 70% ethanol,
vortexed and centrifuged at 13,000 for 10 min at 4°C. In order to resuspend pellet in
nuclease free water, ethanol was removed and pellet was left for 5 min to dry. Generally
cell preparations were resuspended in 10 pi of nuclease free water whereas tissue material
was resuspended in greater volumes.
2.1.13.2 RNA extraction using RNeasy Mini extraction kits
Non-extracted archival and more recently collected human corpora lutea, along with
cultured primary cell RNA was extracted using Qiagen RNeasy Mini kits (Qiagen).
Frozen archival corpora lutea was thawed in enough RNA later solution (Qiagen) to cover
tissue in order to prevent degradation before being immersed in lysis buffer supplemented
with 10 pl/ml P-mercaptoethanol. Tissue was then homogenised (Qiagen Tissue Lyser)
for 2x 3 min at 30 Hz before proteinase K (Qiagen) digestion step at 55°C for 10 min.
Cultured cell isolations were not subjected to these steps and once cells were harvested in
lysis buffer/ P-mercaptoethanol solution they were vortexed and stored at -70°C until
extraction took place.
From this step onwards extraction protocol for tissue and cells was the same.
Suspensions were diluted with an equal volume of 70% ethanol and applied to the mini
columns supplied in kit. Columns were washed with supplied buffers and treated with
DNase solution to remove any contaminating genomic DNA. DNase was then
inactivated by and removed with washing buffers before elution buffers were used. RNA
was eluted twice from columns with 30 pi of RNase-free water.
2.1.14 RNA quantification
2.1.14.1 RNA quantification using the NanoDrop ND-1000
RNA was quantified using the NanoDrop ND-1000 Spectrophometer (NanoDrop
Technologies, Wilmington, USA) which calculates the RNA concentration according to
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the absorbance measured at 260 nm. The integrity of the RNA could also be determined
using the 260/280 nm ratio with a ratio of 1.8-2 indicating the best quality.
2.1.14.2 RNA quantification using the Agilent 2100 Bioanalyser
To double check the integrity of RNA (especially important regarding archival tissue) the
Agilent 2100 Bioanalyser (Agilent Technologies,) was used in conjunction with a RNA
6000 Nano chip. Unlike the NanoDrop method this method displays the ratio of intact
ribosomal RNA peaks (18S/28S) to measure the RNA concentration and integrity.
2.1.15 DNase treatment
RNA that had not been extracted using the Qiagen Mini kits was subjected to DNase
treatment using a Promega (Southampton, UK) protocol mix displayed in Table 2.1.
RNA was incubated in a digestion solution to inactivate any contaminating DNA at 37°C
for 30 min before a stop solution was added to samples to terminate the reaction.
Samples were then incubated at 70°C for 10 min to inactivate the DNase before being
reverse transcribed. Negative controls were included with nuclease-free water substituted




DNase lOx Buffer 1 pi
RNase Inhibitor 0.1 pi
DNase enzyme (1 unit/pl) 1 u/pg RNA
Nuclease-free water to a final vol of 10 pi
2.1.16 Reverse transcription
Reverse transcription (RT) was performed under carefully controlled conditions using a
Taqman Reverse Transcription kit with random hexamers (Applied Biosystems,
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Warrington, UK). A mastermix of the reagents was prepared for the desired number of
reactions and are shown below in Table 2.2.
Table 2.2 Reagents used for reverse transcription reaction
Mix reagents lx
Nuclease-free water 1.85 pi
lOx Taqman buffer 1.0 pi
MgCl2 (25 mM) 2.2 pi
dNTPs (10 mM) 2.0 pi
Random Hexamers 0.5 pi
RNase Inhibitor 0.2 pi
Multiscribe reverse transcriptase 0.25 plxn-0.25
Before the multiscribe enzyme was added to the reaction mixture, 7.75 pi of the
mastermix was removed and used as a negative RT control. Therefore the volume of
enzyme required was 0.25 pi x the number of reactions (n) -0.25 pi. The mastermix was
vortexed and 8 pi aliquots for single reactions or 16 pi aliquots for double reactions were
placed in 0.2 ml Eppendorf tubes followed by 2 pi or 4 pi of RNA respectively. A RT
H20 water negative was also included and the appropriate volume of nuclease-free water
was added in place of RNA. The reverse transcription reaction took place in a
Thermocycle Eppendorf polymerase chain reaction (PCR) machine at the following
temperature cycles; 25°C for 1 h (incubation), 48°C for 45 min (reverse transcription
step) and 95°C for 15 min (denaturing step).
2.1.17 Primer design and validation for semi-quantitative and quantitative
RT-PCR
Oligonucleotide primers for genes investigated using conventional PCR or Lightcyling
quantitative RT-PCR (qRT-PCR) were designed using the Primer 3 software
fhttp://primer3.sourceforge.net/) from DNA sequences obtained from GenBank
(http://www.nchi.nlm.nih.gov/sites/entrez). Primers were synthesised by either MWG-
AG Biotech (Milton Keynes, UK) or Eurogentec (Southampton, UK). All 5' to 3'
sequences are listed in appropriate chapters. Primer probe sets used for qRT-PCR
Taqman analysis were either designed using Primer Express (Applied Biosystems)
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program or obtained from previous publications, sequences verified using GenBank and




Amplifaction of cDNA was carried out using Taq DNA polymerase (Promega) using the
mastermix reaction listed in Table 2.3.
Table 2.3 Reaction mixture for cDNA amplification
Mix reagents lx
Nuclease-free water 4.7 pi
lOx buffer 1.0 pi
MgC12 (25 mM) 0.6 pi
dNTPs (10 mM) 0.2 pi
Forward primer (5 pM) 1.0 pi
Reverse primer (5 pM) 1.0 pi
Taq polymerase (5 u/pl) 0.5 pi
Once all the mix reagents were combined, vortexed and aliquoted into 0.2 ml Eppendorf
tubes, 1 pi of appropriate cDNA was added to each tube to make a final volume of 10 pi
for each reaction. Negative controls were exactly the same as sample tubes with
nuclease-free water in place of cDNA sample. PCR conditions using a Thermocycle
Eppendorf PCR machine were as follows; incubation 95°C for 5 min, 35 cycles of 95°C
for 30 sec, appropriate annealling temperature (primer dependent) for 30 sec, and 72°C
for 90 sec, followed by 72°C for 10 min. Appropriate theoretical annealing temperatures
(Tm) were calculated for each set of primers using the formula;
Tm= 2°C x (number of A and T residues) + 4°C x (number of G and C residues) -5°C
2.1.18.2 Gel electrophoresis
PCR products were separated by size fractions using gel electrophoresis in the presence
of ethidium bromide. PCR products were mixed with a 5x loading dye in a 1:5 ratio
before being loaded into a 2% agarose gel (2.4 g agarose, 120 ml lx tris-acetae-EDTA
(TAE) buffer, 2 pi ethidium bromide) in lx TAE. Product sizes were verified using a
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100-base pair ladder which acts as a reference size marker. Electrophoresis was run at
110 V for 1 h and visualised and photographed under UV transillumination.
2.1.19 Quantitative PCR
Two methods were used in the current study to quantify gene expression of human
corpora lutea and cultured cells.
2.1.19.1 Light cycling qRT-PCR
Each light cycling assay was optimised using placental cDNA to determine annealling
temperature and MgCl2 concentrations favourable for each gene of interest. Eight PCR
reactions were performed as explained above in section 2.1.18.1 using the gradient
facility of the PCR cycler to demonstrate the effectiveness at annealing temperatures.
PCR products were examined by gel electrophoresis as detailed in section 2.1.18.2 to
confirm the presence of a single band at the correct size (products for light cycling
usually range from 150-200 bp). Optimal MgCl2 concentrations were determined on the
Roche LightCycler machine (Roche, Lewes, UK) with test range from 3-5 mM
concentrations. A melting curve analysis was also used to determine the optimal
temperature that would be used to quantify the level of gene expression by minimising
background fluorescence from non-specifically amplified DNA. Therefore all assays had
to demonstrate a single specific melting curve peak in order to be considered for
subsequent analysis.
A standard curve was generated with serial dilutions of standardised cDNA using the
second derivative maximum method provided with the LightCycler software (version
3.3). Reaction mixtures were set up using the Mastermix supplied with the LightCycler
Fast StartNDAMaster SYBR Green 1 kit (Roche) utilising the predetermined optimal
conditions. Reaction mixures are shown in Table 2.4. All reactions were performed in 10
pi volume duplicates. All runs had negative controls whereby nuclease-free water was
substituted for cDNA.
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Table 2.4 Reaction mixture for LightCycler qRT-PCR
Mix reagents lx
SybrGreen mastermix 1 pi
Forward primer 1 pi
Reverse primer 1 pi
MgCl2 (3-5 mM) 2 pi (up to)
cDNA 1 pi
Nuclease-free water 4 pi (up to)
Concentrations for each gene of interest were automatically calculated using the computer
software which compares the sample threshold crossing point reference to the
simultaneously generated standard curve. Ideally, the level of each gene expression
should lay within the boundaries of the corresponding standard curve. Variation for each
assay was typically within 10% and the same placental cDNA sample was used for
corresponding assays. All data was normalised according to the gene expression levels of
glucose-6-phosphate dehydrogenase (G6PDH) determined in duplicate by reference to a
serial dilution calibration curve that was generated for each sample using the LightCycler
software.
2.1.19.2 Taqman ® qRT-PCR
Unlike the Lightcycler qRT-PCR method, Taqman involves an oligonucleotide probe in
addition to the forward and reverse primer sequences. The Taqman probe which has a
fluorescent reporter dye attached to the 5'-end and a quencher moiety coupled to the 3'-
end is carefully designed to hybridise to an internal region of the PCR product.
When the probe is intact, no fluorescence is omitted as the reporter dye emission is
quenched. However, during the PCR reaction in the presence of DNA polymerase the
probe is cleaved, and once separated from the quencher, the reporter dye emits
fluorescence. Therefore, the emission of fluorescence will increase in proportion to the
number of cycles.
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Table 2.5 Reaction mixture for Taqman qRT-PCR
Mix reagents lx
Taqman Universal mastermix 12.5 pi
18S primer/probe 0.375 pi
Forward primer 0.3 pi
Reverse primer 0.3 pi
Nuclease-free water 8.525 pi
Gene probe 1.0 pi
The mix listed above in Table 2.5 was vortexed well, aliquoted into 46 pi volumes per
tube before 4 pi of cDNA was added to each. Tubes were mixed again and 23 pi portions
were added in duplicates to 96-well optical reaction plates. A PCR water control and an
RT-negative control were set up by replacing the cDNA with 4 pi of nuclease-free water
and 4 pi of RT-negative sample respectively. Plates were sealed with optical film and run
out on the ABIPRISM® 7900 heat-cycler system. PCR cycles were in four stages; 50°C
for 2 min, 95°C for 10 min, 95°C for 15 min (40 cycles) and 59°C for 1 min.
Data was analysed using the ABIPRISM® 7900 software and calculate using the
comparative Ct (2~AACt) method which calculates the changes in gene expression as a
relative fold difference between experimental and calibrator sample.
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2.1.20 Commonly used solutions
2.1.21 Cell culture solutions
ITS Serum-free Culture Medium
Insulin (6.25 mg/1), transferrin
(6.25 mg/1), selenious acid (6.25
M-g/l) (ITS)
5 ml
Amphoteracin (2.5 mg/1) 5 ml
Penicillin (50 mg/ml) 5 ml




10% Fetal Bovine Serum (FBS) Culture Medium
10% FBS 50ml
Amphoteracin (2.5 mg/1) 5 ml
Penicillin (50 mg/ml) 5 ml




0.1% BSA in PBS
0.1% w/v BSA 5 mg
PBS 5 ml
Matrigel Basement Membrane Matrix
50% v/v matrigel 400 pi
ITS culture medium 400 pi
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2.1.22 Immunohistochemistry Buffers
PBS










Water up to 10 L
2.1.23 Gelatin zymography
2.1.23.1 Acrylamide gels
Resolving gel (recipe for 2 gels)
Water 3.85 ml
Gelatin (10 mg/ml water) 1.0 ml
Resolving gel buffer 2.5 ml
10% SDS 100 pi
10% Ammonium Persulfate 50 pi
30% Acrylamide/Bis 2.5 ml
TEMED 5 pi
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Stacking gel (recipe for 2 gels)
Water 3.05 ml
Stacking gel buffer 1.25 ml
10% SDS 50 gl
10% Ammonium Persulfate 50 pi




20% v/v Glycerol 10 ml
2% w/v SDS lg
0.04% w/v Bromophenol Blue 20 mg
Water 50 ml
Running Tank Buffer xlO (pH 8.3)
0.25 M Tris 30.3 g
1.9 M Glycine 144 g
1% SDS 10 g
Water up to 1 L
Resolving Gel Buffer (pH 8.8)
1.5 M Tris 18.3 g
Water 100 ml
Stacking Gel Buffer (pH 6.8)
0.5 M Tris 6.06 g
Water 100 ml
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Stock Wash Buffer xlO (pH 8.0)
0.5 M Tris 60.57 g
1.5 M NaCl 90 g
Water 1L
Triton X-100 Wash
2.5% Triton X-100 5 ml
XI TBS 200 ml
Digestion Buffer (pH 7.6)
50 mM Tris 6.07 g
0.2 M NaCl 11.69 g
5 mM CaC12 735 mg
1 pM ZnC12 1 ml of 1 mM sol
0.02% Brij-35 (30% sol) 660 pi
Water up to 1 L
Destaining Solution
30% Methanol 300 ml
10% Glacial Acetic Acid 100 ml
Water 600 ml
Staining Solution
0.5% w/v Coomassie Brilliant Blue lg
Destaining Solution 200 ml
Sodium Dodecyl Sulphate (SDS)
10% w/v SDS 10 g
Water 100 ml
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Gelatin
10 mg/ml w/v Gelatin 0.25 g
Water 25ml
Ammonium Persulfate
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3 In vitro evidence suggests activin A may promote tissue













Activin A is a dimeric glycoprotein that is maximal during the late-luteal phase in the
peripheral semm of naturally cycling women. Interestingly, these high concentrations of
activin A correlate with the time when MMP-2 is also at the peak of its activity. MMP-2
is an important molecule associated with luteolysis not only in women, but in many other
species. Therefore, the focus of this chapter is to determine if activin A is paracrine
regulator of the tissue remodelling associated with luteolysis.
(Peripheral semm concentrations in naturally cycling women from Muttukrishna et ai, 1996)
ANOVA: t* = 0.02
i *—-Jl * 1 I I * II *
I
Follicular phase ovulation Luteal phase
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3.1 Introduction
The human corpus luteum is a highly vascular and active endocrine gland that in the mid-
luteal phase measures up to 2 cm in diameter. However, unless hCG is secreted by a
conceptus, this highly transient structure will undergo functional and structural luteolysis,
(Behrman et al., 1993) becoming a small fibrous remnant within a matter of days. The
process of luteolysis is associated with marked tissue remodelling and vascular
involution. Cellular processes that are known to occur during the regression of the human
corpus luteum include cell death (Fraser et al., 1999), an increase in the expression of
connective tissue growth factor (CTGF) (Duncan et al., 2005b), an influx of macrophages
(Duncan et al., 1998b) and an up-regulation of fibroblast MMP-2 expression and activity
(Duncan et al., 1998a).
MMPs are key proteolytic enzymes involved in the degradation of the ECM, which is
constantly remodeled during luteolysis. Much evidence exists to suggest that MMP-2 is
an important luteolytic agent during the demise of the corpus luteum. In rats, structural
luteolysis was associated with an increase in MMP-2 activity (Endo et al., 1993) whilst in
pigs the expression of MMP-2 was elevated in the regressing corpus luteum (Pitzel et al.,
2000). Additionally, primates (Young et al., 2002) and humans (Duncan et al., 1998a)
show maximal MMP-2 expression in the late-luteal phase, positively correlating with the
functional and structural regression of the corpus luteum. Furthermore hCG during
maternal recognition of pregnancy in women (Duncan et al., 1998a) reduces the
expression of MMP-2. As MMP-2 is up-regulated during luteolysis, and conversely
inhibited in the presence of hCG during maternal recognition of pregnancy, it is likely
that it has an important role in the luteolytic process.
The primary source of MMP-2 in the human corpus luteum is the luteal fibroblasts that do
not express LH/hCG receptors (Duncan et al., 1998a), suggesting that there is a paracrine
regulator of MMP-2 expression (Duncan, 2000). Therefore the present study
hypothesised that in the corpus luteum, MMP-2 is regulated by hCG through an
intermediate molecule. Unlike LH, FSH, progesterone, oestradiol or inhibin A, the
concentrations of activin A in serum are maximal during the late-luteal phase
(Muttukrishna et al., 1996), suggesting it may have a positive luteolytic action. Activins
and other members of the TGF-P superfamily are known to control many diverse
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physiological processes (Massague, 1998), therefore in this study it was hypothesised that
activin A may be a critical intermediate signalling molecule in the human corpus luteum.
As described previously (Duncan et al., 1996a; Duncan et al., 1998a; Duncan et al.,
1998b), this laboratory has developed a system for the collection of carefully dated
human corpora lutea and more recently (Duncan et al., 2005b) a primary cell culture
system using human luteinised granulosa cells and/or novel cultures of fibroblasts-like
cells derived from the luteinising follicle. The aim of the current study was to investigate
whether activin A was a paracrine regulator of luteal tissue remodelling by investigating
its effects on MMP-2 expression and activity using in vitro model systems.
3.1.1 Aims
To establish the source of activin A in the human corpus luteum and primary cultures of
luteinised granulosa cells
To establish an activin signalling pathway and subsequent reception in the human corpus
luteum and primary cultures of luteinised granulosa cells
To understand the changes in activin signalling that occur in the human corpus luteum
To establish and characterise an appropriate in vitro model to study the paracrine
interactions that occurs between neighbouring cells in the human corpus luteum
To understand the effects of activin A on the human corpus luteum using the in vitro
system to investigate a potential paracrine signalling role
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3.2 Materials and Methods
3.2.1 Collection of human corpora lutea
Human corpora lutea (n=18) were collected from women with regular menstrual cycles
undergoing hysterectomy for benign conditions and dated on the basis of the urinary LH
surge as fully described in section 2.1.2.2. In this study, six corpora lutea were classified
as early-luteal (LH+1 to LH+5), six as mid-luteal (LH+6 to LH+10), and six as late-luteal
(LH+11 to LH+14).
3.2.2 Isolation of human luteinised granulosa cells and derivation of
fibroblast-like cells
Isolation of luteinised granulosa cells using Percoll gradient centrifugation was carried
out as described in section 2.1.3. Twenty-four well cell culture plates were precoated
with 25 pi ofmatrigel (BD Biosciences) and 100,000 viable cells per well were plated in
lml of serum-free media.
Fibroblast-like cells were obtained from prolonged cultures of follicular aspirates as
described in section 2.1.4 and 60,000 cells per well were plated in 1 ml of 10% FBS
culture medium on 24-well cell culture plates.
3.2.3 Derivation of fibroblast-like cells from human corpora lutea
Corpora lutea collected during surgery were minced in cell culture conditions and placed
in flasks containing 10% fetal bovine serum. Cultures were left to reach confluence and
grown until sufficient numbers of cells (60,000 per well) could be obtained for
experimental procedures described below.
3.2.4 Primary cell culture treatments
For co-culture experiments, approximately 60,000 fibroblast-like cells were added to the
wells containing approximately 100,000 luteinised granulosa cells after culture for 5-7
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days in serum-free medium. Each pooled experiment for the following treatments was
carried out at least 3 times to avoid biological bias.
3.2.4.1 Treatment of fibroblast-like cells with activin A and inhibin A
Cultures of fibroblast-like cells were plated as above and after 6 hours in serum-free
culture, the medium was removed and replaced with medium containing either
recombinant activin A (R&D Systems, Inc., Abingdon, UK), recombinant inhibin A
(NIBSC, Hertfordshire, UK) or an equivalent amount of 0.1% BSA in carrier as a control.
After 24 h the culture medium was collected for subsequent zymography and the cells
were used for mRNA extraction.
3.2.4.2 Acute hCG treatments in luteinised granulosa cells and co-
culture experiments
Pooled luteinised granulosa cells were cultured for 6-8 days with the medium changed
every 2-3 days over the course of the culture period. A maximal stimulating dose of hCG
(Serono; 100 ng/ml and control) was added. After 24 h medium and cells were stored for
subsequent analysis and mRNA extraction.
After 24 h in serum-free media, co-culture cells had fresh serum-free medium added
containing either hCG (100 ng/ml and control) or follistatin (R&D Systems; 500 ng/ml
and 0.1% BSA control). Follistatin treatments were within physiological levels (100-600
ng/ml) of that previously reported in human follicular fluid (Khoury et al., 1995). Each
control contained the carrier solution equivalent to highest concentration added. After 24
h, mRNA was extracted from co-cultures, and controls consisting of fibroblasts only.
3.2.5 Preparation of cDNA from corpora lutea and cultured cells and
primer design
Messenger RNA was batch extracted from both frozen human corpora lutea and cultured
cells, and reverse transcribed into cDNA using random hexamers as described in section
2.1.16. Oligonucleotide PCR primers for each gene investigated were designed using
Primer3 software (www.genome.wi.mit.edu/cgibin/primer/primer3.www.cgi) from DNA
sequences obtained from GenBank (www.ncbi.nlm.nih.gov). Primers were synthesised by
MWG AG Biotech and the 5'to 3' sequences used in this study are listed in Table 3.1.
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PCR conditions were as follows; incubation 95°C for 5 min, 35 cycles of 95°C for 30 sec,
appropriate annealling temperature (see Table 3.1) for 30 sec, and 72°C for 90 sec,
followed by 72 °C for 10 min. PCR products were separated and viewed as described in
section 2.1.18.2.








MMP-2 ATGACAGCTGCACCACTGAG ATTTGTTGCCCAGGAAAGTG 61
G6PDH CGGAAACGGTCGTACACTTC CCGACTGATGGAAGGCATC 62
Inhibin a CCAGCTGTGAGGACAAGTCA CTAGCAGGGGCTCAGAGCTA 56
PA AGACGCTGCACTTCGAGATT CCCTTTAAGCCCACTTCCTC 56
Follistatin CAGTAAGTCGGATGAGCCTGTCT CCTGGTCTTCATCTTCCTCCTCCT 69
P-glycan CTGTTCACCCGACCTGAAAT CGTCAGGAGGCACACACT TA 67
ActRIIA TTTCCGGAGATGGAAGTCAC GTCCTGGGTCTTGAGTTGGA 54
Alk 2 AAGGCAGGTATGGTGAGGTG ACCACAGCTGGGTACTGGAG 55
Alk 4 GAGATTGTGGGCACTCAAGGG AGCTGGGACAGAGAGTCTTCTTG 60
Smad 2 CTGGGATGGAAGAAGTCAGC CAGTCCCCAAATTTCAGAGC 55
Smad 3 TGAGGCTGTCTACCAGTTGACC CCGCTGTTCCAGTGTGTCTTAG 57
Smad 4 GATTGCAGACCCACAACCTT CTAGGAGCAAGGCAGCAAAC 54
3.2.6 Quantitative analysis of gene expression by RT-PCR
Each assay was optimised using PCR amplification of human placental cDNA. The
assays were optimised for MgCl2 concentrations and annealling temperatures. PCR
amplifications were performed using Thermostart Taq (AB Gene) in a DNA Engine
gradient cycler (MJ Research, Inc.,Watertown, MA) as described in section 2.1.19.1.
Data were normalised according to the expression level of G6PDH, determined in
duplicate by reference to a serial dilution calibration curve generated for each sample
using the standard LightCycler software.
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3.2.7 Gelatin zymography
Gelatin zymography was performed on the culture medium from activin A and inhibin A
treated fibroblast-like cell cultures as described in section 2.1.11.
3.2.8 Measurement of inhibin A and activin A
Inhibin concentrations in culture medium collected from luteinised granulosa cells were
measured using a plate modification of a standard in-house inhibin A radioimmunoassay
kindly performed by Ian Swanson (MRC, HRSU Edinburgh). The sensitivity of this
assay was 2 pg/ml and was carried out as previously described (Groome et al., 1994).
Activin A concentrations were measured using a two-site ELISA kit that measured total
activin A (Knight et al., 1996) (Oxford Bio-Innovation, Oxfordshire, UK), following the
manufacturer's instructions. This assay had a sensitivity of <78 pg/ml and inter and intra-
plate coefficients of variation of <10%.
3.2.9 Immunohistochemistry
Immunolocalisation was carried out using antibodies recognising phosphorylated Smad
2/3 (New England Biolabs, Hertfordshire, UK), activin (3A subunit (concentration
4.3pg/ml, kindly provided by Prof. N. Groome, Oxford Brookes University, Oxford,
UK), ActRIIA and ALK4 (kindly provided by R. Heldin, Ludwig Institute for Cancer
Research, Uppsala, Sweden) in 5 pm paraffin tissue sections of human corpora lutea
prepared on poly-L-lysine-coated microscope slides. These sections were dewaxed,
rehydrated and washed in TBS/0.1% Tween-20 and TBS respectively. Sections for
phosphorylated Smad 2/3 were subjected to antigen retrieval as described in section
2.1.9.3. All sections were washed and placed in 3% H202/methanol as described in
section 2.1.9.4.1.
As described in section 2.1.9.4.3 normal goat serum (NGS) diluted 1:5 in TBS containing
5% BSA (NGS/TBS/BSA) was added to phosphorylated Smad 2/3, ActRIIA and ALK4
sections, while |3A sections were blocked in normal rabbit serum (NRS, Diagnostics
Scotland) 1:5 in TBS for 1 h at room temperature. Primary antibodies were diluted in
respective blocking solutions and incubated on sections overnight at 4°C (phosphorylated
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Smad 2/3; 1:1000, PA; 1:500, ActRILA; 1:400, ALK4; 1:400). Sections were washed and
incubated with secondary antibodies [phosphorylated Smad 2/3, ActRIIA and ALK4;
biotinylated goat antirabbit IgG diluted 1:500 in NGS/TBS/BSA. (1A; rabbit antimouse
diluted 1:25 in TBS (DAKO)] for 1 h.
Phosphorylated smad 2/3, ActRIIA and ALK4 sections were incubated in avidin-biotin
complex-HRP (DAKO) for 1 h, and PA sections were incubated in mouse peroxidase
anti-peroxidase (PAP; DAKO) diluted 1:100 in PBS. Incubations were at room
temperature for 1 h and all sections were washed in TBS (2x5 min) and bound
antibodies visualised by incubation with liquid DAB (DAKO) as described in section
2.1.9.7. Sections were counterstained lightly with hematoxylin to enable cell
identification. Negative controls for each antibody examined were performed identically
to the above protocol with primary antibody incubations substituted with blocking serum.
3.2.10 Double fluorescent immunohistochemistry
Sections were washed, subjected to antigen retrieval, and blocked as described above.
Negative controls were performed as above. Washes detailed below were for 5 min each,
and incubations were at room temperature unless otherwise specified. Rabbit anti-
phosphorylated Smad 2/3 was diluted 1 in 100 in NGS/TBS/BSA and incubated on
sections overnight at 4°C. Sections were washed, incubated with goat anti-rabbit IgG 488
(DAKO) diluted 1 in 200 in PBS for 1 h then washed in PBS. Sections were re-blocked
with NGS/TBS/BSA for 1 h then incubated with mouse anti-CD31 or mouse anti-CD68
(DAKO) diluted 1 in 20 in NGS/TBS/BSA overnight at 4°C. Sections were washed,
incubated with biotinylated goat antimouse IgG (DAKO) diluted 1 in 500 in
NGS/TBS/BSA for 30 min and then washed in TBS.
The fluorochrome streptavidin 546 Alexafluor (Molecular Probes) diluted 1 in 200 in
PBS was incubated on slides for 1 h. For the labelling of nucleic acids, sections were
counterstained with a nuclear-specific blue fluorescent label (To-Pro 3) as described in
section 2.1.10.3.
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3.2.11 Statistical analysis
Statistical analyses were carried out, after confirmation of normal distributions for
parametric analysis, using a paired t-test when treatment and control samples were
analysed or with an analysis of varience (ANOVA) when more than two treatments were
analysed. Where significant differences were observed (p<0.05) using ANOVA, pairwise
comparisons were carried out using Bonferroni's Multiple Comparisons Test. All
statistical tests are highlighted in the Figure legends and differences are given.
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3.3 Results
3.3.1 MMP-2 and MMP-9 activity in primary cell culture
Matrix metalloproteinase activity was examined in primary cell cultures of luteinised
granulosa cells and fibroblast-like cells using gelatin zymography (Figure 6.1). Primary
cultures of luteinised granulosa cells secreted MMP-9 whilst little MMP-2 activity was
detected. Conversely, and as anticipated, fibroblast-like cells secreted large amounts of







Figure 3.1 Representative gelatin zymogram of primary and co-cultures of luteinised
granulosa cells and fibroblast-like cells. Luteinised granulosa cells (LGC) secreted MMP-
9 and very little MMP-2. Fibroblast-like cells (Fib) secreted only MMP-2 whilst co-
cultures (co-cult) of the two cells types show activity for both zymogens.
3.3.2 The effect of activin A on the expression of MMP-2 in fibroblast-like
cells
MMP-2 activity in primary cell cultures was increased by activin A in a dose dependant
manner (10 - 100 ng/ml, p<0.05, r2=0.55, by linear regression). As intrafollicular
concentrations of activin A have been reported to be in the range of 0.42-26.3 ng/ml
(Fujiwara et al., 2000) the response to physiological concentrations of activin A (10
ng/ml, 25 ng/ml) were investigated in detail (Figure 3.2). Both MMP-2 expression
(p<0.05, by ANOVA) and activity (p<0.05, ANOVA) were increased when compared to
controls when fibroblast-like cells were exposed to 25 ng/ml for 24 h (Figure 3.2).
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Figure 3.2 Activin A increases MMP-2 in primary cultures of fibroblast-like cells.
Relative MMP-2 mRNA expression, using real-time quantitative RT-PCR, is shown in
solid bars and MMP-2 activity, using gelatin zymography, is shown in open bars. MMP-2
expression (p<0.05, ANOVA) and activity (p<0.05, ANOVA) was significantly increased
in fibroblast-like cells exposed to 25 ng/ml activin A in culture.
Correspondingly the primary cultures of fibroblasts expressed activin receptors (I and II)
and Smad 2, 3 and 4 as well as MMP-2 (Figure 3.3).
500 bp
200 bp
G6 LHR MMP2 Smad2 Smad3 Smad4 ALK2 ALK4 ActRII Bgly
Figure 3.3 Fibroblast-like cells show mRNA expression for housekeeping gene G6PDH
and MMP-2, however they do not express the LHR, indicative the activin action via hCG
mechanisms is under paracrine control. Furthermore the expression of activin receptors
and signalling pathways can be confirmed in these cells. Bands represent 200 and 500 bp
as indicated. G6=G6PDH, LHR=LH receptor, ALK2=activin like-kinase 2,
ALK4=activin like-kinase 4, ActRII=activin receptor II, Bgly=P-glycan.
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It is believed that the effect of activin A on fibroblast-like cells is specific as cells
exposed to inhibin A show no change in MMP-2 production (p>0.05, ANOVA) as




Figure 3.4 Addition of Inhibin A at various concentrations had no effect upon MMP-2
expression in primary cultures of fibroblast-like cells (p>0.05, ANOVA).
Furthermore, pilot studies (n=2 corpora lutea) on fibroblast-like cells obtained from
prolonged cultures of disaggregated human corpora lutea exposed to 25 ng/ml activin A
also demonstrated the same effects on MMP-2 expression (Figure 3.5). It is therefore
likely that activin A could act as a regulator of luteal fibroblast MMP-2 production at
physiological concentrations.
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Figure 3.5 Pilot studies using fibroblast-like cells derived from disaggregating human
corpora lutea (n=2) demonstrate the same effect for MMP-2 expression to increase in the
presence of 25 ng/ml of activin A.
3.3.3 Identification of activin synthesis and action in human corpora lutea
Corpora lutea, at each stage of the luteal phase, have the potential to synthesize activin A,
respond to activin A and inhibit its action as they express mRNA for pA subunit, activin
receptors (I and II), Smad 2 and 3 and the common Smad 4 as well as inhibin a subunit,
betaglycan and follistatin (data not shown). The activin |3A subunit is localised to the LH-
responsive steroidogenic cells of corpora lutea at each stage of the luteal phase (Figure
3.6A). Although activin receptors can be found on luteal steroidogenic cells, it is notable
that luteal fibroblasts, that secrete MMP-2, express both activin receptors I and II (Figure
3.6B,C) and nuclear phosphorylated Smad 2/3 (Figure 3.6D) at each stage of the luteal
phase.
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3.3.4 Change in Smad signalling across the luteal phase
We investigated phosphorylated Smad 2/3 across the luteal phase by
immunohistochemistry (Figure 3.6D-H). Nuclear phosphorylated Smad 2/3 could be
detected at all stages of the luteal phase in both the steroidogenic (granulosa lutein cells
and theca lutein cells (Figure 3.6D)) and stromal cell compartments. Although it was
detected in the fibroblast layer, it was clear that not all cells in this layer immunostained
equally. Therefore phosphorylated Smad 2/3 was co-localised with other cell markers.
Very little phosphorylated Smad 2/3 immunostaining was noted in endothelial cells
(CD31 +ve cells) when compared to neighbouring stromal cells (Figure 3.6) at any stage
of the luteal phase, although low level staining could be noted in some cells of vessels
(Figure 3.6F). In all sections examined, the fibroblast layer contained macrophages
(CD68 +ve cells). Dual immunostaining suggested that there was less phospho-Smad 2/3
immunostaining in the macrophages (Figure 3.6G,H) than the fibroblasts.
N
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Figure 3.6 Immunolocalisation of factors involved in activin/TGF-P signalling in human
corpora lutea. A, Light-field of a late-luteal human corpus luteum showing positive
brown staining of the (3 A-subunit in the granulosa-lutein cells (GLC) with little or none
observed in the surrounding fibroblast layer. Insert shows no staining in the negative
control serial section. B, Positive staining for the activin receptors ALK4 and ActRIIA
C, in the surrounding fibroblast layer of a mid-luteal corpus luteum localised to cells that
resemble fibroblast cells (arrows). D, Phosphorylated Smad 2/3 is expressed during all
stages of the luteal phase. Positive staining for this receptor activated Smad is evident in
the nucleus of granulosa-lutein cells (GLC), thecal-lutein cells (TLC) and surrounding
fibroblast layer (F) of the corpus luteum with little staining around blood vessels (Bv).
E, Double immunofluorescence of endothelial cells (CD 31) (arrow) in red co-localised
with phosphorylated Smad 2/3 (green) in a mid-luteal corpus luteum. Nuclear
phosphorylated Smad staining is clear in presumptive fibroblast cells (asterisk) located in
the stromal area of the corpus luteum and less marked in the endothelial cells (arrow).
Nuclear staining is depicted in blue. F, High power images illustrate a low level of
phosphorylated Smad 2/3 (green) in some endothelial cells (arrow) in red. G, Low power
image of phosphorylated Smad 2/3 (green) and macrophages (CD 68 +ve cells) (red) in a
late-luteal corpus luteum. Phosphorylated Smad 2/3 is localised to fibroblast cells
(asterisk) and less so in the macrophages (arrow) stained in red. H, Higher power view of
an individual macrophage (red) in the same tissue section (asterix) showing low levels of
phospho-Smad (green). Scale bars A-D, 40 pm E-H, 20 pm.
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3.3.5 Quantification of Smad signalling across the luteal phase
In order to investigate changes in Smad signalling across the luteal phase the expression
of Smad 2 and Smad 3 was investigated using quantitative RT-PCR (Figure 3.7) in
carefully dated corpora lutea. Smad 3 expression increased to a maximum in the late-
luteal phase and was different between early and mid (p<0.05, ANOVA), and early and
late (p<0.01, ANOVA) (Fig. 3.7). The expression of Smad 2 mRNA (Figure 3.7A) was
also assessed over the luteal phase, and although it demonstrated a similar trend to that of
Smad 3, the differences did not reach significance.
Early Mid Late Early Mid Late
Figure 3.7 Expression of the receptor activated Smads in human corpora lutea over the
luteal cycle. A, Real-time quantitative RT-PCR demonstrated that the mRNA expression
of Smad 2 increased over the luteal phase (n=6 for each group), however a non¬
significant trend (p>0.05, ANOVA) was observed. B, The expression of Smad 3 was
significantly increased from the early luteal phase in both mid luteal (p<0.05, ANOVA)
and late-luteal (p<0.01, ANOVA) samples.
3.3.6 Effect of hCG on activin A and its inhibitors in primary cell cultures
of steroidogenic cells
To test the hypothesis that during maternal recognition of pregnancy the exposure of hCG
to the corpus luteum results in less activin A signalling from the steroidogenic cells the
effect of hCG in primary cultures of luteinised granulosa cells was assessed. The
secretion of both inhibin A (range 10-500 pg/ml) (p<0.05, t-test) and activin A (range 1-5
ng/ml) (p<0.05, t-test) was increased by the addition of hCG within 24 h (Figure 3.8).
Experimental results were standardised to their controls to consider variation within
individual experiments.
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Figure 3.8 The effect of hCG on elements of the activin pathway in primary cell cultures.
A, Luteinised granulosa cells show an increase in inhibin A (p<0.05, t-test) and B, activin
A (p<0.05, t-test) production when treated with hCG (100 ng/ml) for 24 h relative to
control samples.
Although exposure to hCG did not change the inhibin:activin ratio, luteinised granulosa
cells markedly increased their expression of the activin-binding protein, follistatin
(p<0.01, t-test) in response to hCG stimulation (Figure 3.9). In the presence of hCG, the
up-regulation of follistatin may therefore be able to reduce the local actions of activin A.
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Figure 3.9 The effect of hCG on the expression of the activin binding protein, follistatin
(p<0.01, t-test) in primary cultures of luteinised granulosa cells.
3.3.7 Evidence that luteal MMP-2 is under the paracrine control of
activin A
To test the hypothesis that hCG could inhibit MMP-2 expression in a paracrine signalling
fashion, a novel primary cell co-culture system of luteinised granulosa cells and
fibroblast-like cells was employed (Duncan et al., 2005b). In these co-cultures the
primary source of MMP-2 in the culture medium are the fibroblast-like cells (Figure 3.1).
The addition of hCG to fibroblast-like cell cultures had no effect on the expression of
MMP-2 (p>0.05, t-test) (Figure 3.10). However, co-cultures exposed to hCG
demonstrated a significant reduction in the expression of MMP-2 (p<0.05, t-test) (Figure
3.10), suggestive that hCG is acting on luteinised granulosa cells to influence fibroblast-
like cell MMP-2 expression in a paracrine manner.
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Fibs Co-cult
Figure 3.10 In vitro model of paracrine signalling in co-culture experiments of luteinised
granulosa cells and luteal fibroblast-like cells demonstrates that MMP-2 expression was
significantly decreased (p<0.05, t-test) in primary co-cultures exposed to hCG (100
ng/ml) for 24 h.
To test the hypothesis that hCG is manipulating MMP-2 expression through a reduction
in activin A activity, secondary to an up-regulation of follistatin expression, physiological
concentrations of follistatin were added to the primary cell cultures. The addition of
follistatin to cultures of fibroblast-like cells had no significant effect upon MMP-2
expression (p>0.05, t-test) (Figure 3.11). However follistatin had the same effect as hCG
in reducing the expression of MMP-2 in co-cultures of luteinised granulosa cells and
fibroblast-like cells (Figure 3.11) (p<0.01, t-test).



























Figure 3.11 Similar to Figure 3.10, the expression of MMP-2 was significantly reduced
(p<0.01, t-test) in co-cultures treated with follistatin (500 ng/ml) for 24 h. Fibroblast-like
cell cultures in both treatment groups were unaffected by either hCG or follistatin
(p>0.05, t-test).
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3.4 Discussion
How luteolysis occurs in women and how it is inhibited by hCG during maternal
recognition of pregnancy is not yet understood. What is clear however is that the
inhibition of luteolysis by hCG involves disparate effects on cell-types in the corpus
luteum that do not express LH/hCG receptors. Previously it has been shown that hCG
regulates luteal fibroblast (Duncan et al., 2005b; Duncan et al., 1998a), macrophage
(Duncan et al., 1998b) and endothelial cell (Wulff et al., 2001) function. This means that
paracrine signalling molecules from steroidogenic cells have key roles in the local
regulation of luteal cell function. To date, the identity of these molecules has remained
largely elusive. This study shows for the first time, using a combination of observational
studies on human corpora lutea combined with interventional studies using human
primary cell culture and co-culture models, that activin A is an excellent candidate
molecule for a paracrine regulator of luteal remodelling during luteolysis whose action
can be inhibited by hCG during maternal recognition of pregnancy.
It has to be highlighted that these studies used luteinised granulosa cells and fibroblast-
like cells from the luteinising follicle. This co-culture model allows information about
the paracrine interactions that occur during luteolysis. It is possible that dispersed cells
from human corpora lutea may respond differently at different stages of the luteal phase.
Unfortunately such comprehensive studies using fresh human luteal tissue are almost
impossible and it is likely that analysis of activin effects on remodelling of luteal cells
will need further assessment in sub-human species.
Activins belong to the structurally related TGF-P superfamily that includes inhibins and
BMPs. Members of this family have been shown to have important paracrine regulatory
roles in diverse physiological processes (Massague, 1998). Indeed, activin signalling has
been shown to be essential in inflammation (Jones et al., 2004), cell proliferation and
apoptosis (Hully et al., 1994), fetal development (Matzuk et al., 1995) and male
reproduction (de Kretser et al., 2002; Risbridger and Cancilla, 2000). In particular, it has
been established that activins may have a paracrine role during the normal ovarian cycle
(de Kretser et al., 2002; Welt et al., 2002). Activin can stimulate the proliferation of
granulosa cells in small follicles (Miro and Hillier, 1996) and enhance their expression of
FSH receptors and aromatase (de Kretser et al., 2002; Xiao et al., 1992). It appears that
one of the roles of activin in the ovary is to stimulate smaller follicles and inhibit
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luteinisation of larger follicles to maintain the follicle in an FSH-responsive state (de
Kretser et al., 2002; Knight and Glister, 2006).
There is evidence to support a paracrine role for activin in the corpus luteum. In the first
instance, the corpus luteum has the mechanism to synthesise and secrete activin. Studies
in women (Roberts et al., 1993) and primates (Fraser et al., 1993) have localised inhibin
a and (1A subunit mRNA and protein to the steroidogenic cells of the corpus luteum.
Dispersed luteal cells in vitro and the intact corpus luteum in vivo secrete inhibin A in a
regulated manner (Illingworth et al., 1996). The same is seen in cultures of human
luteinised granulosa cells. In addition, these cells secrete activin A and activin A is found
in the follicular fluid at the time of ovulation (Fujiwara et al., 2000). Indeed, circulating
activin concentrations change across the ovarian cycle, with an increase towards the end
of the luteal phase (Muttukrishna et al., 1996). As well as expressing the (1A subunit
mRNA and protein, it is likely that the granulosa-lutein cells of the corpus luteum secrete
activin A during the luteal phase.
In addition, this study demonstrates that the corpus luteum has the molecular mechanisms
to respond to locally produced activins. Activins signal through two types of
transmembrane serine/threonine kinase receptor interactions (Chen et al., 1998) and the
cytoplasmic to nuclear translocation of the intracellular Smad proteins (Heldin et al.,
1997). Human corpora lutea express both the type I (ALK 2/4) and type II (A) activin
receptors as well as components of the Smad (2, 3 and 4) signalling pathway that are
induced by activin. Correspondingly, in the present study the receptors and activated
nuclear phosphorylated Smad 2/3 have been localised to both steroidogenic and stromal
cells of the human corpus luteum. Although the nature of the ligand signalling through
the Smad 2/3 pathway is not entirely clear, as TGF-|3 signals through similar Smads,
(Chen et al., 1998; Pangas and Matzuk, 2004) it is likely that the activin signalling
cascade is active and activins do act locally on different cells types in the corpus luteum.
Activin action however is highly controlled in physiological systems. It is tightly
regulated by various inhibitors at the ligand, receptor and post-receptor levels (Harrison et
al., 2005). Follistatin, a local regulator of activin, controls activin signalling by forming
biologically inactive complexes with the (3-subunits of the activin glycoprotein.
Suppression of activin-regulated processes is also achieved by the activin antagonist
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inhibin and its co-receptor, betaglycan. Inhibin opposes activin action by competitively
binding to the same site of the type II activin receptor. Additionally, inhibins have also
been thought to have interactions with specific and high affinity receptors which may
then activate signal transduction pathways, such as the inhibitory Smads, that can oppose
activin action (Robertson et al., 2000). Betaglycan on the other hand, has a high affinity
for inhibin and forms complexes with the type II activin receptor to block the recruitment
of the type I receptor (Lewis et al., 2000) that is required to activate the signalling
cascade. As well as making activin, the corpus luteum has at least some of the molecular
mechanisms required to inhibit activin.
It is not clear whether activin signalling changes across the luteal phase. It is likely there
is more activin available to act in the late-luteal phase as the increase in circulating
activin A at the time of luteolysis (Muttukrishna et al., 1996) is not seen with regards to
its inhibitors, inhibin A (Dlingworth et al., 1996; Muttukrishna et al., 1996) and follistatin
(Schneyer et al., 2000). Futhermore, immunolocalisation of nuclear phosphorylated Smad
2/3 was evident, which would be detected in the presence of activin signalling,
throughout the luteal phase. Although most increases in Smad signalling are through
phosphorylation of the proteins, there are also increases in the expression of Smad mRNA
in response to ligand activation. Therefore this study investigated the expression of Smad
2 and 3 mRNA across the luteal phase. Expression of both Smads tended to be maximal
in the late-luteal phase. These results are compatible with activin action increasing in the
lead up to luteolysis.
Both the expression of activin and its local inhibitors are regulated in the corpus luteum.
The addition of hCG up-regulates the inhibin a subunit and the secretion of inhibin A
from steroidogenic cells in vitro and in vivo (Illingworth et al., 1996; Muttukrishna et al.,
1997). This study hypothesised that the inhibin: activin ratio would increase in the
presence of hCG and tested this using luteinised granulosa cells in culture. However, a
similar stimulation of both activin A and inhibin A was evident with hCG and
consequently no change to the ratio. However, other studies have shown that short-term
gonadotrophin stimulation initially increased activin A secretion, but unlike inhibin A,
this diminishes later in a time- and dose-dependant manner (Vanttinen et al., 2002) and it
is possible that hCG increases the inhibin: activin ratio in the longer-term. In addition,
both bound, inactive, activin and free, active, activin were detected by the assay and it is
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possible that the ratio of inhibin to active activin changes. This is particularly important
as it is clear that follistatin is hormonally regulated. HCG up-regulates follistatin from
luteinised granulosa cells in culture and follistatin concentrations in follicular fluid are
hormonally regulated (Schneyer et al., 2000). For instance, follistatin is up-regulated in
the serum of pregnant women (Khoury et al., 1995). Collectively, these data are
suggestive that luteal activin action, although not necessarily secretion, is inhibited by
hCG during luteal rescue.
There appears to be a role for increased activin activity during luteolysis. Previously,
activin has been shown to inhibit progesterone production by luteal cells in vitro (Di
Simone et al., 1994), and therefore it may have a role in the changes associated with
functional luteolysis. However, this chapter suggests that activin has a role in the
remodelling associated with structural luteolysis. One of the key features associated with
luteolysis is the up-regulation of MMP-2 in stromal cells (Curry and Osteen, 2003;
Duncan et al., 1998a; Endo et al., 1993). Herein it has been shown for the first time that
fibroblast-like cell MMP-2 is up-regulated by concentrations of activin (but not inhibin)
found inside the human ovary. For clarity, the term fibroblast-like cells and stroma is
used to represent the stromal cells that are directly surrounding the steroidogenic cells and
invaginating in between them. Furthermore stromal MMP-2 expression can be inhibited
by hCG in a paracrine manner both in vivo (Duncan et al., 1998a) and in co-culture
models in vitro. The effect of hCG on MMP-2 in these co-cultures can be replicated by
the addition of follistatin at concentrations found within the human ovary. As hCG up-
regulates follistatin, these results suggest that activin A may be involved locally in the
physiological regulation of MMP-2 activity in the corpus luteum.
MMP-2 is not known for being regulated at the level of its expression. Indeed, an
examination of the promoter region of the MMP-2 gene shows less regulatory sequences
than other MMPs (Curry and Osteen, 2003), consistent with a gene that is normally
constantly expressed. However there are clearly certain circumstances when its
expression is regulated. It is increased in fetal membranes during labor (Riley et al.,
1999), in the endometrium during menstruation (Salamonsen and Woolley, 1996) and
more importantly, it is increased during natural and induced luteolysis in a wide range of
different species (Curry and Osteen, 2003; Duncan et al., 1998a; Endo et al., 1993). The
factors involved in this regulation are not certain. There has been a suggestion that
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steroids are involved in its regulation in the endometrium (Salamonsen and Woolley,
1999) and cytokines such as tumor necrosis factor-a (TNF-a) may be important in the
regulation of endometrial fibroblast (Braundmeier and Nowak, 2006) and bovine luteal
(Zhang et al., 2005) MMP-2 expression. Extravillious trophoblasts over-expressing Smad
4 demonstrate a clear up-regulation of MMP-2 production, mimicking the effect of TGF-
(3 in this particular system (Lin et al., 2006). The same theory may apply to activin A in
fibroblast cells of the corpus luteum as it is known they express the Smad proteins
common to both TGF-J3 and activin signalling and that activin A in fibroblast-like cells
increases MMP-2 production. The present study demonstrates that activin A can up-
regulate-luteal MMP-2 expression and activity in vitro at physiological concentrations.
There is some evidence, in other systems, that activin may well regulate MMP-2
expression. Activin A has been found to regulate MMP-2 in both mouse peritoneal
macrophages (Ogawa et al, 2000) and human decidua (Caniggia et al., 1997; Jones et al.,
2006). In addition it has been suggested that activin can up-regulate both MMP-9 and
MMP-2 expression in cultured human cytotrophoblast cells (Caniggia et al., 1997).
However this was thought to be secondary to activin affecting the differentiation status of
these cells. Another molecule from luteal fibroblasts with a role in tissue remodelling
during luteolysis is CTGF (Duncan et al., 2005b). Previous studies have shown that
activin also up-regulates its expression in luteal fibroblast-like cells (Duncan et al.,
2005b), although this does not appear to be the only regulating factor. It is not clear
whether other molecules as well as activin can regulate-luteal MMP-2 expression during
luteolysis.
If activin A is involved in regulating tissue remodelling during luteolysis it is likely to be
self-limiting in nature. This is because the cellular source of activin is the steroidogenic
cells that undergo programmed cell death when the corpus luteum is cleared from the
ovary (Behrman et al., 1993; Fraser et al., 1999). It is difficult to determine if
observations made in non-primate species are relevant to women as there are major
species differences in the regulation of the corpus luteum. In the mouse, where ovarian
activin pA expression has been conditionally knocked out (Roy and Matzuk, 2006), the
ovary contains multiple corpora lutea when examined. While is it tempting to speculate
that luteolysis may be affected, it has to be remembered that inhibin A will also be
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knocked out and this may well result in higher FSH concentrations would be expected to
cause more ovulations.
Observational studies on human corpora lutea inform us that the steroidogenic cells
expressing LH/hCG receptors can secrete activin A and the stromal cells that express
MMP-2 have the molecular machinery to respond to locally produced activin. Such
observations however do not tell us the roles of activin and interventional studies are
required. It is now not practical to collect enough well characterised human corpora lutea
to disaggregate the cells and manipulate these cells in culture and other model systems
have to be used. The culture of luteinised granulosa cells and the derivation of fibroblast-
like cells have the potential to replicate the luteal steroidogenic cell/stromal cell
interactions in vitro. Although luteinised granulosa cells are LH/hCG-responsive and
function in primary culture for 14 days, they may differ from mature granulosa-lutein
cells. In addition, although the phenotype of the fibroblast-like cells is identical to luteal
stromal cells in all the genes so far analysed, (Duncan et al., 2005b) and expression
patterns of MMP-2 from prolonged cultures of fibroblasts obtained from corpora lutea,
there may be differences. Indeed, previous studies have shown that there are at least two
types of fibroblast in the human corpus luteum (Maybin and Duncan, 2004).
Furthermore, in culture, the cells do not have the local interaction with immune cells and
endothelial cells seen in vivo.
Whilst it must be accepted that there are caveats to this model system and indeed, the in
vitro cell culture and co-culture models may not entirely mimic what is happening within
the corpus luteum, such model systems can give valuable insights into mechanistic
functions that otherwise may not be dissected. Therefore care needs to be used in the
interpretation of their findings and used in conjunction with observational studies, this
study has used the most appropriate model to study and manipulate cell-cell interactions
in the human corpus luteum.
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Figure 3.12 Schematic of the model proposed for the paracrine regulation of MMP-2
expression by hCG in human luteal cells. A, Steroidogenic cells (SC), but not fibroblast-
like cells (FC) express the LH/hCG receptor. The fibroblast cells secrete MMP-2 and
express activin receptors. B, During the late-luteal phase increasing activin A action from
the steroidogenic cells up-regulates the expression of MMP-2 from the fibroblast cells.
C, In the presence of hCG during maternal recognition of pregnancy, the increase of
inhibin A will block activin binding to its receptors while follistatin will bind and
biologically inactivate secreted activin A, resulting in decreased activin signalling thus
preventing the increased expression of MMP-2.
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In conclusion, this chapter postulates that activin A may have a physiological role in
luteolysis and part of this role is to stimulate-luteal MMP-2 expression. The physiological
role of hCG may therefore serve to impede activin action (Figure 3.12) and this will
facilitate luteal maintenance by inhibiting luteolysis and allowing the maternal
recognition of pregnancy.
Chapter 4 Cortisol metabolism in the human corpus luteum 98
4 Role of luteal glucocorticoid metabolism during maternal





One of the major enigmas in human luteal physiology is the identification of luteotrophic
and luteolytic factors. Evidence from Chapter 3 clearly suggests that activin A is an
excellent candidate molecule responsible for the tissue remodelling associated with
luteolysis. However luteotrophic paracrine factors still remain elusive. Consequently,
the major focus of this chapter was to investigate a role for Cortisol as a potential
luteotrophin in the human corpus luteum.
(Structure ofCortisol from http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=148533)
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4.1 Introduction
The human corpus luteum develops from the post-ovulatory follicle to become one of the
most active endocrine glands in the body. During the luteal life-span this remarkable
structure will experience very high cell turnover, intense angiogenesis and considerable
steroid production within a 14-day period. Such highly organised events rely upon
stringent paracrine interactions between neighbouring and surrounding cells. In a non-
conception cycle the corpus luteum will undergo luteolysis, a complex process whereby
the tissue is subjected to a loss of structural and functional integrity that is associated with
an immune cell influx (Duncan et al., 1998b), increase in matrix metalloproteinases
(Duncan et al., 1998a), cell death (Fraser et al., 1999) and vascular regression (Fraser and
Duncan, 2005). Remarkably however, such dramatic remodelling and rapid tissue
removal occurs in an orderly fashion without any evidence of permanent scar tissue.
Within the ovary, ovulation and the resulting folliculo-luteal transition has been likened
to inflammatory response, as a result of the acute hemodynamic, cellular and biochemical
changes that occur at the site of follicle rupture (Espey, 1980; Hillier and Tetsuka, 1998).
Key studies have clearly shown that the repetitive damage from consecutive ovulations
must be quickly repaired in anticipation for the next ovulatory cycle, and locally
produced glucocorticoids are involved (Gubbay et al., 2005; Rae et al., 2004a; Yong et
al., 2002). Cortisol, the most important glucocorticoid, is well known to minimise
inflammatory damage to tissues by encouraging wound healing and subsequent repair.
Clear evidence of this phenomenon is apparent from the switch of 11(3HSD1 isoforms
over the ovarian cycle, complemented by the increased concentrations of Cortisol in
follicular fluid following the LH surge (Harlow et al., 1997). At present, both the
presence of lipHSDl (that tends to generate Cortisol) and 11PHSD2 (that tends to
inactivate Cortisol) isoforms, and their activities, have been reported in the ovaries of
several species (Michael et al., 2003).
Throughout the human body, glucocorticoids are well known to exhibit a plethora of
physiological roles. Whilst most of these actions have been best characterised in body
systems such as kidney, liver, adrenal and local inflammatory responses, influences on
human fertility, oocyte maturation and the establishment of a functional corpus luteum
have been suggested (Andersen, 2002; Fateh et al., 1989; Jimena et al., 1992; Michael
and Cooke, 1994). It has also been reported that as glucocorticoids can inhibit
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endothelial cell proliferation (Gaytan et al., 2002), they may have a role in the local
regulation of angiogenesis.
With the knowledge that glucocorticoids are involved in inflammatory-associated events
in the ovary and may adversely affect angiogenesis, it was hypothesised that local Cortisol
action may have a role in the luteolytic process. Although governed by different
luteolytic mechanisms than in women, elegant studies in the rat have however identified a
potential role for 11 (3HSD2 in the regressing corpus luteum (Waddell et al., 1996).
Therefore, based upon the findings in the rat study, coupled with much evidence for
glucocorticoids in tissue and scar regeneration, this study hypothesised that
glucocorticoids were involved across the luteal lifespan.
4.1.1 Aims
To localise and identify a role for glucocorticoid metabolism in the human corpus luteum
To investigate luteal glucocorticoid reception in the human corpus luteum
To establish the role of hCG upon the regulation of local glucocorticoids (via the
lipHSD enzymes and the glucocorticoid receptor) in primary cultures of luteinised
granulosa cells
To establish whether changes in Cortisol synthesis and metabolism might be key events in
the regulation of the tissue remodelling associated with luteolysis.
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4.2 Materials and Methods
4.2.1 Collection of human corpora lutea
Human corpora lutea were collected from women with regular menstrual cycles
undergoing hysterectomy for benign conditions and dated on the basis of the urinary LH
surge as fully described in section 2.1.2.2.
4.2.2 Isolation of human luteinised granulosa cells and derivation of
fibroblast-like cells
Isolation of luteinised granulosa cells using Percoll gradient centrifugation was carried
out as described in section 2.1.3. Twenty-four well cell culture plates were precoated
with 25 pi ofmatrigel (BD Biosciences) and 100,000 viable cells per well were plated in
lml of serum-free media.
Fibroblast-like cells were obtained from prolonged cultures of follicular aspirates as
described in section 2.1.4 and 60,000 cells per well were plated in lml of 10% FBS
culture medium on 24-well cell culture plates.
4.2.3 Primary cell culture treatments
Each pooled experiment for the following treatments was carried out at least 3 times to
avoid biological bias.
4.2.3.1 Assessment of the acute effects of hCG and progesterone
Luteinised granulosa cells plated as above had fresh medium changed every 2-3 days over
course of culture and treatment was carried out on day 6 or 7 of culture. The treatments
groups were, 1) Controls with LDL, (50 mg/1 Sigma), 2) hCG (10 ng/ml, Serono) with
LDL, 50 mg/1, and 3) hCG (10 ng/ml) and LDL (50 mg/1) in conjunction with 100 pM
aminoglutethimide (Sigma). After 24 h, medium and cells were stored for steroid analysis
and mRNA extractions respectively. Progesterone concentrations in the culture media
were determined by an in house radioimmunoassay as described in section 4.2.10.
Chapter 4 Cortisol metabolism in the human corpus luteum 102
4.2.3.2 Manipulation of hCG in prolonged cultures of luteinised
granulosa cells
In order to mimic the luteal phase in primary cell culture, luteinised granulosa cells were
plated as described above and grown for 12 days as described in section 2.1.3.1. Briefly,
cells were stimulated with low dose hCG (1 ng/ml) with LDL (50 mg/1) beginning on day
2 and this was repeated every 2nd day until day 7 when treatments were replaced with
maximal doses of 100 ng/ml hCG/LDL or LDL alone. Cells were analysed after seven
days with hCG and on day 12 in the presence or absence of hCG to mimic the
progesterone secretion profile of late-luteal and luteal rescue stages respectively (Duncan
et al., 2005a).
4.2.3.3 Relative cell counts for various steroid and steroid inhibitor
treatments
Pooled luteinised granulosa cells were cultured as above for seven days in the presence of
the same carrier ethanol concentrations in each well. The experiments were piloted to
determine the appropriate concentrations of reagents and final experiments were repeated
three times in triplicate. The treatments were, 1) control, 2) aminoglutethimide (100 pM),
3) RU486 (100 pM; Sigma) 4) RU486 (100 pM) with progesterone (500 pM; Sigma), 5)
RU486 (100 pM) with Cortisol (500 pM; Sigma) and 6) RU486 (100 pM) with hCG (100
ng/ml). After seven days, the cells were removed by trypsinisation, resuspended and
counted using a haemocytometer. Values were taken as the mean of at least four separate
counts by an observer blinded to the treatments and related to controls.
4.2.3.4 Treatment of cultured fibroblast-like cells with Cortisol
Cultures of fibroblast-like cells were plated as above. After 6 hours in serum-free culture,
the medium was removed and replaced with medium containing either Cortisol (100 nM)
or an equivalent amount of the ethanol carrier as a control. After 24 hours the culture
medium was collected for subsequent zymography and the cells were used for mRNA
extraction.
4.2.4 Preparation of cDNA from human corpora lutea and cultured cells
Messenger RNA was batch extracted from frozen human corpora lutea and reverse
transcribed into cDNA using random hexamers as described in section 2.1.16. Cultured
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cell mRNA was extracted using RNeasy mini-spin columns after lysis by the addition of
RNeasy lysis buffer (Qiagen). Lysates were frozen until processed as per manufacturers'
protocols then DNase treated with on-column DNasel (Qiagen) and quantified using the
NanoDrop ND-1000 Spectrophometer (NanoDrop Technologies). Messenger RNA was
then reverse transcribed into cDNA using random hexamers (Applied Biosystems).
4.2.5 Quantitative analysis of gene expression by RT-PCR
Quantitative real-time PCR was carried out on the ABI PRISM 7700 sequence detection
system (Applied Biosystems) using specific primers and probes (Eurogentec) for each
gene of interest (Table 4.1) and levels were related to a ribosomal 18S internal control
(Applied Biosystems). QRT-PCR was performed with an extension temperature of 72°C,
and 30 cycles of amplification. All samples were performed in duplicate and a relative
comparison was made to an appropriate tissue control, either human placental or liver
cDNA.
Table 4.1 List of all primer/probe sequences used for Taqman qRT-PCR. Sequences for
lipHSDl, 11(3HSD2 and GRa obtained from Rae et al (Rae et al., 2004a).
















(Jordan et al., 2004)
4.2.6 Histology
Masson's modified trichrome staining was carried out on 5 pm paraffin sections of
human corpora lutea. Briefly, sections were dewaxed, rehydrated in alcohol and washed
in water. Sections were then placed in Celestine blue for 3 min, washed, placed in
Mayer's acid haematoxylin solution for 3 min, washed and then counter-stained with
Biebrich scarlet-acid fuchsin solution for 15 min. After washing the sections were
Chapter 4 Cortisol metabolism in the human corpus luteum 104
differentiated in 5% phosphotungstic acid for 15 min before being placed directly into
aniline blue solution for 5-10 min, washed, dehydrated and mounted for microscopy.
4.2.7 Immunohistochemistry
Immunolocalisation of GR was carried out using a rabbit polyclonal antibody (ABR,
Cambridge Bioscience, UK) in 5 pm paraffin tissue sections of human corpora lutea
prepared on poly-L-lysine-coated microscope slides. These sections were dewaxed,
rehydrated, washed in PBS, subjected to antigen retrieval as described under section
2.1.9. All sections were washed and blocked in 3% E^CVmethanol, avidin/biotin and
normal goat serum as described in section 2.1.9.
GR antibody was diluted 1:2000 in blocking solution and incubated on sections overnight
at 4°C. After rinsing, slides were incubated with the biotinylated goat anti-rabbit
immunoglobulin G (IgG; diluted 1:500 in NGS/TBS/BSA) secondary antibody (DAKO)
for 1 h. After washing, the sections were incubated in ABC-HRP (DAKO) and binding
was visualised by incubation with liquid DAB (DAKO). Sections were counterstained
lightly with hematoxylin to enable cell identification. Negative controls were performed
identically to the above protocol with primary antibody incubations substituted with
blocking serum.
4.2.8 Fluorescent immunohistochemistry
Sections were washed, subjected to antigen retrieval, and blocked as described above and
negative controls were performed as above. Rabbit anti-GR and rabbit anti-lipHSDl
(Cayman/IDS Ltd, Bolton UK) diluted 1 in 100 in NGS/PBS/BSA were incubated on
sections overnight at 4°C. Sections were washed and slides were incubated with goat anti-
rabbit IgG 488 (DAKO) diluted 1 in 200 in PBS for 1 h.
Sections that were labelled with anti-GR were subjected to further co-localisation
experiments. Sections were re-blocked with NGS/PBS/BSA for 1 h then incubated with
mouse monoclonal antibodies anti-CD31 (DAKO; 1 in 20 in block), anti-CD68 (DAKO;
1 in 20 in block) or anti-a smooth muscle actin (aSMA, DAKO; 1 in 500 in block)
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overnight at 4°C. Sections were washed and incubated with the fluorochrome
streptavidin 546 Alexafluor (Molecular Probes) diluted 1 in 200 in PBS for 1 h.
Sections that were labelled with anti-1 lpHSDl were re-blocked with normal donkey
serum (NDS)/PBS/BSA for 1 h and then incubated with sheep anti-1 ipHSD2 (kind gift
from Prof. Ian Mason, The University of Edinburgh, UK) diluted 1 in 50 in donkey
serum. Sections were washed and incubated with donkey anti-sheep peroxidase (DAKO)
1 in 200 in NDS/PBS/BSA for 30 min before washing and incubating for 10 min with
tyramide Cy3 (TSA plus cyanine 3 system; Perkin-Elmer Life Sciences) as described in
section 2.1.10.2.3 to amplify the lipHSD2 immunostaining with red fluorescence.
Nucleic acids were labelled with To-Pro 3 and washed and mounted in Permafluor
(Beckman Coulter). Fluorescent images were captured using an LSM 510 Axiovert 100M
confocal microscope as describe in section 2.1.10.4. Images of 1 lpHSDl and 1 ipHSD2
were analyzed comparatively by standardising the computer settings for each isoform.
Therefore the relative intensity of staining for each isoform approaches the relative
abundance of protein levels.
4.2.9 Measurement of net 11PHSD oxidoreductase activity
Inter-conversion of cortisone to Cortisol via 11-oxoreductase activity was assessed in the
presence and absence of hCG. Pooled luteinised granulosa cells were either stimulated
with 100 ng/ml of hCG in serum-free medium or serum-free medium alone for 24 h.
Controls included incubations containing no cells with only matrigel. After hCG
stimulation, culture media was discarded from wells and replaced with culture medium
containing 100 nM of cortisone substrate and 0.1 pCi of [3H] cortisone to give a final
volume of 500 pl/well. All incubations were in triplicate for 4 h at 37°C with 95% air-
5%C02. After incubation, media was added to glass tubes containing 5 ml aliquots of
dichloromethane and vortexed thoroughly. To separate the aqueous and organic phases,
tubes were centrifuged at 12,000 rpm for 10 min. After the aqueous phase was removed,
samples were evaporated to dryness under nitrogen gas at 45°C. Steroid residues were
re-suspended in 100 pi of dichloromethane and samples along with one [3H]-cortisol and
one [3H]-cortisone blot were transferred to silca gel-precoated plastic sheets for thin-layer
chromatographic (TLC) separation of precursor and product in the solvent system of
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chloroform:ethanol (92:8 by vol) (Merck, Hoddesdon Herts UK). TLC plates were then
scanned using a Bioscan System 200 detector (Lablogic Systems, Sheffield UK) and
corresponding peaks were analysed for enzymatic activity in each sample and
consequently each treatment group. Results are expressed as amount of cortisone
converted to Cortisol (pmoles) per hour.
4.2.10 Measurement of progesterone concentrations in the culture medium
of luteinised granulosa cells
Progesterone concentrations were measured from collected culture medium using a plate
modification of a standard progesterone RIA (Djahanbakhch et al., 1981) kindly
performed by Nancy Evans (HRSU MRC, Edinburgh). The intra-assay co-efficient of
variation was <4% and the inter-assay co-efficient of variation was <11%. The detection
limit of the progesterone assay was 0.1 nmol/litre.
4.2.11 Gelatin zymography
Gelatin zymography was performed on the culture medium from Cortisol treated
fibroblast-like cell cultures as described in section 2.1.11.
4.2.12 Statistical analysis
Statistical analyses used are highlighted in the figure legends. Parametric statistics were
used if the data was normally distributed with similar standard deviations. Groups were
analysed by ANOVA with Bonferroni pairwise comparisons; if the data was not normally
distributed non-parametric statistics were used. Groups were analysed by Kruskal-Wallis
test with Dunn's Multiple Comparison Test. A paired t-test was used when treatment and
control samples were analysed. Differences were considered significant at p<0.05 level.
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4.3 Results
4.3.1 Expression and localisation of UpHSDs in the human corpus luteum
The granulosa-lutein cells of the corpus luteum can easily be identified by their
localisation and morphological characteristics (Figure 4.1). Both isoforms of the Cortisol
metabolising enzyme lipHSD (type 1 and type 2) could be immunolocalised to the
cytoplasm of granulosa-lutein cells in human corpora lutea (Figure 4.1B,C). Specific
immunostaining for each isoform could be detected in each corpus luteum analysed from
each stage of the functional luteal phase. No staining could be detected in negative
control sections (Figure 4.1C inset). The corpus luteum of women therefore has the
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Figure 4.1 Immunolocalisation of Cortisol metabolising enzymes in the human corpus
luteum. A, A mid-luteal human corpus luteum (stained with Masson's Trichrome) is a
heterogeneous tissue comprised of the steroidogenic granulosa-lutein (GLC) and theca¬
lutein (TLC) cells; inner and outer supportive stromal layer which consists of
predominantly fibroblast (F) layers and blood vessels (BV); and the central clot (CC) that
was once comprised the antral cavity of the follicle B, Immunofluorescence staining
demonstrates that the GLC of the corpus luteum express the Cortisol metabolising
enzymes lipHSDl (green with blue nuclear stain) and C, llpHSD2 (red with blue
nuclear stain). Negative control shown as inset in 1C. Scale bars A=200 pm; B,C=40 pm
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4.3.2 Expression and localisation of genomic glucocorticoid receptors in
the human corpus luteum.
Nuclear glucocorticoid receptor immunostaining could also be detected in human corpora
lutea. GR were also localised to the nuclei of granulosa-lutein cells (Figure 4.2A), but
unlike the 11|3HSD isoforms, GR could be localised to non-steroidogenic cell types. Dual
staining immunohistochemistry with a-SMA demonstrated GR expression in stromal
myofibroblasts and pericytes (Figure 4.2B,C). Dual immunostaining with CD68 and
CD31 demonstrated specific nuclear GR expression in macrophages (Figure 4.2 D) and
endothelial cells (Figure 4.2E) in each corpus luteum examined. This pattern of GR
immunostaining was detected in corpora lutea from each stage of the luteal phase.
Various different cells in the human corpus luteum therefore have the capacity to respond
to both systemic and locally produced Cortisol, in an autocrine, paracrine or endocrine
manner.
Figure 4.2 Localisation of the glucocorticoid receptor in the human corpus luteum.
A, The GR protein is ubiquitously expressed in the corpus luteum as seen by the positive
brown DAB staining with light microscopy. B, Immunofluorescence however further
confirms that GR can be co-localised with other cells types. For example, nuclear GR
(green) is present in the GLC whilst aSMA-positive cells represent stromal
myofibroblasts and pericytes (red). C, High power images reveal that GR (green) is
localised to the presumptive fibroblast cells (red) D, macrophages (red, CD68) and E,
endothelial cells (red, CD31) of the corpus luteum. Nuclear staining depicted in blue.
GLC= granulosa-lutein cell, TLC=thecal lutein cells, BV= blood vessel.
Scale bars E=40 pm; D=100 pm; F,H=10 pm; G=20 pm.
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4.3.3 The effect of hCG on 11(3HSD and GR expression in primary cultures
of luteinised granulosa cells.
In order to determine whether the expression of GR and Cortisol metabolising enzymes in
steroidogenic cells could be acutely regulated, the effect of hCG was examined in
primary cell cultures of human luteinised granulosa cells. The addition of hCG for 24 h
resulted in a 30-fold up-regulation of lipHSDl expression (p<0.05, Kruskal-Wallis)
(Figure 4.3A). At the same time 11 (3HSD2 was down-regulated (p<0.05, Kruskal-Wallis)
(Figure 4.3B) while GR expression was also up-regulated (p<0.05, ANOVA) (Fig. 2C).
In order to determine the functionality of the enzyme and the direction of 11pHSD
activity 11-oxoreductase activity was assessed in the presence and absence of hCG. This
confirmed that hCG stimulated reductase activity to promote Cortisol generation (P<0.05,
t-test) (Figure 4.3E).
As luteinised granulosa cells have genomic progesterone receptors, and hCG stimulates
progesterone secretion (range 460-890 ng/ml), cells were cultured with the progesterone
synthesis inhibitor aminoglutethimide to separate hCG effects from progesterone effects
(Duncan et al., 2005b) (Figure 4.3D). Aminoglutethimide reduced progesterone (range
160-400 ng/ml) secretion to control levels (170-200 ng/ml respectively) in the presence of
hCG (Figure 4.3D) (p<0.0001, ANOVA). While aminoglutethimide had no effect on
hCG-stimulated up-regulation of lipHSDl and GR it inhibited the hCG-induced down-
regulation of 11PHSD2 (Figure 4.3B). This suggests that progesterone may be involved
in the local regulation of lipHSD isoform expression. Overall, these data suggest that
Cortisol metabolism and reception may be hormonally regulated in luteal steroidogenic
cells.
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(p<0.05)
hCG
Figure 4.3 HCG modulates the 1 lpHSD enzymes and GR in luteinised granulosa cells in
primary culture. A, The expression of 1 tpHSDl is up regulated by hCG independently
of progesterone as evident by the addition of progesterone synthesis inhibitor
aminoglutethimide (p<0.05, Kruskal-Wallis). B, HCG however decreased the expression
of 11PHSD2 (p<0.05, Kruskal-Wallis), whilst in the presence of aminoglutethimide
inhibition of the type 2 isoform was prevented. C, Similar to that of llpHSDl, hCG
increased GR expression in luteinised granulosa cells (p<0.0001, ANOVA) whilst the
addition of aminoglutethimide had no effect. D, HCG stimulated an increase of
progesterone (p<0.0001, ANOVA) and this increase was blocked by the addition of
aminoglutethimide. E, HCG increases 11-oxoreductase activity which acts to generate
Cortisol (p<0.05, t-test) . n.s.=no significant difference.
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4.3.4 The effect of chronic manipulation of hCG in cultures of human
luteinised granulosa cells.
In order to determine if hCG could regulate the expression of lipHSDs and GR in more
physiologically relevant prolonged culture conditions, 12-day cultures of luteinised
granulosa cells, designed to mimic the luteal phase (Duncan et al., 2005b), were
examined. Withdrawal of hCG in culture down-regulated 11 pHSDl (p<0.05, Kruskal-
Wallis) while its expression was maintained in the presence of hCG (Figure 4.4A).
Conversely hCG withdrawal had no effect on 11PHSD2 expression while maintenance of
hCG did not alter its expression as the trend towards reduction did not reach significance
(p>0.05, Kruskal-Wallis) (Figure 4.4B). The expression of GR showed a similar pattern
to that of lipHSDI but there were no significant changes detected (Figure 4.4C) (p>0.05,
ANOVA). These data suggest that Cortisol metabolising enzymes may continue to be
differentially regulated by hCG under chronic conditions.
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day 7 day12(-) day 12 (+)
Figure 4.4 Chronic manipulation with hCG in cultures of luteinised granulosa cells
designed to mimic the luteal phase involved low dose hCG stimulation until day 7, which
was either replaced by maximal dose hCG on day 12 (+) or removal of hCG on day 12(-).
A, Withdrawal of hCG at day 12 down-regulated the expression of 11 (3HSD1 (p<0.05,
Kruskal-Wallis) whilst expression was maintained in the presence of hCG. B, Expression
levels of 11 pi ISD2 remained unchanged (p>0.05, Kruskal-Wallis) by hCG withdrawal or
maintenance. C, The expression of GR demonstrated a tendency to decrease with hCG
withdrawal and maintain levels with hCG (p<0.05, ANOVA). n.s. = no significant
difference.
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4.3.5 The effect of hCG on the expression of 11|5HSDs in human corpora
lutea in vivo.
In order to determine the effect of hCG of luteal 11 (3HSD expression in women, archival
tissues collected in the late-luteal phase in the absence or presence of exogenous hCG to
rescue the corpus luteum and mimic the changes of early pregnancy were examined
(Duncan et al., 1998a). In vivo, the effects of hCG did not quite reach significance
(p>0.05, t-test), although there was a clear differential effect on the expression of
11PHSD1 and 11PHSD2 (Figure 4.5). Exogenous hCG tended to increase lipHSDl
(Figure 4.5A) while tending to reduce llpHSD2 (Figure 4.5B). There were no specific
effects of hCG on the expression of GR in the corpus luteum of women (Figure 4.5C).
These data suggest that the differential regulation of Cortisol metabolism in luteinised
granulosa cells in vitro may also occur in the human corpus luteum in vivo.
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Figure 4.5 Modulation of ll(3HSDs and GR in human corpora lutea in vivo did not reach
significance during hCG rescue. However a tendency for Cortisol regeneration during
hCG rescue. A, The relative expression levels of 11 (3HSD1 tended towards an increase
during hCG-induced luteal rescue compared with that of the late-luteal phase. B,
Conversely the opposite was true for 11 pHSD2 whereby expression levels tended
towards a decline during hCG-induced luteal rescue compared to the late-luteal phase. C,
Expression of GR remained relatively unchanged in the presence or absence of hCG. n.s.
= no significant differences. (n=6 per group).
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4.3.6 The effect of RU486 on primary cultures of luteinised granulosa cells
As hCG seems to promote the generation and action of Cortisol it was hypothesised that
Cortisol may function as a local luteotrophic factor during luteal rescue and that Cortisol
withdrawal may have a role during luteolysis. It was therefore investigated whether
Cortisol could function as a survival factor in cultures of luteinised granulosa cells. The
Cortisol and progesterone rececptor antagonist RU486 reduced the number of luteinised
granulosa cells in culture (pcO.OOl, ANOVA) after seven days treatment (Figure 4.6).
This effect was not seen when progesterone synthesis was inhibited by aminoglutethimide
(Figure 4.6). This decrease in cell number in the presence of RU486 could be prevented
by the addition of Cortisol (p>0.05, ANOVA) so that cell numbers were no different to
controls (Figure 4.6). Conversely, the addition of saturating concentrations of
progesterone or hCG in the presence of RU486 did not increase the cell number beyond
that of RU486 alone (p>0.05, ANOVA) (Figure 4.6). These data crudely suggest that
Cortisol may have direct actions on luteinised granulosa cells in vitro.
Control Amino RU486 Prog Cort hCG
RU486
Figure 4.6 The effect of RU486 and steroids on luteinised granulosa cell survival after
seven days in culture. Culturing the cells with aminoglutethimide had no effect on the
number of remaining after seven days (p>0.05, ANOVA), while RU486 reduced cell
numbers by 50% (p<0.001, ANOVA). The addition of progesterone to RU486 did not
return cell numbers to control levels (p<0.05, ANOVA) whereas the addition of Cortisol
increased cell numbers (p<0.05, ANOVA) to control levels (p>0.05, ANOVA). The
addition of hCG to RU486 had no effect (p>0.05, ANOVA) with numbers less than
controls (P<0.01, ANOVA) and RU486 with Cortisol (p<0.01, ANOVA).
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4.3.7 The effect of Cortisol on non-steroidogenic cells
As well as the steroidogenic cells of the corpus luteum GR can be localised to non-
steroidogenic cells. This suggests that Cortisol has the potential to function as a paracrine
regulatory factor. Therefore, the current study investigated the effect of Cortisol on novel
primary cultures of ovarian fibroblast-like cells derived from the luteinising follicle
(Duncan et al., 2005b; Myers et al., 2007a). These cells secrete MMP-2 that is regulated
in a paracrine manner by hCG through intermediary molecules (Duncan, 2000). In vivo,
hCG inhibits the expression of luteal fibroblast MMP-2 (p<0.05, t-test) (Figure 4.7A). In
vitro the fibroblast-like cells express MMP-2 mRNA and proteolytic activity. The
addition of exogenous Cortisol inhibited both the expression (p<0.001, t-test) and activity
(p<0.0001, t-test) of MMP-2 (Figure 4.7B,C). This suggests that Cortisol may have the
potential to have relevant effects on neighbouring non-steroidogenic cells.
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Figure 4.7 MMP-2 expression and activity appear to be modulated by glucocorticoids in
primary cell cultures of fibroblast-like cells. A, The expression of MMP-2 was down-
regulated during hCG-induced luteal rescue in human corpora lutea (p<0.05, t-test).
B, Primary cell cultures of fibroblast-like cells treated with Cortisol mirror the effect of
hCG during luteal rescue as Cortisol inhibits MMP-2 expression (pcO.OOl, t-test). C,
Gelatin zymography further confirms that Cortisol reduces MMP-2 activity (p<0.0001, t-
test) in these fibroblast-like cells from the luteinising follicle.
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4.4 Discussion
This chapter hypothesised that locally produced Cortisol may be involved in regulating
tissue remodelling during luteolysis. The present study has shown that the human corpus
luteum expresses the enzymes required to increase or decrease the local availability of
Cortisol and the receptor pathways required to respond to glucocorticoids. Combination
studies in human corpora lutea with primary human cell culture models to show that the
expression of the 1 lflHSD enzymes, that control the local availability of Cortisol, is
hormonally regulated. As discussed previously, luteinised granulosa cells in vitro are not
a perfect representation of granulosa-lutein cells in vivo (Myers et al., 2007a) and for this
reason the in vitro and in vivo paradigms are complementary. Both paradigms suggest
that in women there is a change in 11 fiHSD isoforms across the luteal phase that is
associated with the functional state of the gland. This is complimentary to the only other
study investigating 11 piISD in the corpus luteum that suggested there may be more
11 [3HSD2 in the regressing rat corpus luteum (Waddell et al., 1996).
It is uncertain what role Cortisol has in the human corpus luteum. Roles for active
glucocorticoids in the ovary have certainly been proposed and described during
folliculogenesis and ovulation (Michael et al., 2003). Previous experiments have
demonstrated that hCG has the ability to regulate many different cell types and their
molecular functions within the corpus luteum and highlighted the important role for
locally produced intermediate regulatory molecules (Duncan, 2000; Duncan et al., 2005b;
Fraser et al., 2005; Myers et al., 2007a). Herein, it is hypothesised that glucocorticoids
may be regulatory molecules with signalling roles within the corpus luteum. This may be
a result of hCG, which acts to promotes the generation of active glucocorticoids which
have a luteotrophic role in the human corpus luteum such that the structural remodelling
associated with luteolysis is inhibited and maintenance of early pregnancy is facilitated.
Similarly, removal of local Cortisol may facilitate luteal regression in the absence of hCG.
The lipHSDs catalyse the inter-conversion of active (Cortisol) and inactive (cortisone)
glucocorticoids by isoforms type 1 and 2 respectively. The temporal and spatial
expressions of both isoforms have been documented in the ovary of other species
(Ricketts et al., 1998; Smith et al., 2000; Tetsuka et al., 1997; Yong et al., 2000). It is
well established that 11PHSD2 is the predominant isoform during the follicular phase of
the ovarian cycle, localised to the non-luteinised granulosa cells prior to the LH surge
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(Tetsuka et al., 1997). This is an important concept as too much Cortisol during the
follicular phase is reported to disrupt FSH-stimulated granulosa cell
development/function (and presumably oestradiol production) (Hsueh and Erickson,
1978), that would consequently inhibit successful folliculogenesis. In addition, during
folliculogenesis, the predominant steroid is oestradiol, and unlike progesterone (as
discussed below), oestradiol has a very low affinity for CBP (Dunn et al., 1981) and thus
will not displace Cortisol. As it has also been reported that oestradiol can increase the
hepatic production of CBP (Hammond, 2002), another mechanism may exist during the
follicular phase to lower free Cortisol. It seems that in the follicular phase local Cortisol
generation and action tends to be inhibited.
This is not the case, however, in the peri-ovulatory period. Once the dominant follicle is
exposed to the mid-cycle pre-ovulatory gonadotropin surge, the predominant isoform
switches from type 2 to type 1 lipHSD (Tetsuka et al., 1997; Yong et al., 2000). This
phenomenon can also be seen by a rise of free Cortisol that is 50-times higher in follicular
fluid after the LH surge (Andersen and Hornnes, 1994; Harlow et al., 1997), indicative
that expression levels of the 11PHSD enzymes in the ovary are an accurate measure for
the direction of glucocorticoid biosynthesis. Indeed it has been suggested that this process
is involved in facilitating fertility. Some studies report that IVF patients with higher
Cortisol to cortisone ratio in their follicular fluid have greater pregnancy success rates
(Lewicka et al., 2003; Michael et al., 1999) although others do not agree (Andersen and
Hornnes, 1994; Andersen et al., 1999). It is likely however that the switch in isoforms
around ovulation has effects on the oocyte as well as regulating the inflammatory reaction
associated with follicular rupture and its resolution (Hillier and Tetsuka, 1998). Such
findings further support the hypothesis that 11 PHSD enzyme activities in the human
ovary are developmentally and hormonally regulated (Yong et al., 2000).
The expression of 11PHSD 1 in luteinising granulosa cells is maintained in the granulosa
lutein cells of the corpus luteum. Additionally, in the present study 11PHSD2 was also
detected in the corpus luteum. Type 2 lipHSD mRNA expression and protein has
previously been reported to be very low or undetectable in freshly isolated luteinised
granulosa cells of both rats and humans (Michael et al., 1997; Tetsuka et al., 1999;
Tetsuka et al., 1997; Thurston et al., 2003). This suggests that as the corpus luteum is
formed there may be a recovery of 1 ipHSD2 expression. Indeed all cultures of luteinised
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granulosa cells expressed 110HSD2 and they had been cultured for at least seven days
before analysis. Although 11 (3HSD1 remains the most abundant isoform in luteinised
granulosa cells in culture and in the corpus luteum both isoforms are expressed. HCG
inhibited the expression of 11 [3HSD2 in vitro and tended to do the same in vivo. In
contrast, hCG stimulated 11|3HSD1 expression acutely, and in prolonged cultures, and
tended to do the same in vivo. The regulation of lipHSDl, like in the peri-ovulatory
period, seems to a direct effect of hCG signalling. However as the inhibition of 11 (3HSD2
by hCG was blocked when progesterone synthesis was inhibited, progesterone rather than
hCG may be involved in the inhibition of 11PHSD2 expression. This finding supports a
similar experiment in granulosa cells by Thurston et al. (Thurston et al., 2003) and
demonstrates the same principles of progesterone actions observed in the kidney and
placenta (Lopez Bernal et al., 1980; Quinkler et al., 1999; Sun et al., 1998) whereby
progesterone inhibits 11PHSD2. Indeed, as progesterone receptor expression is down-
regulated as the corpus luteum matures this may be a mechanism for the re-emergence of
steroidogenic cell 1 ipHSD2 expression in the corpus luteum (Duncan et al., 2005a).
The effect of hCG on lipHSDl expression was mirrored by 11-oxoreductase activity
levels and the generation of Cortisol from cortisone. Unfortunately, it is not possible to
assess Cortisol metabolism in the late-luteal and rescued corpus luteum to confirm this in
vivo. However it is believed that changes in the expression of different 11PHSD isoforms
in tissues informs the direction of cortisol/cortisone metabolism (Yong et al., 2000) and it
is clear that lipHSDl has the potential to act as a bi-directional enzyme (given the
appropriate co-enzyme environment) (Morris et al., 2003). However, previous detailed
studies on the direction of metabolism in luteinised granulosa cells (Thurston et al., 2003;
Yong et al., 2000), ovarian surface epithelial cells (Rae et al., 2004a; Rae et al., 2004b;
Yong et al., 2002) and other tissues (Jamieson et al., 2000; Seckl and Walker, 2004;
Walker and Seckl, 2003) as well as the phenotype of 11 |3HSD knockout mice (Hadoke et
al., 2001) have suggested that in vivo lipHSDl preferentially generates Cortisol.
However as pointed out by Jonas et al., recent studies have established that the net
direction of 11 [3HSD1 is dependant upon the cells availability of hexose-6-phosphase
dependent NADPH that may be different in high steroidogenically active tissues (Jonas et
al., 2006) and the direction of Cortisol metabolism in vivo remains to be studied.
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The human corpus luteum has the potential to respond to locally generated Cortisol as it
expresses nuclear GR. Indeed GR has been localised previously to many cell
compartments in the ovary (Tetsuka et al., 1999). Although the primary receptor for
Cortisol is GR, Cortisol also has a high affinity for the mineralocorticoid receptor (MR).
The expression of MR was not analysed in the present study however it is reported to be
expressed in the ovary (Tetsuka et al., 1999). The GR is localised to the nuclei of
steroidogenic cells and these cells of the human corpus luteum are also reported to
express other important nuclear steroid receptors such as oestrogen and progesterone
receptors (Hosokawa et al., 2001; Maybin and Duncan, 2004; Misao et al., 1999). It is
unclear whether other steroids can influence glucocorticoid signalling by receptor
dependent mechanisms but it is likely that Cortisol has direct effects on the cells
expressing the 11J3HSD enzymes involved in its synthesis and metabolism.
It is not clear if the expression of GR in the corpus luteum is regulated. Duncan et al.,
have previously shown that steroidogenic cell progesterone receptors are differentially
regulated in the corpus luteum across the luteal phase (Duncan et al., 2005a) although
their role has not yet been elucidated (Stouffer, 2003). In contrast, there were no obvious
changes in steroidogenic cell GR immunostaining across the luteal phase. Indeed in the
endometrium, where glandular progesterone receptor expression in the secretory phase
shows changes similar to that in luteal steroidogenic cells (Duncan et al., 2005a; Koh et
al., 1995), there was no change in GR expression across the functional menstrual cycle
(McDonald et al., 2006). However, in vitro hCG, tended to up regulate GR expression
similar to its effects on 11 |3HSD1. Whether GR expression in corpora lutea is hormonally
regulated but masked by detection methods is not entirely clear. What is clear is that
multiple cell types in each corpus luteum express nuclear GR.
Luteal endothelial cells and macrophages express nuclear GR. Protein co-localisation of
GR with CD31 demonstrates specific nuclear staining of endothelial cells. The effect of
Cortisol on luteal endothelial cells is not clear but glucocorticoids have been shown to
suppress angiogenesis (Small et al., 2005) and this is most notably due to the suppression
of vascular endothelial growth factor (VEGF) action (Nauck et al., 1998; Small et al.,
2005). In the human corpus luteum, however, there continues to be some angiogenesis
stimulated by hCG during luteal rescue (Wulff et al., 2001) in response to the marked up-
regulation of VEGF after exogenous hCG (Wulff et al., 2000). Immune cells, most
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notably macrophages (CD68+ve cells), that also express GR, accumulate in the corpus
luteum during luteolysis and show a marked reduction in number during hCG-induced
luteal rescue (Duncan et al., 1998b). The role of Cortisol in luteal macrophage
accumulation and action is not clear but as glucocorticoids are known to regulate cytokine
signalling and macrophages in both health and disease (Rogatsky and Ivashkiv, 2006) it
may affect the immune cell mediated processes during luteolysis. Luteal myofibroblasts
are known to express macrophage chemotractant protein-1 (MCP-1) (Senturk et al., 1999)
and these cells also express nuclear GR.
When considering a role for glucocorticoids in the corpus luteum it is very important to
establish the relationship between Cortisol and the marked excess of, structurally related,
progesterone. Cortisol exists in one of two forms, bound and free, that regulate its
bioavailability. In most systems, the majority of the steroid is bound to plasma proteins
(notably CBP) with only a fraction free and unbound (Andersen, 2002). Although CBP
has the highest affinity for Cortisol of all the binding globulins, other steroids such as
progesterone and particularly 170H-progesterone have high binding affinities to CBP
(Andersen, 2002; Dunn et al., 1981). Therefore very high concentrations of progesterone
and progesterone metabolites (such as in the corpus luteum) will displace Cortisol from
CBP, that acts as a buffer reservoir, resulting in the environment becoming enriched with
free Cortisol. This scenario is known as the 'free hormone hypothesis' (Andersen, 2002;
Dunn et al., 1981) and predicts that the bioactivity of Cortisol is proportional to free
hormone concentrations and not total concentration which includes the protein-bound
fraction. This is an important paradigm to consider as the concentration of free
biologically active Cortisol in pre-ovulatory follicular fluid is 10 times greater than that of
serum (Andersen and Hornnes, 1994). It is likely that, because of high local progesterone
concentrations, rather than being mainly bound to CBP in the corpus luteum, locally
generated Cortisol is more likely to be free and functional at lower concentrations.
It is still not clear what effects Cortisol has on luteal cells. This chapter hypothesised that
it may affect the survival of luteinised granulosa cells. The current observations and those
of others (Rothchild, 1996) suggested that RU486 reduced survival of these cells in
culture. Utilising simple cell counting to document the effect on RU486 on cell survival
and treating cells with the progesterone synthesis disruptor aminoglutethimide, that
blocks P450scc, the current study showed no change in their morphology or viability.
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Furthermore, the effect of RU486 could not be fully reversed by hCG or exogenous
progesterone. Unlike a previous study using human luteinised granulosa cells, under
slightly different conditions (Rothchild, 1996), the present study could not fully reverse
the RU486 effects using progesterone. Surprisingly however, the effect of RU486 was
reversed using Cortisol. It is not clear if this effect is at the level of the receptor as the
concentration of Cortisol would not be expected to fully displace the RU486. It may be
that Cortisol affects the cell susceptibility to RU486 in different ways. There may be
specific effects of RU486 not mediated by hormone antagonism. Direct actions of RU486
have been reported in ovarian epithelial cancer cells and human endometrium, whereby it
down-regulated molecules involved in signal transduction pathways by cytokines, growth
factors and other physiological stimuli that control cell functions (Catalano et al., 2003).
Indeed in cultured luteinised granulosa cells, Cortisol and dexamethasone offer protection
against serum deprivation and induced apoptosis (Sasson and Amsterdam, 2003; Sasson
et al., 2001) through mechanisms that include stabilisation of the actin cytoskeleton
(Sasson and Amsterdam, 2002). Whatever the mechanism of action, these results crudely
suggest that Cortisol may have direct effects on luteal steroidogenic cells. Indeed if
Cortisol has any direct genomic effects in vivo they are more likely to promote, rather than
inhibit, steroidogenic cell survival and function.
If Cortisol does have luteotrophic actions it may also have specific actions on the non-
steroidogenic cells of the corpus luteum that are key regulators of tissue remodelling
during luteolysis. Luteal fibroblasts are the main source of MMP-2, a key proteolytic
enzyme involved in tissue remodelling associated with luteolysis in women (Duncan et
al., 1998a) and in many other species (Endo et al., 1993; Pitzel et al., 2000; Young et al.,
2002). Both primates (Young et al., 2002) and women (Duncan et al., 1998a) show
maximal MMP-2 expression in the late-luteal phase. However, during maternal
recognition of pregnancy, MMP-2 production is considerably reduced (Duncan et al.,
1998a), suggestive that hCG is regulating the enzymatic expression through intermediate
molecules (Duncan, 2000). Furthermore, it is tempting to speculate that active
glucocorticoids may also prevent luteolysis by inhibition of intraluteal prostaglandin
synthesis (Wang et al., 1993). Whilst this is an attractive suggestion, the actual role of
prostaglandins in the human corpus luteum remains elusive.
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In the present study, these novel findings suggest that Cortisol may be involved in
paracrine interactions that control tissue remodelling. Recently, a published in vitro study
from the current thesis demonstrated by modelling the human corpus luteum that activin
A is a paracrine factor secreted from luteinised granulosa cells which may up-regulate
fibroblast MMP-2 secretion (Chapter 3;(Myers et al., 2007a)) in the absence of hCG. In
contrast to activin A (Myers et al., 2007a), this chapter demonstrates that Cortisol
treatment of luteal fibroblast-like cells in culture results in a reduction in the production
of MMP-2, a pattern reflecting MMP-2 expression in exogenous hCG rescued luteal
tissue (Duncan et al., 1998a). Indeed glucocorticoids decreased MMP-2 activity in rat
aortic smooth muscle cells (Pross et al., 2002) and in a fibrosarcoma cell line (Saadat et
al., 2005). It seems that the non-steroidogenic cells forming the corpus luteum have the
ability to directly respond to Cortisol. If these effects do occur in vivo it is likely that
Cortisol tends to inhibit rather than stimulate the remodelling associated with luteolysis,
and may therefore be considered to be luteotrophic in nature.
In the present study it was hypothesised that during luteolysis more Cortisol is generated
in the local environment, consequently preventing aberrant scarring to the tissue. It is
clear however from the result obtained from this study that luteolysis is not associated
with an increase in Cortisol, and the opposite is true. This study has shown that hCG
tends to generate Cortisol by up-regulating 11 pHSDl and down-regulating 11PHSD2.
This chapter clearly demonstrates that the corpus luteum has the potential to react to this
Cortisol and that the effect on steroidogenic and neighbouring cells tends to be
luteotrophic rather than luteolytic. In summary, observational and interventional in vivo
and in vitro models have generated results that suggest that Cortisol tends to be withdrawn
during luteolysis and maintained during luteal rescue. Glucocorticoids may have a role in
the local luteal regulation ofmaternal recognition of pregnancy in women.
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5 Activin A reduces luteinisation of human iuteinised granulosa
cells and has opposing effects to hCG in vitro
So far, the previous result chapters have begun to elicit the differential effects of activin
A and hCG in the human corpus luteum. Chapter 3 has clearly shown that activin A may
be involved in promoting luteolysis at the end stage of the luteal phase, whilst Chapter 4
has shown that hCG-derived Cortisol may play a luteotrophic role during the maternal
recognition of pregnancy. The focus of the current chapter was to determine if activin A
was an anti-luteal agent at the start of the luteal phase and if so, could it inhibit the
process of luteinisation?
(The folliculo-luteal transition in a marmoset monkey ovary, kindly provided by Prof Hamish
Fraser)
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5.1 Introduction
The transition of a dominant follicle into the corpus luteum is one of the fundamental
processes in reproductive biology. It involves the transformation of follicular cells into
the most active steroidogenic endocrine gland in the body. Luteinisation, the process
whereby follicular granulosa cells differentiate into the granulosa-lutein cells of the
corpus luteum involves marked and disparate morphological, biochemical and cellular
changes. The granulosa cells become terminally differentiated, such that they do not
divide again, and develop the enzyme machinery necessary for massive progesterone
synthesis. This highly organised process, that is tightly orchestrated by steroid hormones,
gonadotrophins and growth factors, is associated with structural and functional changes
that characterise the folliculo-luteal transition. In a conception cycle, a viable corpus
luteum is essential to the success of early gestation whilst in a non-conception cycle its
demise is necessary for the next wave of folliculogenesis.
The molecular pathways involved in the luteinisation of granulosa cells are not entirely
clear. Whilst the pre-ovulatory LH surge, or addition of LH or hCG during an assisted
conception programme, can initiate luteinisation, experimental work clearly shows that
removal of granulosa cells from the follicle causes spontaneous luteinisation in the
absence of LH. Indeed this hampers the study of follicular granulosa cells in vitro. It is
therefore believed that luteinisation is a differentiation pathway that is programmed
before antral formation, and the only way the follicles can escape this fate is by inhibitory
factors (Wehrenberg and Rune, 2000). Literature suggests that the follicle itself can
provide a mileu in order to discourage luteinisation (Channing et al., 1980; Eppig et al.,
1997; Murphy, 2000) and inhibitor(s) of such magnitude may actually be present in
follicular fluid (Channing et al., 1978; Ledwitz-Rigby et al., 1977) or come directly from
the oocyte itself (Brankin et al., 2003; Vanderhyden and Macdonald, 1998). It therefore
appears that the LH surge is able to remove such inhibitory factors, disrupt connections
between granulosa cells and the oocyte and/or induce genes that facilitate luteinisation.
One molecule that may have a role in the prevention of luteinisation is activin A, a
dimeric glycoprotein and member of the transforming growth factor TGF-P superfamily.
Activin A is found in follicular fluid and can delay granulosa cell luteinisation and/or
atresia by decreasing basal and hCG-induced progesterone secretion in human (Di
Simone et al., 1994; Rabinovici et al., 1990), monkey (Brannian et al., 1992) sheep
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(Shidaifat et al., 2001) and goat (Shidaifat, 2001) granulosa cells. In addition this thesis
has shown that activin A action may be involved in promoting luteolysis at the end stage
of the luteal phase (Chapter 3; (Myers et al., 2007a)). This study shows that during
maternal recognition of pregnancy one of the roles of hCG may be to inhibit activin
action. Therefore it was hypothesised that activin A was anti-luteal and at the start of the
luteal phase one of the roles of the preovulatory LH surge is to remove activin A and
facilitate luteinisation. At the end of the luteal phase activin A action increases to promote
luteolysis and in early pregnancy hCG, acting through the LH receptor, continues to
inhibit activin A action and facilitate luteal maintenance.
5.1.1 Aims
To determine if activin A and hCG have opposing effects in luteinised granulosa cells in
vitro
To establish if the luteinisation of granulosa cells involves a differentiation step that is not
terminal and that activin A can return the luteinised granulosa cell to a more follicular
phenotype
To determine the effects of hCG and activin A on luteal steroidogenesis
To localise the protein expression of genes which are modulated by the preovulatory LH
surge in an antral follicle and corpora lutea
To establish if hCG and activin can modulate the expression of genes known to change
during the follicular-luteal transition
To determine if there is a dose effect of activin A required to attenuate maximal
stimulating doses of hCG in cultures of luteinised granulosa cells
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5.2 Materials and Methods
5.2.1 Collection of human ovarian tissue
Normal ovarian tissue was collected (n=3) from women with regular cycles undergoing
hysterectomy for benign conditions. Tissue collection was approved by the local medical
research ethics committee and all women gave informed consent.
5.2.2 Isolation of human luteinised granulosa cells
Isolation of luteinised granulosa cells using Percoll gradient centrifugation was carried
out as described in section 2.1.3. Twenty-four well cell culture plates were precoated
with 25 pi ofmatrigel (BD Biosciences) and 100,000 viable cells per well were plated in
1 ml of serum-free media.
5.2.3 Activin A and hCG treatments in primary cultures of luteinised
granulosa cells
Pooled luteinised granulosa cells in serum-free medium were refreshed with serum-free
culture medium every 2 days after until day five when they were treated with the
combinations of human recombinant activin A (R&D Systems) or a maximally
stimulating dose of hCG (Serono). The following six treatments were added to luteinised
granulosa cells; 1) 0.1% BSA in sterile PBS; 0.1% BSA with 2) 100 ng/ml hCG; 3) 25
ng/ml activin A; 4) 100 ng/ml activin A; 5) 25 ng/ml activin A with 100 ng/ml hCG; and
6) 100 ng/ml activin A with 100 ng/ml hCG. Each pooled experiment for the following
treatments was carried out at least three times to avoid biological bias.
5.2.4 Preparation of cDNA from luteinised granulosa cells cultures
Luteinised granulosa cell mRNA was extracted using RNeasy mini-spin columns after
lysis by the addition of RNeasy lysis buffer (Qiagen). Lysates were frozen until processed
as per manufacturers' protocols then DNase treated with on-column DNasel (Qiagen) and
quantified using the NanoDrop ND-1000 Spectrophometer (NanoDrop Technologies).
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Messenger RNA was then reverse transcribed into cDNA using random hexamers
(Applied Biosystems).
5.2.5 Quantitative analysis of gene expression by RT-PCR
Quantitative real-time PCR was carried out on the ABI PRISM 7900 heat-cycler
sequence detection system (Applied Biosystems) using specific primers and probes
(Eurogentec) for each gene of interest (Table 5.1) and levels were related to a ribosomal
18S internal control (Applied Biosystems). All samples were performed in duplicate and
a relative comparison was made to an appropriate tissue control tissue cDNA.
Table 5.1 List of all primer/probe sequences used for Taqman quantitative RT-PCR and
reference obtained from.
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3PHSD Assay on demand (Applied
Biosystems Hs00605123_ml)
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5.2.6 Immunohistochemistry
Immunolocalisation of ERa was carried out using a mouse monoclonal antibody (Vector)
in 5gm paraffin tissue sections of human ovary prepared on poly-L-lysine-coated
microscope slides. These sections were dewaxed, rehydrated, washed in PBS and
subjected to antigen retrieval as described in section 2.1.9. All sections were washed and
blocked in 3% P^CVmethanol, avidin/biotin block and normal goat serum as described in
sections 2.1.9. Sections were incubated overnight in primary antibody diluted 1 in 20 in
NGS blocking solution at 4°C.
All sections were then washed twice for 5 min in PBS before incubation with biotinylated
goat anti-mouse secondary antibody (DAKO) 1 in 500 in PBS. Incubations lasted for 1 h
and were followed by two washes for 5 min. Thereafter, sections were incubated in
avidin-biotin complex-HRP (DAKO) for 1 h as manufacturers' instructions. Incubations
were at room temperature for 1 h and all sections were washed in PBS (2x5 min) and
bound antibodies visualised by incubation with liquid DAB (DAKO). Sections were
counterstained lightly with hematoxylin to enable cell identification. Negative controls
for each antibody examined were performed identically to the above protocol but with
primary antibody incubations substituted with blocking serum.
5.2.7 Fluorescent immunohistochemistry
Co-localisation studies of type 11PHSD1 and 11PHSD2 were performed as described in
section 4.2.8.
5.2.8 Statistical analysis
Statistical analyses used are highlighted in the Figure legends. Parametric statistics were
used if the data was normally distributed with similar standard deviations. Groups were
analysed by ANOVA with Bonferroni pairwise comparisons; if the data was not normally
distributed non-parametric statistics were used. Groups were analysed by Kruskal-Wallis
test with Dunn's Multiple Comparison Test. A paired t-test was used when treatment and
control samples were analysed. Differences were considered significant at p<0.05 level.
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5.3 Results
5.3.1 The effects of activin and hCG on luteinised granulosa cell
steroidogenic pathway
Luteinised granulosa cells express the enzymatic machinery to synthesise progesterone.
Maximally stimulating doses of hCG (100 ng/ml) maintained the high LH receptor and
low FSH receptor expression and increased the expression of StAR (p<0.001) and
3pHSD (p<0.001). In contrast, physiological concentrations of activin A (25 ng/ml)
inhibited LH receptor expression (p<0.01) and induced FSH receptor expression (p<0.05)
(Figure 5.1) In concurrence with previous studies (Brannian et al., 1992; Di Simone et al.,
1994) activin A also negated gonadotrophin-induced progesterone secretion from
luteinised granulosa cells (data not shown).
Figure 5.1 Differential effects of activin A and hCG on key genes involved in the
steroidogenic pathway. A, HCG maintained the expression of LHR (p>0.05, Kruskal-
Wallis) however activin A inhibited receptor expression in primary cultures of luteinised
granulosa cells (p<0.01, Kruskal-Wallis). B, Key regulators of the steroidogenic pathway,
StAR (p<0.001, Kruskal-Wallis) and C, 3|3HSD (p<0.001, ANOVA) were up-regulated
by hCG treatment whilst activin A had no effect upon these genes (p>0.05). D, Like LHR
expression, hCG maintained the expression of FSHR in vitro however treatment with
activin A significantly up-regulated receptor expression (p<0.05, ANOVA).
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5.3.2 The effects of activin and hCG on the protein expression of other
molecules that change during luteinisation
The lipHSD enzyme isoforms change during luteinisation (Michael et al., 1997; Tetsuka
et al., 1997; Thurston et al., 2003; Yong et al., 2000). The predominant isoform in
follicular granulosa cells is 11|3HSD2 (Figure 5.2 A-C) while the predominant isoform in
granulosa-lutein cells of the corpus luteum is lipHSDl (Figure 5.2 D-F). This suggests
that during luteinisation lipHSDl is up-regulated while 11J3HSD2 is down-regulated. In
addition immunolocalisation of ERa. is different in the follicle and in the corpus luteum
(Saunders et al., 2000). Granulosa cells of the antral follicle clearly express ERa while
expression in the granulosa-lutein cells of the corpus luteum appears negligible (Figure
5.2 G-H). This suggests that ERa expression is down-regulated during luteinisation.




Figure 5.2 Immunolocalisation of 1 lpHSD types 1 and 2 and ERa in the human ovary.
Double immunofluorescence of lipHSDl in green (panels A, D) and 11(3HSD2 in red
(panels B, E) in the mural granulosa cells (gc) of an antral follicle (A-C) and the
granulosa-lutein cells (glc) of the corpus luteum (D-F). A, Single immunofluorescence
clearly demonstrates that lipHSDl is not expressed in the granulosa cells of an antral
follicle whilst, B, 1 ipHSD2 is indeed localised to these cells C, A merge image of panels
A and B clearly showing only 11PHSD2 protein expression in the follicular granulosa
cells (fgc). D, The steroidogenic cells of the corpus luteum express both 11PHSD1
(green) and E, 11PHSD2 (red). F, A merge image of panels D and E demonstrates
predominance of 1 ipEISDl isoform over 1 ipHSD2 in the granulosa-lutein cells (glc). G,
Light field image of an ovarian section showing both a corpus luteum and an antral
follicle demonstrates that ERa is localised to the granulosa cells of the follicle (fgc) but
not the adjacent thecal cell (tc) layer. The follicular fluid in the antral cavity of the follicle
is denoted by (ft). ERa. staining in the granulosa-lutein cells (glc) and theca-lutein cells
(tic) of the corpus luteum is negligible. H, A negative control for ERcx shows no staining
in either cell type. Scale bars A-F=20 pm, G=40 pm, H=60 pm
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5.3.3 The effects of activin and hCG on the mRNA expression of other
molecules that change during luteinisation
As expected (Myers et al., 2007b), hCG markedly up-regulated the expression, of
lipHSDl (p<0.001), in cultures of luteinised granulosa cells by over 30-fold (Figure
5.3A). Although activin A (at either at either 25 or 100 ng/ml) alone had no effect upon
lipHSDl expression, it was evident that when added simultaneously with hCG, activin
opposed the effect of hCG (p<0.01) (Figure 5.3A). The opposite effect tended to be seen
when 11PHSD2 isoform was examined. HCG tended to reduce, while activin A tended to
increase, 11 [3HSD2 expression (Figure 5.3B). The action of activin A on the expression
of 11(1HSD2 was inhibited by hCG (Figure 5.3B). A similar pattern was seen when
expression of ERa was investigated (Figure 5.3C). In cultures of luteinised granulosa
cells hCG decreased receptor expression (p<0.05) (Figure 5.3C). Activin A (25 or 100
ng/ml) maintained ERa expression although in simultaneous treatments with hCG, hCG
tended to attenuate this response (Figure 5.3C).
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11 pHSD type 1
b
B 1ipHSD type 2
C hCG ActA hCG/ActA
Figure 5.3 Expression of genes that change during luteinisation. A, HCG up-regulated
lipHSDl by over 30-fold (p<0.001, ANOVA) in primary cultures of luteinised
granulosa cells, whilst activin A alone had no effect (p>0.05, ANOVA). However when
added simultaneously with hCG, activin A attenuated the hCG response (p<0.01,
ANOVA). B, In contrast, 11(1HSD2 tended to be up-regulated by activin A treatment,
whilst hCG significantly attenuated this effect (p<0.05, Kruskal-Wallis). C, Expression
of ERa. was decreased by hCG in vitro (p<0.05, Kruskal-Wallis) whilst activin A
maintained receptor expression. HCG added simultaneously with activin A tended to
reduced expression levels of ERa similar to those of hCG.
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5.3.4 Activin A inhibits hCG effects in a dose-dependent manner
To further elucidate the disparate effects of activin A and hCG, activin A was added at
two different concentrations (25 and 100 ng/ml) simultaneously with hCG (100 ng/ml) to
cultures of luteinised granulosa cells (Figure 5.4). Activin A and hCG had opposing
effects on the expression of candidate genes in a dose-dependent fashion. Increasing
concentrations of activin A significantly (p<0.01) decreased the expression of the LH
receptor (Figure 5.4) in a dose-dependent manner in the presence of hCG and similar
patterns were also observed for StAR (p<0.001) and 11 [3HSD1 (p<0.01) (Figure 5.4). In
contrast, FSH receptor expression tended to increase with the dose of activin A (Figure
5.4).
hCG hCG/Act25 hCG/Act100 hCG hCG/Act25 hCG/Act100
Figure 5.4 Activin acts in a dose-dependent manner to attenuate the response of hCG. A,
Activin A attenuated the hCG effect on LHR (p<0.01, Kruskal-Wallis), B, StAR
(p<0.001, Kruskal-Wallis) and C, 1 IpHSDl (p<0.01, ANOVA) by minimising hCG
action in a dose-dependent manner in primary cultures of luteinised granulosa cells. D,
The opposite trend was observed with the FSHR whereby expression tended to increase
with the dose of activin A.
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5.3.5 The likely effects of activin A and hCG on activin A action.
Activin action can be inhibited at several levels including synthesis, secretion and
reception. Increasing the expression of the inhibin a subunit will increase inhibin A and
reduce activin A synthesis. Follistatin will bind to activin A and inhibit its action and the
expression of P-glycan facilitates inhibin A inhibition of activin action at a receptor level.
The addition of hCG increased the expression in inhibin a subunit (p<0.01), and its p-
glycan receptor (pcO.OOl) (Figure 5.5). Activin A significantly (p<0.01) lowered the
hCG-stimulated expression of follistatin and tended to increase the expression of the
activin PA subunit (Figure 5.5).
A a subunit B pA subunit
Figure 5.5 The likely effect of hCG and activin A on activin action. A, In primary
cultures of luteinised granulosa cells, hCG up-regulated the expression of the inhibin a
subunit (p<0.01, ANOVA) whilst activin A tended to attenuate this effect. B, HCG alone
had no effect upon the expression of the common (1A subunit (p>0.05, ANOVA) whilst
activin A tended to up-regulate it. The activin A effect was dimished in cultures exposed
to hCG and activin A concurrently. C, HCG tended to increase the expression of the
activin inhibitor follistatin, whilst activin A alone had no effect, it reduced the hCG effect
in co-treatments (p<0.01, ANOVA). D, The inhibin co-receptor P-glycan was
significantly augmented with hCG (p<0.001, ANOVA) and although activin A had no
effect on receptor expression, co-treatment with hCG tended to decrease the hCG
response.
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5.4 Discussion
The current study has investigated the effects of activin A and hCG on human luteinised
granulosa cells in vitro. Already, studies from this thesis have suggested that hCG and
activin have opposing effects on the regulation of tissue remodelling associated with
luteolysis (Chapter 3; (Myers et al., 2007a)). Herein, it is suggested that hCG and activin
A have opposite effects on the luteinised granulosa cells involved in luteal formation.
Activin A appears to reduce the luteinisation of luteinised granulosa cells so they have a
more follicular phenotype, while hCG increases the luteinisation to a more luteal
phenotype. The effect of activin on granulosa cells has been previously documented
(Hutchinson et al., 1987; Shukovski et al., 1993; Shukovski et al., 1991). However this
investigation serves to highlight three concepts; 1) that hCG and activin A tend to have
opposing actions on luteinised granulosa cells, 2) that activin A can reverse features of
luteinisation once it has occurred and 3) that some of the effects of activin A are seen
only in the presence of hCG. These studies increase our understanding of the role of
activin in the folliculo-luteal transition.
Luteinisation of follicular granulosa cells into the granulosa-lutein cells of the corpus
luteum is a key element of the folliculo-luteal transition. The formation of the corpus
luteum itself involves a co-ordinated interplay of fundamental processes such as cell
proliferation, cell differentiation, tissue remodelling and angiogenesis that is unparalleled
in any other tissue in the adult mammal (Fraser and Duncan, 2005; Murphy, 2000;
Stouffer, 2006). The mechanism and regulation of this process in not fully understood
but it is driven by a complex co-ordination of steroid hormones, gonadotrophins,
cytokines, growth factors and disparate paracrine signalling molecules. There are marked
changes to steroidogenic cell functions during luteinisation. Granulosa cells become
terminally differentiated, cell division ceases, the cells undergo marked hypertrophy and
there are marked changes in the expression of different molecules including steroidogenic
enzymes and hormone receptors (Murphy, 2000; Stocco et al., 2007). The proximal
event that initiates ovulation and luteinisation is the pre-ovulatory LH gonadotrophin
surge (Filicori, 1999; Murphy, 2000), mimicked by hCG, acting via LH/hCG receptors.
LH/hCG may directly induce the disparate and marked changes within the follicular
granulosa cells phenotype that are necessary for appropriate luteal cell function whilst
simultaneously withdrawing factors that are thought to inhibit luteinisation.
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Inhibitors of luteinisation have been reported in many studies and indeed candidate
molecules have been suggested. Indeed it is clear that luteinisation can occur in the
absence of LH/hCG when granulosa cells are removed from the follicular environment.
The physical presence of the oocyte has been reported to inhibit luteinisation in many
species, for example, the mouse (Vanderhyden et al., 1993), pig (Coskun et al., 1995) and
human (Seifer et al., 1996) with candidate factor(s) acting in a paracrine signalling
fashion from the oocyte to the granulosa cells. Furthermore, factor(s) in the follicular
fluid of small, but not large follicles, have also proved to be inhibitory (Channing et al.,
1978; Ledwitz-Rigby et al., 1977; Murphy, 2000). The nature of these molecules is not
entirely clear but it is likely that members of the TGF-(3 family are involved (Glister et
al., 2005; Shimasaki et al., 1999).
One member of the TGF-P superfamily that does have a role in follicular granulosa cell
function is activin A. Activin A, is locally produced by follicles, predominantly smaller
follicles, during their growth phase (Knight and Glister, 2006). As a follicle matures,
activin continues to be produced but the follicular microenvironment becomes less activin
dominant and more inhibin/follistatin dominant (Hillier, 1991b; Roberts et al., 1993;
Schneyer et al., 2000; Yamoto et al., 1992). However, it is well established that activins
are essential for follicular granulosa cell proliferation, FSH receptor regulation, FSH-
induced aromatase expression, decreased theca cell androgen production, and increased
oocyte maturation (Knight and Glister, 2006). While a trophic role in the follicle is
apparent, the role for activin A in the corpus luteum is less clear. Indeed, in women
plasma concentrations of activin A tend to increase towards luteolysis (Muttukrishna et
al., 1996) and its local actions appear to facilitate luteolysis (Chapter 3; (Myers et al.,
2007a)). As activin A appears to have a positive role in the follicle and a negative role in
the corpus luteum, activin action appears to be withdrawn at the follicular-luteal
transition.
Activin action is tightly regulated at several different levels (Harrison et al., 2005). The
expression of the pA subunit itself is regulated (Hillier, 1991b; Roberts et al., 1993) and
in the presence of pA, up-regulation of the p subunit will push the synthesis of inhibin A
rather than activin A. Inhibin A will also inhibit activin A at the level of its receptor by
binding to p-glycan to complex with the activin receptor and inhibit activin action (Lewis
et al., 2000). In addition follistatin secretion is also regulated. Follistatin binds
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irreversibly to activin to neutralise its bioactivity (Kogawa et al., 1991; Nakamura et al.,
1990). The present chapter hypothesised that during ovulation one of the actions of
LH/hCG was to change the follicular environment to inhibit activin action and this would
facilitate luteinisation. This study was designed to analyse the effect of hCG on the
expression of luteinisation and activin-associated genes in primary cultures of luteinised
granulosa cells and investigate whether maintaining activin A action was able to inhibit or
interfere with the effects of hCG in these already luteinised cells.
One of the effects of hCG is to promote the expression of genes involved in the synthesis
of progesterone. Whilst follicular granulosa cells predominantly secrete oestradiol the
granulosa-lutein cells are also able to secrete up to 100-fold greater amounts of
progesterone. Indeed, it has been estimated that the human corpus luteum can secrete up
to 40 mg of progesterone per day during the menstrual cycle (Lipsett, 1978). This is
secondary to the increasing expression of LH receptors, StAR, P450scc and 3|3HSD during
luteinisation. The expression of StAR and 3PHSD in luteinised granulosa cells was
increased by hCG while activin A could inhibit the increase in response to hCG in a dose
dependent manner. Activins are well known to have inhibitory effects upon basal and
hCG-induced progesterone secretion in dispersed cultures of granulosa-lutein cells in
both the macaque (Brannian et al., 1992) and in women (Di Simone et al., 1994).
However activin A does not just interfere with hCG action as it has direct actions on
luteinised granulosa cells. Activin A decreased LH receptor expression directly and
increased FSH receptor expression in a dose dependent fashion using physiologically
relevant concentrations. FSH and its seven-transmembrane receptor are essential for
successful follicular development and granulosa cell function (Dierich et al., 1998;
Kumar et al., 1997), however once granulosa cells have differentiated into those of the
corpus luteum FSH receptors in the human corpus luteum are minimally expressed
(McNeilly et al., 1980). Studies in rats have shown that FSH receptor expression is down
regulated during luteinisation (Camp et al., 1991) whilst in vitro cell studies have shown
that hCG treatment completely abolishes the receptor expression (Nakamura et al., 1991).
As well as inhibiting hCG-induced progesterone synthesis activin A directly induced a
more follicular phenotype on already luteinised granulosa cells. These results highlight
the importance of adequately suppressing active activin action during luteinisation and
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maintaining this suppression in the functional luteal phase so that progesterone synthesis
is not interrupted.
It is not just the progesterone synthesis pathway that changes during luteinisation.
Another change is in the metabolism of Cortisol by steroidogenic cells during the
follicular and luteal phases. The lljlHSD enzymes control Cortisol metabolism by their
type 1 (that tends to generate Cortisol) and type 2 (that tends to inactivate Cortisol)
isoforms. Numerous studies have shown clear evidence that there is a switch in 11J3HSD
isoforms associated with the follicular-luteal transition (Michael et al., 1997; Tetsuka et
al., 1997; Thurston et al., 2003; Yong et al., 2000). This has been further confirmed in
Chapter 4, whereby the switch in women at a protein level and localised expression to the
granulosa/granulosa-lutein cells of the ovary. Type 1 lipHSD protein is not found in
antral follicular granulosa cells whilst type 2 11(3HSD is abundant. Similar to the mRNA
transcripts patterns observed in the human corpus luteum (Chapter 4; (Myers et al.,
2007b)), both lipHSD isoforms are present in granulosa-lutein cells, however there has
been a marked switch in the predominant isoform to type 1 with only low levels of type 2
still detectable. The current study demonstrates that activin A suppresses hCG actions on
type 1 lipHSD expression, whilst hCG attenuates activin actions on type 2 11(3HSD.
These responses in luteinised granulosa cells give important insights into the switch in
lipHSD isoforms that consequently predict the local Cortisol environment in the
follicular or luteal phase and highlight the regulation of llf>HSD expression, and the
opposing actions of hCG and activin, during luteinisation.
The opposing action of hCG and activin A during luteinisation can also be seen when the
expression of ERa is investigated. Although the corpus luteum of women and primates
express oestradiol receptors in the form of ER|3 (Duffy et al., 2000; Saunders et al., 2000)
the steroidogenic cells of the primate corpus luteum, unlike follicular granulosa cells, are
generally thought not to express ERa (Chandrasekher et al., 1994; Iwai et al., 1990).
Herein ERa has been immunolocalised to the nuclei of granulosa cells of antral follicles
and clearly absent in the granulosa-lutein cells of the corpus luteum. This is most likely
due to the preovulatory LH surge which may be involved in switching off follicular ERa
expression as the granulosa cells differentiate into granulosa-lutein cells of the corpus
luteum. Results from cell culture in the present study suggest that ERa is differentially
regulated by activin A and hCG in luteinised granulosa cells as without activin A in the
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system, hCG down regulated ERa expression. These findings are consistent with work
involving the oestrogen receptor null mice that suggest that ERa, unlike ER|3, tends not
to facilitate granulosa cell differentiation in the peri-ovulatory period (Couse et al., 2005).
The role of LH/hCG in luteinisation is clear and facilitated by the reduction in activin
action.
It is important to inhibit activin action during luteinisation. This is evident from the
present study whereby the effect of activin A alone or in inhibiting hCG action is dose
dependent. The effect of hCG in luteinised granulosa cells is to continue to remove
activin action. In corpora lutea and luteal cells in vitro (Illingworth et al., 1996;
Muttukrishna et al., 1997) and in cultured luteinised granulosa cells (Myers et al., 2007a)
hCG increases inhibin A expression. Furthermore, hCG up-regulated the (3 subunit and
activin A itself inhibited this response. Similarly hCG increases (5-glycan expression and
this is attenuated in the presence of activin. Indeed hCG up-regulates follistatin (Myers et
al., 2007a) and activin inhibits this effect. As activin A itself seems to be involved in
promoting activin action it is likely that continued LH/hCG effects during luteinisation,
and in the corpus luteum, by inhibiting activin, would further reduce activin action in a
feedback loop. As LH action seems to be abrogated in the corpus luteum during luteolysis
(McNeilly et al., 1980; Messinis, 1997) the inhibition of activin action will be reduced
and activin may feed-forward to increase its action and facilitate a role in luteolysis
(Myers et al., 2007a) that will be self-limiting as steroidogenic cells are removed from the
ovary (Yuan and Giudice, 1997).
One of the features of luteinisation is terminal differentiation and the cessation of cell
division. The effect of activin A on the potential of the luteinised granulosa cells to divide
has not yet been investigated. However by showing that activin A can induce a more
follicular granulosa cell phenotype of these cells it may be suggested that the
differentiation state of these cells may be more plastic that expected. A marker of the cell
cycle, such as cyclin D2 is up-regulated by FSH and down-regulated by LH in granulosa
cells (Sicinski et al., 1996). Conversely, p27kip l, a cdk inhibitor protein that inhibits entry
into the cell cycle and maintains differentiation (Robker and Richards, 1998) is known to
be expressed in granulosa cells in response to LH and along with p21cipl is maintained at
high levels in (mouse) corpora lutea (Deng et al., 1995; Robker and Richards, 1998).
Furthermore, mice deficient in the p27kip"' gene show that corpora lutea formed after
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luteinisation do not stop proliferating (Tong et al., 1998). It could by postulated that
activin A may be able to facilitate cell division in luteinised cells just as it can in FSH-
treated unluteinised granulosa cells (Kumar et al., 1997; Li et al., 1995; Matzuk et al.,
1996; Ogawa et al., 2003). Indeed a preliminary report suggested increased cell numbers
in cultures of human luteinised granulosa cells grown in the presence of activin A
(Rabinovici et al., 1990) although it should be noted that this study only reports an
increase in cell number and it cannot be excluded that the increase in number may be
attributed to other contaminating cell types (ie fibroblasts, endothelial cells) (Duncan et
al., 2005b) that are not terminally differentiated. It is clear from both in vivo and in vitro
studies that activins do promote follicular granulosa cells proliferation, however whether
or not they can 'rescue' or 'reverse' the luteinised granulosa non-dividing phenotype type
remains unknown.
The identification of activins having a role in luteinisation is not novel. This research
however focuses on the luteinised granulosa cell as a luteal cell that has already been
luteinised by hCG in vivo. In that circumstance activin A action appears to be inhibited. If
activin A is put back in the system it can inhibit hCG action and has a direct anti-
luteinisation effect. It seems that removal of activin is important to allow formation of
the corpus luteum. As increased activin A in the late-luteal phase can facilitate removal of
the corpus luteum it appears that activin A is anti-luteal at both extremes of the luteal
lifespan (Myers et al., 2007a). The Smad4 conditional knockout mouse model is another
system that provides evidence for activin A as an inhibitor of luteinisation. These mice
demonstrate a loss of both TGF-|3 and activin signalling with targeted disruption of the
common Smad 4 in ovarian granulosa cells (Pangas et al., 2006). Premature luteinisation
of the follicular granulosa cells was one of the key phenotypes of this mouse, which was
clearly evident by an up-regulation of genes associated with luteinisation. Luteal markers
such as the LFI receptor, StAR, P450scc and 3PHSD were all up regulated in the absence
of activin signalling, whilst FSHR was slightly down regulated. Indeed disrupted activin
A action in mature ovaries of the mouse resulted in an excess of corpora lutea (Pangas et
al, 2007).
In summary, this chapter has presented evidence that activin A and hCG have opposing
molecular effects upon genes involved in the follicular-luteal transition in the ovary.
These results suggest that removal from, or at least suppression of activin in, the system is
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very important for successful luteal function. Furthermore, local activin action may be
detrimental to luteal function and structure and therefore successful luteal function
requires inhibition of activin action whereas luteal involution is facilitated by an increase
in activin activity during luteolysis (Myers et al., 2007a).
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Activin A Activin B
One of the major findings of this thesis has been characterisation of activin A as a
luteolysin in the human corpus luteum. For the first time, this thesis provides good
evidence to suggest a functional role for activin A in the human corpus luteum. Although
we are beginning to understand more about this activin form, less is known about activin
B. Therefore, the focus of Chapter 6 is to investigate a potential role for activin B in the
human corpus luteum and to determine whether it has similar or different paracrine or
endocrine interactions to activin A.
(The basic molecular structures of the activin A and activin B isoforms)
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6.1 Introduction
Activins and inhibins are members of the TGF-P superfamily that have been well
characterised for their roles in reproductive development. Structurally related, yet
functionally diverse the activins (P:P) and inhibins (a:P) are composed ofmature subunit
chains linked together by disulphide bonds. The P-subunit expression determines the
activin/inhibin subtype, with PA forming either inhibin A (a:pA) or activin A (PA:pA)
and the pB chain conferring inhibin B (a:pB) or activin B (pB:PB). Futhermore, activin
AB (PA:PB) also exists. Initially discovered for their opposing abilities to regulate
pituitary FSH, much work over the past decades has focused upon the disparate roles of
these glycoproteins.
Assays for inhibin and activin have greatly increased our knowledge of the expression
patterns of these glycoproteins across the ovarian cycle. These precise and replicable
results have clearly shown the diverse expression patterns of the inhibin A, inhibin B,
activin A and activin AB in naturally cycling women (Evans et al., 1997; Groome et al.,
1994; Groome et al., 1996; Groome et al., 1995; Knight and Muttukrishna, 1994). Such
assays have proved successful by utilising panels of monoclonal antibodies to synthetic
peptide immunogens that were used to construct enzyme-linked immunosorbent assays
(ELISA) (Lockwood et al., 1998b). Unfortunately, due to the lack of a readily available,
reliable activin B assay, this protein remains less characterised across the ovarian cycle in
the current literature.
However with the information from invaluable previous work detailing the protein
expression patterns of inhibin A, inhibin B and activin A across the menstrual cycle in
women, coupled with interventional in vitro work, well-informed hypotheses can be
made. With the reported low concentrations of inhibin B during the luteal phase
(Illingworth et al., 1996), and the localisation of flB in the corpus luteum, the present
chapter hypothesised that activin B may indeed be a product of the human corpus luteum
and potentially have an endocrine or paracrine role. More recently, a mechanistic role for
activin A was suggestesd during human luteolysis (Myers et al., 2007a). Already activin
A and activin B have been shown to exhibit both differential (Matzuk et al., 1995;
Vassalli et al., 1994) yet overlapping roles within the ovary (Brown et al., 2000).
Therefore the aim of the current study was to seek out a role for activin B in the human
corpus luteum and if so, to determine if it is different to that of activin A. This chapter
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documents preliminary results with an Oxford Brookes University-developed activin B
assay that is still currently under optimisation. However, a prelude into some of the
future work and working hypotheses will give an insight into potential roles for activin B
in the human corpus luteum.
6.1.1 Aims
To identify and localise the PB subunit of activin B in the human corpus luteum
To assess the gene expression and regulation of the PB subunit in primary cultures of
luteinised granulosa cells
To utilise a reliable ELISA assay for the activin B protein which does not cross-react with
the PA subunit such that activin B is easily distinguishable from activin A and inhibin A.
To utilise this assay for in vitro experiments to further understand potential endocrine and
paracrine signalling molecules that may have effects upon activin B secretion.
To investigate a possible paracrine role for activin B in the human corpus luteum by
assessing the expression and activity of the proteolytic enzyme MMP-2
To determine if activin A and activin B have differential role in the human corpus luteum
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6.2 Materials and Methods
6.2.1 Collection of tissues and cells
Ovarian/corpora lutea tissue (n=3) and cells were obtained as described in section 2.1.2
2.1.3. Human endometrial tissue (n=3) was obtained at the time of collection of the
corpus luteum and dated in the same manner (section 2.1.2.2) (Duncan et al, 1996b).
Informed consent was obtained from all patients and the study was approved by the
research ethics committee.
6.2.2 Isolation of human luteinised granulosa cells and derivation of
fibroblast-like cells
Isolation of luteinised granulosa cells using Percoll gradient centrifugation was carried
out as described in section 2.1.3. Twenty-four well cell culture plates were precoated
with 25 pi of matrigel (BD Biosciences) and 100,000 viable cells per well were plated in
1 ml of serum-free media.
Fibroblast-like cells were obtained from prolonged cultures of follicular aspirates as
described in section 2.1.4 and 60,000 cells per well were plated in 1 ml of 10% FBS
culture medium on 24-well cell culture plates.
6.2.3 Primary cell culture treatments
Each pooled experiment for the following treatments was carried out at least 3 times to
avoid biological bias.
6.2.3.1 Activin A and hCG treatments in primary cultures of luteinised
granulosa cells
Pooled luteinised granulosa cells in serum-free medium were refreshed with serum-free
culture medium every 2 days after until day five when they were treated with the
combinations of human recombinant activin A (R&D Systems) or a maximally
stimulating dose of hCG (Serono). The following six treatments were added to luteinised
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granulosa cells; 1) 0.1% BSA in sterile PBS; 0.1% BSA with 2) 100 hCG; 3) 25 ng/ml
activin A; 4) 100 ng/ml activin A; 5) 25 ng/ml activin A with 100 ng/ml hCG; and 6) 100
ng/ml activin A with 100 ng/ml hCG. Each pooled experiment for the following
treatments was carried out at least three times to avoid biological bias.
6.2.3.2 Manipulation of hCG in prolonged cultures of luteinised
granulosa cells
In order to mimic the luteal phase in primary cell culture, luteinised granulosa cells were
plated as described above and grown for 12 days as described in section 2.1.3.1. Briefly,
cells were stimulated with low dose hCG (1 ng/ml) with LDL (50 mg/1) beginning on day
2 and this was repeated every 2nd day until day 7 when treatments were replaced with
maximal doses of 100 ng/ml hCG/LDL or LDL alone. Cells were analysed after seven
days with hCG and on day 12 in the presence or absence of hCG to mimic the
progesterone secretion profile of late-luteal and luteal rescue stages respectively (Duncan
et al., 2005a).
6.2.3.3 Treatment of fibroblast-like cells with activin B
Cultures of fibroblast-like cells (n=3, experiments) were plated as above and after 6 hours
in serum-free culture, the medium was removed and replaced with medium containing
recombinant activin B (R&D Systems, 25 ng/ml) or an equivalent amount of 0.1% BSA
in carrier as a control. After 24 h the culture medium was collected for subsequent
zymography and the cells were used for mRNA extraction.
6.2.4 Preparation of cDNA from corpora lutea and cultured cells
Messenger RNA was batch extracted from frozen human corpora lutea and reverse
transcribed into cDNA using random hexamers as described in section 2.1.16. Cultured
cell mRNA was extracted using RNeasy mini-spin columns after lysis by the addition of
RNeasy lysis buffer (Qiagen). Lysates were frozen until processed as per manufacturers'
protocols then DNase treated with on-column DNasel (Qiagen) and quantified using the
NanoDrop ND-1000 Spectrophometer (NanoDrop Technologies). Messenger RNA was
then reverse transcribed into cDNA using random hexamers (Applied Biosystems).
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6.2.5 Quantitative analysis of gene expression by RT-PCR
Quantitative real-time PCR was carried out on the ABI PRISM 7900 heat-cycler
sequence detection system (Applied Biosystems) using specific primers and probes
(Eurogentec) for the PB subunit and levels were related to a ribosomal 18S internal
control (Applied Biosystems). All samples were performed in duplicate and a relative
comparison was made to an appropriate tissue control tissue cDNA. Primer and probes
are listed in Table 6.1.
Table 6.1 Table of all primer/probe sequences used for Taqman quantitative RT-PCR and
reference obtained from.






















(Springer et al., 2004)
6.2.6 Gelatin zymography
Gelatin zymography was performed on the culture medium from activin B treated
fibroblast-like cell cultures as described in section 2.1.11.
6.2.7 Measurement of activin B in primary cell culture medium
Activin B concentrations were measured in primary cell culture samples with a newly
developed activin B ELISA assay. Optimised and performed by Helen Ludlow and Nigel
Groome at Oxford Brookes University (Headington, Oxford), this assay uses the newly
developed 46A/F pB antibody for both capture and detection. This assay is still in
developmental stages and consequently the results presented in this thesis are
preliminary. The observed patterns of the assay are most likely true, however further
validation and optimisation of the assay will further confirm specificity and validity of
actual values obtained. This assay is currently being optimised for serum samples which
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will prove extremely useful for further characterising the concentrations of
activin/inhibins over the human ovarian cycle.
6.2.8 Immunohistochemistry
To allow staining with the [3B antibody in a controlled and easily repeatable manner, the
Bond-X automated immunostaining machine (Vision Biosystems, Newcastle, UK) was
utilised. Human ovary paraffin sections were cut, deparaffinised, rehydrated and
subjected to antigen retrieval in 0.01 M citrate buffer as described in sections 2.1.9.2,
2.1.9.3 and 2.1.9.3 before being place on the Bond-X machine. This method on the
Bond-X automated machine utilises a specific polymer high contrast program. Briefly,
slides were peroxidase blocked for 5 min, incubated for 2 h with the primary antibody
diluted 1 in 500 in the diluent supplied and then incubated with the post-primary reagent
for 15 min. Control sections were incubated with diluent alone or mouse IgGl protein
(Serotec) diluted to the same concentration as primary antibody in supplied diluent to
confirm antibody specificity. Sections were then incubated with the polymer reagent for
15 min to increase sensitivity of detection prior to DAB detection for 10 min. Sections
were counterstained in haematoxylin for 5 min. Slides were then removed from the
machine and dehydrated and mounted using Pertex.
6.2.9 Statistical analysis
Statistical analyses used are highlighted in the Figure legends. Parametric statistics were
used if the data was normally distributed with similar standard deviations. Groups were
analysed by ANOVA with Bonferroni pairwise comparisons; if the data was not normally
distributed non-parametric statistics were used. Groups were analysed by Kruskal-Wallis
test with Dunn's Multiple Comparison Test. A paired t-test was used when treatment and
control samples were analysed. Differences were considered significant at p<0.05 level.
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6.3 Results
6.3.1 Localisation of the activin/inhibin PB subunit in various reproductive
tissues using the 46A/F antibody.
With the newly developed mouse monoclonal PB antibody (46A/F) (kind gift from Helen
Ludlow and Nigel Groome, Oxford Brookes University), localisation of the (IB subunit in
various reproductive tissues was explored. Unlike the previous monoclonal anti-PB
subunit antibody (C5) which had 0.5% cross reactivity with the PA subunit, the new
monoclonal anti- PB (46A/F) antibody has only 0.0006% cross-reactivity with activin A
subunits (Ludlow el al., personal communication). Localisation of the PB subunit in
ovarian and endometrial tissue was investigated using the improved antibody. Positive
staining was observed in all sections assessed. In the secretory staged endometrial tissue
(Figure 6.1A) staining was clearly noted in the glandular endothelium (notably the
luminal epithelium) and to a lesser extent the surrounding stromal tissue compartments.
This staining concurred with other publications (Jones et al., 2000b; Mylonas et al.,
2004) that used other PB antibodies in secretory endometrium, however the staining in
the current study using the 46A/F antibody demonstrated much cleaner, more specific
staining. This is most likely due to the low cross-reactivity of the 46A/F antibody with
the PA compared to that of the other antibodies. Localisation of the PB subunit was also
evident in the ovary of follicle of different developmental stages (Figure 6.1B-C).
Subunit expression was clearly evident in the pre-granulosa cells and oocyte of the
primordial follicle (Figure 6.1A) and many cell types of an antral follicle. Specific
staining was confirmed with a mouse IgGl negative control (Figure 6. ID inset). It is also
interesting to note that when used under the exact same conditions (including antibody
concentration), localisation of the C5 PB antibody on a section with an antral follicle, had
a very dirty, less specific staining phenotype compared to that of the 46A/F antibody
(Figure 6.1C-D) that was much cleaner. Presumably, this is a result of the greater
incidence of cross-reactivity of the C5 antibody with the PA subunit, which is also
localised to these cells types and consequently amplifies the observed detection signal.
Consistent with the rest of this chapter the PB subunit, utilising the newly developed
antibody, was detected in the cells of the human corpus luteum (Figure 6.1E,F). At low
power this was most notable in the steroidogenic cells however at a higher magnification
it became evident that PB was expressed in both granulosa-lutein and theca-lutein cells
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and to a much lesser extent the surrounding stromal area. A negative control section

















Figure 6.1 Immunohistolocalisation of the (IB subunit in the human endometrium and
ovary. A, Human endometrium in the secretory phase shows pB localised to the
glandular epithelium (gl), particularly in the luminal side (pointing arrow on inset), and to
a lesser extent in the stromal (St) compartment. B, The PB subunit can be found in the
smallest of follicles, the primordial which demonstrated positive staining around the
nucleus of the oocyte (oo) and in the cytoplasm of the surrounding squamous
pregranulosa cells (pgc). C, PB is present in the many cell types of an antral follicle with
the strongest staining in the granulosa cells (gc). Surrounding thecal cells (tc) are also
positive for pB and indeed a blood vessel (bv) within this layer also shows localisation of
the activin/inhibin subunit. As expected, the PB subunit is also evident in the follicular
fluid (ff) of the antral cavity. D, Interestingly, replacing the 46A/F antibody with the C5
antibody in the exact same conditions results in staining in the same cell types of the
antral follicle, however to a much greater extent. Inset demonstrates that staining of the
follicle is specific as the IgGl control is negative for panels C and D. E, The corpus
luteum exhibits positive staining for the PB subunit. At low power PB is clearly evident
in the granulosa-lutein cells (glc). F, At high power however it is clearly evident that PB
is also localised to the adjacent theca-lutein cells (tic) and the endothelial cells of a blood
vessel (bv) in the surrounding stromal (St) area. Scale bars, A=200 pm, B=30 pm, C=50
pm D=100 pm E=1000 pm F=50 pm
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6.3.2 Quantification of the o and f3B subunits of activin and inhibin B
across the human luteal phase
To investigate the changes in the a chain of inhibin and the PB chain of inhibin B and
activin B across the luteal phase, carefully dated human corpora lutea were investigated
using quantitative RT-PCR (Figure 6.2). Expression of the a subunit remained constant
over the luteal phase (Figure 6.2A) however in the presence of exogenous hCG, during
luteal rescue, expression was markedly increased (p<0.05, Kruskal-Wallis). The same
was true for the PB subunit where by expression also remained constant across the normal
luteal phase, however the opposite occurred during luteal rescue whereby PB tended to
decline (Figure 6.2B). The marked increase in a subunit suggests that during maternal
recognition of pregnancy the increase in a and decrease in PB suggests that the potential
for activin B synthesis is reduced.
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Figure 6.2 Expression of the a chain of inhibin and the pB chain common to both activin
B and inhibin B across the luteal phase in the human corpus luteum. A, Real-time
quantitative RT-PCR shows the a subunit is significantly up regulated during luteal
rescue (p<0.05, Kruskal-Wallis). B, Whilst the PB subunit tends to decrease at this stage
it did not reach significance.
6.3.3 Expression of the PB subunit and activin B concentrations in the
'artificial' luteal cycle mirror the human luteal phase
Primary cultures of luteinised granulosa cells treated to mimic the luteal phase
demonstrate that both the pB subunit (Figure 6.3A) and concentrations of activin B
(Figure 6.3A) (range 7-26 pg/ml) as detected with the newly developed ELISA, mirror
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the mRNA expression patterns observed with the PB subunit over the human luteal phase
in Figure 6.2B. These results suggest that activin B is regulated by gonadotrophins and
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Figure 6.3 Chronic manipulation with hCG in cultures of luteinised granulosa cells
designed to mimic the luteal phase involved low dose hCG stimulation until day 7, which
was either replaced by maximal dose of the hCG on day 12 (+) or removal of hCG on day
12 (-). A, Expression of the PB subunit in primary cell culture did not change with hCG
withdrawal, however chronic stimulation with hCG significantly decreased mRNA
expression (p<0.05, Kruskal-Wallis). B, Concentrations of activin B mirror the observed
pattern of subunit expression in primary cell culture.
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6.3.4 Expression of the pB subunit is differentially regulated by activin A
and hCG in primary cultures of luteinised granulosa cells
HCG and activin A had differential effects upon the PB subunit in vitro. Activin A up
regulated the mRNA expression of the PB subunit at 25 and 100 ng/ml (p<0.01, Kruskal-
Wallis). HCG alone tended to decrease PB subunit expression, and when added
simultaneously with activin A treatments it was able to inhibit the activin effect.
C hCG AdA25 ActA2S/hCG ActAIOQ Act10G/hCG
Figure 6.4 PB subunit mRNA expression is differentially regulated by hCG and activin A
in primary cultures of luteinised granulosa cells. Activin A significantly up regulated PB
expression at both low (p<0.01, Kruskal-Wallis) and high (p<0.01, Kruskal-Wallis)
doses, whilst hCG tended to attenuate this effect.
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6.3.5 Activin B concentrations in activin A and hCG treatments of
iuteinised granulosa cells
Unlike the mRNA expression, activin B concentrations (in the range of 7-100 pg/ml)
were not as tightly regulated by activin A and hCG. Low or high (25 or 100 ng/ml)
activin A treatments (Figure 6.5) demonstrate trend to increase however this was not
statistically significant. In contrast to chronic treatments with hCG (Figure 6.3), 24 h
treatments did not downregulate activin B concentrations (Figure 6.5). This may be due to
|3B subunits still being present after only 24 h of gonadotrophin treatment, however after
longer hCG treatment the activin B (as evident in chronic treatments) and indeed the
inhibin B concentrations may decrease when the PB subunit production decreases. In any
case, combination treatments with activin A and hCG demonstrate a trend to lower
activin B concentrations although this was not statistically significant.
Figure 6.5 Activin B concentrations in primary cultures of luteinised granulosa cells.
HCG and activin A do not regulate activin B in 24 h treatments.
6.3.6 Preliminary results suggest that activin B does not regulate the
proteolytic MMP-2 expression or activity in fibroblast-iike cells
Unlike activin A (Myers et al., 2007a), preliminary results suggest that activin B does not
regulate the expression or activity of MMP-2 in fibroblast-like cells. Consequently,
activin B may not be involved in the tissue remodelling associated with luteolysis and
may exhibit differential actions to that of activin A in the human corpus luteum.
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Figure 6.6 Activin B does not regulate MMP-2 in primary cultures of fibroblast-like
cells. Relative MMP-2 expression using real-time quantitative RT-PCR, is shown in
solid bars and MMP-2 activity, using gelatin zymography, is shown in open bars. MMP-
2 expression (p>0.05, t-test) and activity (p>0.05, t-test) was not altered in fibroblast-like
cells exposed to 25 ng/ml of activin B in culture (n=3 experiments).
6.3.7 Activin A and Activin B up regulate Smad 7 in fibroblast-like cells
As activin A and activin B are thought to act through the same receptor system this
difference may be due to different binding at a receptor level or in modification affinities
of signalling. Therefore the effect on inhibitory Smad 7 was analysed. Activin A and
activin B have the same effect upon Smad 7 in fibroblast-like cells. Activin A tended to
increase the expression of Smad 7 in fibroblast-like cells and preliminary studies in
fibroblast-like cells show activin A exhibiting a similar effect. Smad 7 is indeed
expressed in the human corpus luteum (data not shown), however this is yet to be fully
documented.



























Figure 6.7 Activin A and activin B exhibit similar effects on the cytoplasmic protein
Smad 7 in fibroblast-like cells. A, Whilst the up-regulation of Smad 7 in activin A
treated cells was not significant (p>0.05, t-test) B, preliminary treatments (n=2) with
activin B demonstrate that both activins have the effects on this Smad protein.
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6.4 Discussion
The marked interest in activin/inhibin actions in ovarian biology over the past few
decades has resulted in a surplus of information regarding these glycoproteins and related
TGF-J3 superfamily members. From the initial isolation and purification over some 20
years ago, the discovery of the activins and inhibins has created a whole new niche in
reproductive biology. This has indeed been the direct result the careful development of
highly specific and sensitive two-site enzyme-linked immunoassays, for both in vivo and
in vitro experimental conditions, coupled with the more recent transgenic mouse models
of ovarian failure. Such studies have proven clear and definitive roles for activins and
inhibins whilst simultaneously raising a plethora of new and exciting questions.
One of the current unanswered questions in activin/inhibin biology is a potential role for
these proteins in luteal physiology. Expression of activin/inhibin subunits has been well
explored in corpora lutea of many species (human, primate, rodent) however until very
recently, a functional role had not yet been elucidated. Studies from the current thesis
describe a potential paracrine role for activin A in the human corpus luteum, utilising
mechanistic in vitro and observational in vivo approaches (Chapter 3; (Myers et al.,
2007a)). This chapter however raises a different question; does activin B have a similar
or disparate role to that of activin A in the human corpus luteum? To date, a (functional)
role for activin B in the human corpus luteum remains to be explored.
Activin B has been well characterised to the smaller pre-antral follicles in the many
species studied, with the expression of the (IB subunit reported to be in excess of the |3A
and a subunits (Roberts et al., 1993). This suggests that activin B is preferentially
produced/secreted by the smaller, less mature follicles (Liu et al., 2001). Indeed inhibin
B is a marker of small follicles (Bath et al., 2003) and is detected at its highest
concentrations in the plasma of women during their follicular phase (Groome et al.,
1996). Consistent with primary cell culture reports, induction with gonadotrophins (to
mimic the preovulatory surge) increases PA and a subunit, whereas PB expression is
reduced (Liu et al., 2001; Tuuri et al., 1996). Therefore several lines of evidence exist to
suggest that activin B is at least produced if not functional in the human corpus luteum.
In accordance with many studies (Davis et al., 1987; Fraser et al., 1993; Schwall et al.,
1990) the current study demonstrates that the PB subunit is expressed in the
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primate/human corpus luteum and is indeed regulated by gonadotropins and/or activin A
(Eramaa et al., 1995; Liu et al., 2001; Tuuri et al., 1996). However, unlike the previous
reports, this study involved using the newly improved 46A/F mouse monoclonal (3B
antibody.
The availability of the newly developed 46A/F mouse monoclonal anti-PB, allows
detection of the PB chain to be carried out with more confidence in specificity. Already
the 46A/F has proven successful for use in an inhibin B ELISA such that the protocol has
been simplified and quality improved (Ludlow et al., personal communication) from the
previous C5 antibody method (Groome et al., 1996). Until recently however, detection of
activin B has been met with limited success, and with no clear definite explanation
(Evans and Groome, 2001). This is in contrast to the highly successful activin A assay
which utilised the E4 (anti-pA) monoclonal antibody's ability to sandwich itself (Knight
et al., 1996). This chapter describes for the first time (and consequently still a 'work in
progress') results from the 46A/F antibody for the activin B ELISA (kindly performed by
Helen Ludlow) and immunohistochemistry applications.
In contrast to a previous study using an anti-rabbit PB antibody (Roberts et al., 1993), the
present study clearly demonstrates that the human corpus luteum expresses the PB
subunit in many cell types. Staining with the 46A/F antibody localised PB to the
granulosa-lutein cells and theca-lutein cells, suggesting that both steroidogenic cells types
have the capacity to make activin B and potentially inhibin B (dependent upon the
presence of the a chain). Activin B is indeed produced by the luteinised granulosa cells
in vitro and concentrations from primary cultures of treated with hCG to mimic the
human luteal phase mirror the expression pattern of PB. Additionally, Illingworth and
co-workers have clearly shown that exogenous hCG treatments mimicking maternal
recognition of pregnancy in women reduces already low inhibin B concentrations
(Illingworth et al., 1996), further confirming that the corpus luteum is not a source of
inhibin B. There may however be a role for activin B in the corpus luteum, moreover in
the late-luteal phase when the a chain and inhibin concentrations have severely declined
(Fraser et al., 1995; Lockwood et al., 1998a; Muttukrishna et al., 1995). In the late-luteal
phase PB expression and subsequent inhibin B concentrations remain unchanged (Fraser
et al., 1995; Illingworth et al., 1996). Therefore, it is tempting to speculate that during
luteolysis, alike that of activin A, the human corpus luteum may be a source of activin B.
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Indeed, activin A is maximal during this stage of the luteal cycle (Muttukrishna et al.,
1996) and has been identified a potent inducer of (IB subunit expression (Eramaa et al.,
1995).
If activin B is up regulated or indeed an endocrine factor of the corpus luteum during the
late-luteal phase, does it have the same biological actions to that of activin A? Recently,
work from this thesis published evidence suggesting that activin A has a physiological
role in the tissue remodelling process associated with luteolysis (Myers et al., 2007a).
This is indicative that hCG serves to impede activin action, to facilitate luteal
maintenance by inhibiting luteolysis and allowing the maternal recognition of pregnancy
(Myers et al., 2007a). In order to test this hypothesis and determine if the same induction
in tissue remodelling observed with activin A was applicable to activin B, primary cell
cultures were treated with activin B and MMP-2 expression and activity was assessed.
However, in contrast to activin A, activin B had no effect on MMP-2 in fibroblast-like
cells. This suggests that activin B is not associated with the tissue remodelling during
luteolysis (at least not in regards to MMP-2), however it does not rule out a potential
endocrine role for activin B in the human corpus luteum. Furthermore, activin A and
activin B may both be produced by the corpus luteum yet elicit differential responses.
This concept could be further tested by the addition of excess activin B to determine if it
can compete out activin A effects. Preliminary results however suggest that activin A and
activin B added together are in fact additive (data not shown).
Clear evidence for differential developmental roles of activins is evident in mice null for
PB that are viable and fertile compared to neonatal lethality seen with pA null mice
(Matzuk et al., 1995; Vassalli et al., 1994). Such models have proven invaluable in
providing an insight into the lack of functional redundancy between activin A and activin
B. Indeed insertion of the inhibin |3B locus into the inhibin (1A locus rescues phenotypes
and can partially replace activin A as an ovarian growth factor, however it is unable to
maintain all aspects of follicular growth (Brown et al., 2000). Furthermore, the
conditional |3A knockout phenotypes suggests that activin A plays an integral role in
luteal remodelling as these mice are reported to have ovaries with abundant corpora lutea
(Pangas et al., 2007) that do not dissolute, whilst PB mice are reproductively competent.
It would be interesting to compare the abundant (due to a lack tissue remodelling
associated with luteolysis) corpora lutea between conditional PA null mice with those of
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mice with the (3B insertion into PA locus, to assess whether there is functional
redundancy in regards to luteal remodelling. Such data however was not presented
(Brown et al., 2000).
If there are indeed differential roles of the activins, it may be a direct consequence of the
receptor binding patterns elicited by each subunit. Of the three activin isoforms A, AB
and B, activin B has lowest biological activity (Nakamura et al., 1992), and this has often
been a question indicative of the existence of different receptors for this isoform
(Mathews and Vale, 1991; Nakamura et al., 1992). Activins signal through type I and II
serine/threonine kinase receptors and the intracellular Smads. Generally, the type I
receptor that activins signal via is ALK 4, however recent data from murine pancreatic
(Tsuchida et al., 2004) and murine pituitary cells (Bernard et al., 2006) suggest that
activin B and activin AB can signal through ALK 7. Whether this is the case for the
ovary or indeed the corpus luteum remains to be explored, however ALK 7 is reported to
be present in granulosa cells (Wang et al., 2006). In the present study although activin A
and activin B had differential effects upon MMP-2 in fibroblast-like cells, they had same
tendency to affect Smad 7 expression.
In conclusion, distinct patterns of activin and inhibin isoforms exist over the human
menstrual cycle. This information suggests that differential roles exist not only between
activin and inhibin, but also potentially between each isoform. This chapter describes the
use of the newly improved |3B antibody which is useful for both immunoassay and
immunohistochemistry applications. Whilst the activin B ELISA is still under final
development, it did produce some convincing results which mirror mRNA expression and
therefore yield convincing results. Further optimisation of the activin B assay will result
in more accurate individual values and development of an assay format which is
applicable to both cell culture and serum samples. Consequently, concentrations of
serum samples from naturally cycling women across the menstrual cycle will provide a
more definitive answer regarding a potential role for activin B. Whilst this work suggests
that there are potential differential effects for activin A and activin B in MMP-2 induced
tissue remodelling during luteolysis, this is by no means conclusive. Further work needs
to address a potential role for activin B as it is regulated differentially by hCG and activin
A, suggestive that it is under paracrine and/or autocrine control in the corpus luteum.
Taken together, these results suggest that activin B is a potential endocrine molecule of
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the human corpus lutem that although regulated by activin A, may have
during luteolysis.
■
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7 General Discussion
The corpus luteum is absolutely fundamental in the regulation of human reproduction. It
is undoubtedly necessary for the maintenance of pregnancy and its demise is crucial in
the initiation of the next ovarian cycle. Much of the research relating to the human
corpus luteum in the current literature describes observational data which has indeed
proved essential to get to our current stage of knowledge. Functional studies that do exist
regarding the corpus luteum are most often in animal model systems, which although
valuable regarding some aspects of luteal function, are not a good model for others.
There are marked species differences in the regulation of the corpus luteum. This is most
notable in the rodent corpus luteum and limits the relevance of transgenic and knockout
mouse models in corpora lutea function. Indeed, even in large mono-ovular species such
as ruminants the role of the uterus in luteal regulation, not seen in women, again limits
the applicability of research in infra-primate species. Therefore the best model system to
study the human corpus luteum is indeed, the human corpus luteum. However, it is not
always practical to collect human tissue and furthermore carry out interventional
procedures. This thesis reports several novel findings regarding the functional luteal
lifespan with the use of an in vivo system of carefully dated human corpora lutea
(including the novel and important stage of early pregnancy) that has been stimulated by
physiological concentrations of exogenous hCG, accompanied by a more mechanistic in
vitro model. Together these models complement each other and have proved invaluable
in exploring the functional and mechanistic roles within the human corpus luteum. The
complementary use of these paradigms in this thesis has allowed the development and
testing of hypotheses about the paracrine regulation of human luteal function for the first
time.
7.1 Gonadotrophic regulation of the human corpus luteum
It has been well recognised for many decades that gonadotropins regulate the lifespan of
the corpus luteum in women. Formation of this extraordinary endocrine gland during
luteinisation is a consequence of the preovulatory LH surge, whilst maintenance of the
gland during early pregnancy is absolutely dependent upon conceptus-derived hCG.
Indeed, the corpus luteum is not an autonomous gland and in the absence of
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gonadotrophs support its function will rapidly cease. However the mechanisms by
which gonadotrophins regulate or maintain corpora lutea function remains an enigma.
The corpus luteum will undergo luteolysis in the presence of maintained LH pulses
(Zeleznik and Pohl, 2006). Whilst endocrinological removal of LH causes luteolysis
pharmologically, the pituitary gland is not involved in regulating natural luteolysis. In
ruminants PGF2a from the uterus is the luteolysin (McCracken et al., 1999). This
however, is not the case in women as hysterectomy has no effect on ovarian function.
These observations point to the fact that if there is a luteolysin in women it must be
locally derived and locally active. That is not the case during maternal recognition of
pregnancy as hCG has a clear endocrinological role in preventing luteolysis. As hCG has
effects on cells that do not express the LH/hCG receptor such as fibroblasts (Duncan et
al., 2005b; Myers et al., 2007a), immune cells (Duncan et al., 1998b) and endothelial
cells (Fraser and Duncan, 2005), the regulation of paracrine signalling molecules from
steroidogenic cells must be involved. This suggests that important molecules involved in
luteolysis or luteal rescue are LH/hCG responsive factors whose receptors are on
disparate populations of luteal cells. Even now it is not clear apart from stimulating
progesterone synthesis, what role hCG has upon the molecular functions, if any, in the
human corpus luteum. Furthermore, in the absence of gonadotrophic support it is still
uncertain how the corpus luteum undergoes luteolysis and how hCG prevents or delays
this during maternal recognition of pregnancy. Previous studies leading up to this thesis,
aimed to investigate these unresolved issues (Duncan, 2000; Duncan et al., 2005b; Fraser
et al., 2005) and consequently such studies have provided the backbone to the current
thesis and its investigation into corpora lutea regulation.
It is increasingly clear that hCG has the ability to inhibit luteolysis and regulate many
different cells types, and their molecular functions within the corpus luteum on cells that
do not necessarily express the hCG/LH receptor. One explanation for this is that hCG
inhibits the production of a luteolysin from the steroidogenic cells of the corpus luteum
and it is the luteolysin that is responsible for inducing genes involved in luteolysis in
different luteal cell populations. Another explanation may be that hCG directly
stimulates molecules that have a local luteotrophic effect that inhibit the luteolytic
process that would occur in their absence. The focus of the studies presented in this
thesis was to investigate paracrine signalling in the human corpus luteum. The main
objectives of this thesis were (1) to identify potential paracrine molecules in the human
Chapter 7 General Discussion 168
corpus luteum that have a luteolytic effect, (2) to identify potential paracrine molecules
that have a luteotrophic effect, (3) to determine the effect of these molecules on
fundamental luteal processes, (4) to establish the role that such molecules and their
interactions may play in the regulation of corpora lutea function and (5) to devise a
mechanistic model to explain how hCG effects disparate cell functions at a tissue level.
In order to do this, combinations of human tissue and cell cultures models were utilised.
The starting point was the knowledge of some regulated molecules known to be involved
in luteolysis. Novel in vivo experiments have elegantly shown that luteal fibroblast
MMP-2 production is up-regulated during luteolysis, and inhibited by hCG during
maternal recognition of pregnancy in women (Duncan et al., 1998a). More recently, hCG
has also been shown to regulate fibroblast CTGF production in the corpus luteum
(Duncan et al., 2005b) and this could be modelled in vitro using novel cell culture
methods. Using a combination of the up-regulation of MMP-2 during luteolysis, that has
been shown to occur in all species investigated, and the cell culture models previously
used to confirm that CTGF was regulated by hCG, through unknown paracrine
intermediary molecules, activin A was identified as a possible luteolysin.
7.2 Activin A is an-anti luteal agent in the human corpus luteum
Activin A as an intermediate paracrine molecule in the human corpus luteum forms the
foundation of this thesis and consequently has shaped the basis of each of the chapters
presented. Synthesised predominantly by the steroidogenic cells of the human corpus
luteum, activin A concentrations fluctuate over the luteal lifespan unparalleled to other
hormones such as inhibin A, oestradiol and progesterone (Muttukrishna et al., 1996).
Many of the cell types which comprise the corpus luteum, such as the steroidogenic cells
and stromal fibroblasts express the extracellular activin receptors and intracellular Smad
signalling proteins required for activin signal transduction. Furthermore, the corpus
luteum also possesses the ability to modulate activin action by regulation of activin
inhibitors such as inhibin, follistatin and P-glycan. Activin A certainly fitted the criteria
for a regulated molecule from luteal steroidogenic cells that could have actions on a wide
range of cell types within the corpus luteum. More importantly however, it up-regulated
the marker of luteolysis in vitro, MMP-2.
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Peripheral serum concentrations of activin A are maximal at the time of luteolysis
(Muttukrishna et al., 1996). If indeed these reported serum levels reflect the intra-luteal
patterns of activin A (and one would predict so, as the ovary seems to be the predominant
source of regulated activin subunit expression) then it could be questioned how activin A
becomes maximal during the late-luteal phase. It must be remembered that during natural
luteolysis, cessation of progesterone synthesis is not due to a decline in trophic support
but more appropriately abrogation of LH action at a local level. Indeed, the LH/hCG
receptors do not decline in number (Duncan et al., 1996a), but more likely become
uncoupled from their second messenger systems which consequently result in
desensitisation of the receptor (Segaloff and Ascoli, 1993). This has been thought to
explain why increasing concentrations of hCG are required during pregnancy to maintain
sufficient progesterone production (Duncan et al., 1996a).
During the late-luteal phase, desensitised receptors, coupled with the absence of
logarithmically increasing hCG serve to reduce LH action in the corpus luteum.
Withdrawal of LH action will lower progesterone secretion and affect the local action of
activin A. Reduced LH action will lower the inhibin a subunit leaving more chance for
[3A dimer formation and subsequently activin A synthesis. In addition by lowering
follistatin and (3-glycan expression activin action is further facilitated. This could then
result in a feed-forward loop whereby activin A can continue to promote its own
production, inhibit genes involved in luteal steroidogenesis (see Chapter 5) and contribute
to the structural remodelling associated with luteolysis (see Chapter 3). It is likely that
activin A action in the late-luteal corpus luteum is increasing rapidly and this can
facilitate luteolysis. This will be self-limiting in nature as when the luteal steroidogenic
cells undergo apoptosis the predominant source of activin A is removed.
7.2.1 Activin A as a luteolysin in women
A potential role for activin A during luteolysis became evident when the fibroblast cells
responsible for secreting the proteolytic MMP-2 up regulated their expression and activity
of MMP-2 in the presence of activin (Chapter 3). Although probably not the sole
regulator of MMP-2, activin A was an attractive candidate signalling molecule for several
reasons. Synthesised, secreted and transduced in the corpus luteum, activin A was clearly
regulated by hCG, both directly and indirectly at the level of inhibitors. Furthermore,
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peripheral serum levels were maximal during the late-luteal phase at the time of luteolysis
(Muttukrishna et al., 1996) and indeed when MMP-2 activity was greatest (Duncan et al.,
1998a). Accordingly, luteal fibroblast MMP-2 activity was up-regulated by activin A in
primary cell cultures and importantly, these effects were inhibited by hCG. Through a
rodent model, the importance of activin A upon structural luteolysis became further
evident in the granulosa cell specific [3A mouse knockout (Pangas et al., 2007). These
mice demonstrate an ovarian phenotype with abundant corpora lutea, providing a unique
opportunity to study a role for activin A in an in vivo model. Collectively, these data
suggest activin A plays an integral role in the tissue remodelling associated with
luteolysis and that this effect might not be limited to women. It seems that one of the key
roles of hCG during maternal recognition of pregnancy is to inhibit activin A action.
Further work on activin A in corpora lutea mammal models is clearly indicated to
replicate these findings and allow further dissection of the molecular regulation of tissue
remodelling that can be further assessed in the human model used here. In order to
determine if the |3A conditional knockout model exhibits abundant corpora lutea due to
lack of MMP-2, it would be very interesting to localise or quantify the expression of this
enzyme in these mouse ovaries. Furthermore, another interesting molecule which could
be assessed across the luteal phase and during maternal recognition of pregnancy and
indeed in the f3A null mice is a-2 macroglobulin. Studies have shown that a-2
macroglobulin inhibits both activin A and MMP-2 (Baker et al., 2002; Niemuller et al.,
1995). Therefore it could be hypothesised that hCG may up regulate the expression of
this inhibitor during maternal recognition of pregnancy to tightly regulate activin-induced
tissue remodelling. Whatever the detailed mechanisms, activin A action seems to be
involved in the removal of the corpus luteum (Figure 7.1).
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Cells
Figure 7.1 Schematic model of the proposed mechanisms which contribute to human
luteolysis. In the late-luteal phase, activin A action from the steroidogenic cells is up
regulated as inhibitors of activin action (inhibin A and follistatin (FS)) are markedly
reduced. Fibroblast-like cells express activin receptors (green). As a result of the rising
activin A levels, fibroblast-like cells up regulate the activity of MMP-2 which plays a
major role in the tissue remodelling associated with luteolysis.
7.2.2 Activin A and formation of the corpus luteum
Since the studies on tissue remodelling during human luteolysis revealed that increasing
activin A was important, the obvious next question is whether activin A is removed
during luteal formation. As previously discussed, formation of the corpus luteum
involves marked and disparate changes. The preovulatory LH surge induces the
expression of important regulatory molecules that play a key role in the steroidogenesis
that takes place in the newly formed granulosa-lutein cells. As discussed in Chapter 5, it
is often postulated that luteinisation might be a 'default' pathway and granulosa cells are
pre-programmed to undergo this transition. If this is the case, then inhibitory factors must
be present within the follicular entity and are potentially products of either oocyte or
granulosa cell origin. It became apparent throughout these studies that one of the roles of
activin A may be to inhibit luteinisation. Whether or not activin A alone can actually
prevent luteal formation or luteinisation remains elusive. However it appears to play
some role in the prevention of luteal tissue. The negative effects of activin A upon key
genes involved in the steroidogenic pathway, in the presence and absence of hCG
suggests that one of the roles of activin A is probably to promote a more follicular type
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environment, whilst hCG (mimicking the preovulatory LH surge) facilitates luteal
development. Therefore it seems likely that there are similarities between the LH surge
during luteal formation and hCG during luteal rescue. Both appear to, through similar
mechanisms act to remove activin A action. This implies that activin A is anti-luteal at
both extremes of the luteal lifespan and normal luteal function involves suppressing
activin A action (Figure 7.2).
\-£'
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Figure 7.2 A schematic diagram representing the patterns of activin A (ActA) and
progesterone (P4) secretion across the luteal phase in luteolysis and during luteal rescue
with exogenous hCG. A, During the late-luteal phase activin A levels begin rise due to a
lack of trophic support. The rise in activin A may disrupt progesterone secretion that
rapidly declines at this time. Furthermore the increase of activin A also up regulates
MMP-2 and tissue remodelling associated with luteolysis. B, In contrast however, luteal
rescue is a result of hCG trophic support and consequently progesterone concentrations
are maintained as it the tissue integrity as hCG suppresses activin A action within the
corpus luteum.
It is unlikely that activin A alone is responsible for preventing luteinisation or promoting
a follicular-like environment, however it is likely to have a major role. This has been
highlighted in mouse models whereby activin A has been shown to be anti-luteal (Pangas
et al., 2006). Accordingly, one of the key phenotypes in mice null for the common
intracellular Smad (Smad 4) gene is premature luteinisation of the granulosa cells (Pangas
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et al., 2006). In parallel with Chapter 5, many of the same genes were regulated in a
similar fashion as those in the Smad 4 knockout mouse. Importantly however, deletion of
Smad 4 in these mice does not only interfere with activin signalling, it also interrupts
TGF-P transduction. With many molecules working through the same signalling
pathways it makes is hard to know whether there exists a division of labour between the
activins, BMPs, and GDFs or whether they act redundantly with respect to luteinisation
(Pangas et al., 2006). An attractive additional candidate molecule already known to be
involved in prevention of luteinisation is GDF9 (Elvin et al., 1999a; Elvin et al., 1999b;
Eppig et al., 1997; Vanderhyden et al., 1993). Notably, as GDF9 uses similar Smad
signalling pathways as activin it would be very interesting to see if unluteinised granulosa
cells treated with activin A and GDF9 both separately and simultaneously to determine if
they have similar and/or synergistic roles with respect to the prevention of luteinisation.
Activin receptors are indeed localised to the oocyte in humans (Pangas et al., 2002) and it
could be postulated that activin therefore may signal to the oocyte to augment GDF9
expression. It should be reiterated that the granulosa cells used in the current study are
already luteinised, and it remains unknown whether or not they can be 'unluteinised'.
Whether or not activin A can indeed prevent or revert the luteinised phenotype of a
granulosa-lutein cell remains elusive. However, there are most definitely effects at a
molecular level on key genes involved in luteal formation and function which clearly
antagonise or exhibit differential effects to the trophic actions of hCG.
Activin A appears to be an important paracrine molecule in the human ovary. It is anti-
luteal and needs to be removed for the corpus luteum to function. One key finding of this
thesis is the struggle between LH/hCG action and activin A action as both seem to be able
to inhibit the effects of the other. When LH/hCG action dominates the corpus luteum
retains its functional and structural integrity, however when activin A dominates, the
functional and structural integrity of the tissue is lost.
7.3 A luteotrophic role for Cortisol in the corpus luteum
The identification of potential luteotrophic molecules suggests that hCG many have other
actions than just suppressing luteolysins. These results shed light upon the trophic effects
that Cortisol potentially has upon luteal maintenance. For the first time, data published
from this thesis suggests that Cortisol may indeed be a luteotrophic agent during maternal
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recognition of pregnancy (Chapter 4; (Myers et al., 2007b)). This study clearly
demonstrated that the MMP-2 induced tissue remodelling associated with luteolysis was
reduced in Cortisol treated fibroblast-like cells. Furthermore, activin A and hCG
exhibited clear differential effects upon the 1lpHSD isoforms responsible for Cortisol
metabolism (Chapter 5) such that, by up-regulating 1 lpHSDl, it promoted local Cortisol
synthesis. It seems that during luteal rescue the suggested increase in local Cortisol
generation from steroidogenic cells can act on neighbouring cells with glucocorticoid
receptors to inhibit MMP-2 induced tissue remodelling (Figure 7.3). Indeed, the
promotion and withdrawal of local Cortisol synthesis has important parallels with activin
A action.
Figure 7.3 Schematic model of the proposed model of luteal rescue. During maternal
recognition of pregnancy, hCG provides trophic signals to luteal cells. Steroidogenic
cells, but not fibroblast cells express the LH/hCG receptor (black). HCG induces
lipHSDl which generates Cortisol in the steroidogenic cells and can act on the
glucocorticoid receptor (purple) on fibroblast-like cells resulting in inhibition of MMP-2
tissue remodelling from fibroblast cells.
Activin A up regulated 11PHSD2 expression suggesting that it tends to remove Cortisol
from the system. Indeed activin A has been shown to inhibit Cortisol secretion in other in
vitro systems (Vanttinen et al., 2003) and an important role of activin A inhibition in the
corpus luteum is most likely to remove any inhibition upon MMP-2 tissue remodelling.
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MMP-2 tissue remodelling associated with luteolysis (Figure 7.3). Again, this is







Figure 7.4 A schematic diagram depicting the differential patterns of the lipHSD
isoforms over the late follicular phase and throughout the luteal phase in luteolysis and
luteal rescue with exogenous hCG. A, The pre-ovulatory LH surge clearly involves a
switch in the predominance of lipHSD2 to lipHSDl, which is maintained over the
luteal phase until the late-luteal phase when high activin A (ActA) levels potentially
'switch' back to a predominance of type 1 1 lpHSD. B, During luteal rescue however in
the presence of gonadotrophic support, lipHSDl is maintained, presumably to promote
generation of Cortisol and inhibit the tissue remodelling associated with luteolysis.
7.4 The balance between luteotrophic and luteolytic signals
When activin A dominates in the late-luteal phase, the luteotrophic signals are inhibited.
However when hCG dominates the luteolytic signals are inhibited. Although this model
is simplistic and belies a large amount of complexity, it is a model system that for the first
time can begin to allow us to understand the molecular regulation of the corpus luteum of
women. This remains one of the great enigmas of reproductive biology. Now hypotheses
can be generated and investigated using human tissue in combination with culture
systems and these basic mechanistic conclusions.
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In the absence of luteolysis, conceptus-derived hCG maintains the structural and
functional integrity of the corpus luteum. It is likely that there are other luteotrophic and
luteolytic molecules to be determined. Although the luteal rescue tissue used in the
current study only mimics the first week of pregnancy, it is provides a good indicator of
what might be expected until the placenta assumes principal role. Although peripheral
serum levels of activin A are reported to increase over the course of pregnancy, this does
not necessarily reflect intra-luteal concentrations (Muttukrishna et al., 1996). Indeed the
placenta has the ability to produce activins and is most likely the key source of the rising
concentrations during the weeks of pregnancy. As a consequence of the work in this
thesis, it is hypothesised that intra-luteal activin inhibition would continue to be
maintained by hCG, at least until the luteo-placental shift so that adequate progesterone
synthesis is maintained and MMP-2 tissue remodelling is limited. Furthermore there is
good evidence to also suggest that active Cortisol would be maintained until the luteo-
placental shift as elegant rat studies demonstrate that an increase in 11PHSD type 2 is a
local mechanism to facilitate luteal regression (Waddell et al., 1996). Whatever happens
as pregnancy progresses, the corpus luteum needs more and more trophic signals to
maintain its function. This is a losing battle as the corpus luteum has no role after eight
weeks gestation and the exponential rise of hCG cannot be maintained beyond 10-12
weeks. Even in the presence of hCG, the luteolysins will predominate and hCG can only
delay the inevitable. This thesis suggests that a major luteolysin is activin A.
7.5 Is the role of activin B in the corpus luteum the same as activin A?
A functional role for activins within the luteal lifespan became clearly evident over the
course of these studies, however it remained elusive whether these actions were unique to
activin A or indeed were similar to activin B. Although a reasonable question, it has not
always been particularly easy to answer. Most studies in the literature investigate activin
A when considering a physiological role for activins. However, with the availability of
recombinant activin B and the development of specific antibodies, more definite
investigations into this protein are possible. Although still in its preliminary stages,
Chapter 6 aimed to investigate a potential endocrine role of activin B in the human corpus
luteum. These early results suggest that activin B has both disparate and similar effects to
that of activin A. Further development of the activin B assay and assessment in serum
samples from across the ovarian cycle will give a greater insight into a functional role for
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this glycoprotein. The differential effects of activin B to that of activin A make it an
exciting prospect to investigate, especially as it has different receptor and follistatin
binding properties.
7.6 Future Work
Studies from this thesis are complete enough to stand as scientific publications in
important international journals (Myers et al., 2007a; Myers et al., 2007b). Whilst
enlightening our understanding on some of the more functional aspects of corpora lutea
biology, in particular human luteolysis, the studies in this thesis have also raised many
more investigative questions. There are clear pathways ahead for future studies using the
work of this thesis as a starting point.
1) What is the role of activin B? Activin B effects and the relationship to hCG and
activin B should be determined using similar paradigms as the investigation of activin A.
This would be enhanced where antibodies or different follistatin proteins could
specifically inhibit one or the other activin in the presence of the other. Already studies
have shown that follistatin binds activin A at a 10-fold higher affinity than it does activin
B (Schneyer et al., 2003) and these studies would be of general interest as very little data
is published in this field.
2) The expression of other members of the TGF-P superfamily in the human corpus
luteum. The TGF-P family are markedly understudied in the human corpus luteum.
Their synthesis, action and localisation is unknown. The paradigms could be used to
study TGF-p, BMPs, AMH and GDF9 synthesis and regulation.
3) The interaction and actions of different TGF-P family members. As the TGF-P family
members signal through the common Smad 4, it is possible that they can modulate each
others actions. Pilot experiments have shown that the Smad 1,5 and 8 (involved notably
in BMP signalling) are expressed in the same cells as Smad 2 and 3 (data not shown).
Cell culture models should be used to dissect out these possible interactions in luteal
cells.
4) Manipulation of activin A action in vitro. The cell culture model provides a system
whereby activin A action can be manipulated. Pilot studies have shown that these cells
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can be transfected wih the inhibitory Smad 7 using adenoviral vectors (data not shown).
The manipulation of Smads, pA subunit, a subunit and follistatin using expression
vectors and RNA interference (RNAi) technologies could be used to dissect these
pathways out further.
5) The synthesis and effects of prostaglandins on luteal cells. It is likely that there are
common regulators of the corpus luteum in different species. Findings from animal
models may inform us of some of the common pathways to investigate. Indeed work
from this thesis may inform researches working on luteolysis in non-human species
including infra-primate species. Prostaglandins are major regulators in other species
including the smallest primate model investigated, the marmoset monkey whereby
systemic prostaglandin F2a is luteolytic. Since last studied in women, much more
information is known, and readily available, regarding prostaglandin synthesis and
effects. Revisiting prostaglandins in human corpora lutea using the current molecular
techniques is timely and may yield important findings.
6) Is there a change of differentiation state of granulosa lutein cells during luteolysis?
Many of the molecules expressed by the steroidogenic cells during luteolysis, such as
11(1HSD2, activin and possibly CTGF are expressed by follicular granulosa cells. This
raises the intriguing possibility that there is a de-differentiation of luteinised granulosa
cells to a more follicular or less mature phenotype during luteolysis. Preliminary
evidence has shown that hCG tends to inhibit cyclin expression and promote the
differentiation factor p27cipl and that activin A does the opposite (data not shown).
Indeed it was suggested at a recent international conference that luteal cells may re-enter
the cell cycle as a prelude to apoptosis during luteolysis (Dr Susan Quirk, Cornell
University NY, personal communication). The influence on cell differentiation in luteal
cells remains uncertain and would make a fascinating story.
7.7 Conclusion
Collectively these results suggest that activin is an excellent anti-luteal molecule whose
paracrine/endocrine actions are to remove or potentially inhibit luteal tissue formation,
and moreover to facilitate human luteolysis. It appears that one of the physiological roles
of the gonadotrophins in the human corpus luteum is to impede activin action. The
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preovulatory LH may serve to promote luteinisation by subsequently inducing expression
of key genes that are involved in successful luteal formation, and equally as important,
suppress activin A which may be detrimental to the system. Additionally, during
maternal recognition of pregnancy, the biological actions of activin A remain inhibited by
conceptus-derived hCG that has marked and disparate changes on surrounding cell types
that do not expression the hCG receptor. In addition to suppressing activin A-induced
proteolytic activity, hCG will facilitate Cortisol production via up-regulation of 1 lpHSDl,
to further impede MMP-2 tissue remodelling. Consequently, luteolysis is prevented, as
luteal fibroblast-like MMP-2 is inhibited and hCG-derived Cortisol production promotes
the maternal recognition of pregnancy. In summary this thesis for the first time identifies
activin A as an excellent candidate molecule for the elusive luteolysin in women, and
highlights Cortisol as a potential novel luteotrophic molecule.
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In Vitro Evidence Suggests Activin-AMay Promote
Tissue Remodeling Associated with Human Luteolysis
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Luteolysis inwomen is associated with an up-regulation ofthe
expression and activity ofmatrix metalloproteinase-2 (MMP-
2),which is inhibited by human chorionic gonadotropin (hCG)
during maternal recognition of pregnancy. Because the pri¬
mary source of MMP-2 is fibroblasts that do not express LH/
hCG receptors, we aimed to investigate the regulation of
MMP-2. Women with regular cycles having hysterectomy for
nonmalignant conditions and women undergoing oocyte re¬
trieval for assisted conception were used in this current
study. Novel primary cultures and cocultures of luteinized
granulosa cells and fibroblast-like cells in conjunction with
human corpora lutea from different stages of the luteal phase
were used to investigate the role of activin-A in the corpus
luteum. The effect ofhCG, activin-A, and follistatin on MMP-2
activity and expression was assessed by gelatin zymography
and quantitative RT-PCR in primary cell cultures. Confirma¬
tion of signaling pathways involved in the activation of
MMP-2 was assessed by immunofluorescence, RT-PCR, and
quantitative RT-PCR. In primary cell culture, steroidogenic
cells secrete activin-A and its inhibitors, inhibin-A and fol¬
listatin. Follistatin expression is up-regulated by hCG (P <
0.05). The fibroblast-like cells producing MMP-2 have the ma¬
chinery for activin reception, expressing both type I and type
II activin receptors and Smad proteins. Activin-A up-regu¬
lated both activity and expression ofMMP-2 in fibroblast-like
cells (P < 0.05). This activity was inhibited in cocultures of
luteinized granulosa cells and fibroblast-like cells in the pres¬
ence of hCG (P < 0.05) or follistatin (P < 0.01). Activin-A is an
excellent candidate for an effector molecule in human lute¬
olysis whose paracrine action is inhibited during maternal
recognition of pregnancy. (Endocrinology 148: 3730-3739,
2007)
THE HUMAN CORPUS luteum is a highly vascular andactive endocrine gland that in themidluteal phase mea¬
sures up to 2 cm in diameter. However, unless human cho¬
rionic gonadotropin (hCG) is secreted by a conceptus, this
highly transient structure will undergo functional and struc¬
tural luteolysis (1), becoming a small fibrous remnantwithin
a matter of days. The process of luteolysis is associated with
marked tissue remodeling and vascular involution. Cellular
processes that are known to occur during the regression of
the human corpus luteum include cell death (2), an increase
in the expression of connective tissue growth factor (3), an
influx ofmacrophages (4), and an up-regulation of fibroblast
matrix metalloproteinase-2 (MMP-2) expression and activity
(5).
MMPs are key proteolytic enzymes involved in the deg¬
radation of the extracellular matrix, which is constantly re¬
modeled during luteolysis. Much evidence exists to suggest
that MMP-2 is an important luteolytic agent during the de¬
mise of the corpus luteum. In rats, structural luteolysis was
associated with an increase inMMP-2 activity (6), whereas in
pigs, the expression ofMMP-2 was elevated in the regressing
corpus luteum (7). Additionally, primates (8) and humans (5)
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Abbreviations: ActRIIA, Activin receptor IIA; ALK4, activin receptor
like-kinase 4; G6PDH, glucose-6-phosphate dehydrogenase; hCG, hu¬
man chorionic gonadotropin; MMP-2, matrix metalloproteinase-2; NGS,
normal goat serum; TBS, Tris-buffered saline.
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show maximal MMP-2 expression in the late luteal phase,
positively correlating with the functional and structural re¬
gression of the corpus luteum. Furthermore, hCG during
maternal recognition of pregnancy in women (5) reduces the
expression of MMP-2. Because MMP-2 is up-regulated dur¬
ing luteolysis, and conversely inhibited in the presence of
hCG during maternal recognition of pregnancy, it is likely
that it has an important role in the luteolytic process.
The primary source of MMP-2 in the human corpus lu¬
teum is the luteal fibroblasts that do not express LH/hCG
receptors (5), suggesting that there is a paracrine regulator of
MMP-2 expression (9). We therefore hypothesized that in the
corpus luteum, MMP-2 is regulated by hCG through an
intermediate molecule. Unlike LH, FSH, progesterone, es¬
tradiol, or inhibin-A, the concentrations ofactivin-A in serum
are maximal during the late luteal phase (10), suggesting it
may have a positive luteolytic action. Activins and other
members of the TGF-j3 superfamily are known to control
many diverse physiological processes (11); therefore, we hy¬
pothesized that activin-A may be a critical intermediate sig¬
naling molecule in the human corpus luteum.
As described previously (4, 5, 12), we have developed a
system for the collection of carefully dated human corpora
lutea and more recently (3) a primary cell culture system
using human luteinized granulosa cells and/or novel cul¬
tures of fibroblasts-like cells derived from the luteinizing
follicle. The aim of the current study was to investigate
whether activin-A was a paracrine regulator of luteal tissue
remodeling by investigating its effects on MMP-2 expression
and activity using our model systems.
3730
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Materials and Methods
Collection of human corpora lutea
Tissue collection was approved by the local medical research ethics
committee, and allwomen gave informed consent. Human corpora lutea
(n = 18) collected over the past 12 yr (3,5) were enucleated at the time
of surgery from women with regular menstrual cycles undergoing hys¬
terectomy for benign conditions and dated on the basis of the urinary
LH surge as described previously (9,13). In this study, six corpora lutea
were classified as early-luteai (LH+1 to LH+5), six as mid-luteal (LH+6
to LH+10), and six as late-luteal (LH+11 to LH+14). At operation,
the corpus luteum was quartered to ensure that each quarter con¬
tained all cellular elements. Two quarters were immediately frozen
and stored at -70 C until RNA extraction was carried out. The
remaining tissue was fixed in 10% neutral buffered formalin for
subsequent immunohistochemistry.
Isolation of human luteinized granulosa cells and
derivation offibroblast-like cells
The medical ethics committee separately approved the collection of
cells from patients undergoing assisted conception. With patient con¬
sent, follicular fluid was collected fromwomen undergoing transvaginal
oocyte retrieval for in vitro fertilization after ovarian stimulation using
a standard procedure (14). Isolation of luteinized granulosa cells using
Percoll gradient centrifugation was carried out as described previously
(3). Fibroblast-like cells were obtained from prolonged cultures of fol¬
licular aspirates as described previously (3).
Derivation offibroblast-like cells from human corpora lutea
Corpora lutea collected during surgery (as described above) were
minced in cell culture conditions and placed in flasks containing 10%
fetal bovine serum as described previously (3). Cultures were left to
reach confluence and grown until sufficient numbers of cells (60,000 per
well) could be obtained for experimental procedures described below.
Primary cell culture
Fibroblast-like cells (60,000 per well) were added to 24-well plates.
After 24 h in serum-free conditions (supplemented DMEM/F12 Ham
mixture; Life Technologies, Inc., Gaithersburg, MD), as described pre¬
viously (3), fresh medium was added containing human recombinant
activin-A (R&D Systems, Inc., Abingdon, UK; 10-100 ng/ml and con¬
trols) or inhibin-A (NIBSC, Hertfordshire, UK; 25 ng/ml and control).
All controls contained the carrier solution equivalent to the highest
concentration added. After 24 h, culture medium was stored for sub¬
sequent analysis, and cells were collected for mRNA extraction. Three
to four replicates were performed in at least three separate experiments.
Pooled luteinized granulosa cells (100,000 per well) were cultured in
24-well plates precoated with Matrigel (BD Biosciences, Bedford, MA)
in serum-free medium (supplemented DMEM/F12 Ham mixture), as
described previously (3). Medium was changed every 2-3 d over the
course of the culture period. After 6-8 d in culture, a maximally stim¬
ulating dose of hCG (Serono Laboratories, WelwynGarden City,UK; 100
ng/ml and control) was added. After 24 h, medium and cells were stored
for subsequent analysis and mRNA extraction. Three experimental rep¬
licates were carried out in duplicate.
For coculture experiments, approximately 60,000 fibroblast-like cells
were added to the wells containing approximately 100,000 luteinized
granulosa cells after culture for 5-7 d. After coculture for 24 h in serum-
free medium, fresh serum-free medium was added containing either
hCG (100 ng/ml and control) or follistatin (R&D Systems; 500 ng/ml and
control). Follistatin treatments were within physiological levels (100-
600 ng/ml) of that previously reported in human follicular fluid (15).
Each control contained the carrier solution equivalent to the highest
concentration added. After 24 h, mRNA was extracted from cocultures
and controls consisting of fibroblasts only. Each coculture and control
treatment was replicated six times in three separate experiments.
Preparation of cDNA from corpora lutea and cultured cells
and primer design
mRNA was batch extracted from both frozen human corpora lutea
and cultured cells and reverse transcribed into cDNA using random
hexamers as described previously (3). Oligonucleotide PCR primers for
each gene investigated were designed using Primer3 software (http://
primer3.sourceforge.net/) from DNA sequences obtained from Gen-
Bank (www.ncbi.nlm.nih.gov). Primers were synthesized by MWG-AG
Biotech (Milton Keynes,UK) and the 5' to 3' sequences used in this study
are listed in Table 1. PCR conditions were as follows: incubation at 95
C for 5 min, 35 cycles of 95 C for 30 sec, appropriate annealing tem¬
perature (Table 1) for 30 sec, and 72 C for 90 sec, followed by 72 C for
10 min. PCR products were separated by applying 110 V for 1 h to 2%
agarose gels with ethidium bromide and visualized and photographed
under UV transillumination.
Quantitative analysis ofgene expression by RT-PCR
Each assay was optimized using PCR amplification of human pla¬
cental cDNA. The assays were optimized for MgCl2 concentrations and
annealing temperatures. PCR amplifications were performed using
Thermostart Taq (ABGene, Surrey, UK) in a DNA Engine gradient cycler
(MJ Research, Inc., Watertown, MA) as previously described (3). Data
were normalized according to the expression level of glucoses-phos¬
phate dehydrogenase (G6PDH), determined in duplicate by reference to
a serial dilution calibration curve generated for each sample using the
standard LightCycler software.
Gelatin zymography
Cell culture medium was collected from serum-free cultures and
subsequently frozen at -20 C. Aliquots of 200 /idwere subjected to freeze
drying for 2-3 h until they resembled a powder and then reconstituted
in 20 p.1 sterile dH20. One microliter of the reconstituted sample was
added to sample buffer [10% (vol/vol) glycerol, 1% (wt/vol) SDS, and
0.04% (vol/vol) bromophenol blue] and applied to an 11% (wt/vol)
polyacrylamide gel containing 1 mg/ml gelatin and 0.1% (wt/vol) SDS.
Gels were incubated in 2.5% Triton X-100 for 45 min after electrophoretic
separation of proteins and then incubated at 37 C overnight in digestion
buffer [50 mmol/liter Tris-HCl (pH 7.6) containing 0.2 mol/liter NaCl,
5mmol/liter CaCl2, and 0.02% (wt/vol) Brij 35] as described previously
TABLE 1. Sequence of primers and annealing temperatures used for qualitative and quantitative RT-PCR
Gene Forward primer (5' to 3') Reverse primer (5' to 3') Annealing temperature (C)
MMP-2 ATGACAGCTGCACCACTGAG ATTTGTTGCCCAGGAAAGTG 61
G6PDH CGGAAACGGTCGTACACTTC CCGACTGATGGAAGGCATC 62
Inhibin a CCAGCTGTGAGGACAAGTCA CTAGCAGGGGCTCAGAGCTA 56
RA AGACGCTGCACTTCGAGATT CCCTTTAAGCCCACTTCCTC 56
Follistatin CAGTAAGTCGGATGAGCCTGTCT CCTGGTCTTCATCTTCCTCCTCCT 69
R-Glycan CTGTTCACCCGACCTGAAAT CGTCAGGAGGCACACACTTA 67
ActRIIA TTTCCGGAGATGGAAGTCAC GTCCTGGGTCTTGAGTTGGA 54
Alk2 AAGGCAGGTATGGTGAGGTG ACCACAGCTGGGTACTGGAG 55
Alk4 GAGATTGTGGGCACTCAAGGG AGCTGGGACAGAGAGTCTTCTTG 60
Smad2 CTGGGATGGAAGAAGTCAGC CAGTCCCCAAATTTCAGAGC 55
Smad3 TGAGGCTGTCTACCAGTTGACC CCGCTGTTCCAGTGTGTCTTAG 57
Smad4 GATTGCAGACCCACAACCTT CTAGGAGCAAGGCAGCAAAC 54
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(5). Gels were stained in staining solution [30% (vol/vol) methanol, 10%
glacial acetic acid, and 0.5% (wt/vol) Coomassie brilliant blue G250] and
then destained in the same solution minus the Coomassie staining dye.
The bands on the zymography gels reflect the activity of MMP-2 and
were analyzed by transmission densitometry (G-700 densitometer; Bio-
Rad, Hemel Hempstead, Hertsfordshire, UK) and integrated software
(Quantity One; Bio-Rad). All densitometry measurements were made
between samples on the same gel or between gels run under identical
conditions with a common control sample on each gel to ensure
comparability.
Measurement of inhibin-A and activin-A
Inhibin concentrations in culture medium collected from luteinized
granulosa cells were measured using a plate modification of a standard
in-house inhibin-A RIA. The sensitivity of this assay was 2 pg/ml and
was carried out as previously described (16). Activin-A concentrations
were measured using a two-site ELISA kit that measured total activin-A
(17) (Oxford Bio-Innovation, Oxfordshire, UK), following the manufac¬
turer's instructions. This assay had a sensitivity of less than 78 pg/ml
and inter- and intraplate coefficients of variation of less than 10%.
lmmunohistochemistry
Immunolocalization was carried out using antibodies recognizing
phosphorylated Smad 2/3 (New England Biolabs, Hertfordshire, UK),
activin j3A subunit (concentration 4.3 p.g/ml, kindly provided by Prof.
N. Groome, Oxford Brookes University, Oxford, UK), activin receptor
IIA (ActRIIA), and activin receptor like-kinase 4 (ALK4) (kindly pro¬
vided by R. Heldin, Ludwig Institute for Cancer Research, Uppsala,
Sweden) in 5-/xm paraffin tissue sections of human corpora lutea pre¬
pared on poly-L-lysine-coated microscope slides. These sections were
dewaxed, rehydrated, and washed in Tris-buffered saline (TBS)/0.1%
Tween 20 and TBS, respectively. Sections for phosphorylated Smad 2/3
were subjected to microwave antigen retrieval in 0.01 m citric acid (pH
6.0) for 10 min and left to cool to room temperature. All sections were
washed and placed in 3% H202/methanol for 30 min to block any
endogenous peroxidase activity.
Normal goat serum (NGS; Diagnostics Scotland, Edinburgh, UK)
diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) was added to
phosphorylated Smad 2/3, ActRIIA, and ALK4 sections, whereas /JA
sections were blocked in normal rabbit serum (Diagnostics Scotland) 1:5
in TBS for 1 h at room temperature. Primary antibodies were diluted in
respective blocking solutions and incubated on sections overnight at 4
C (phosphorylated Smad 2/3,1:1000; /3A, 1:500; ActRIIA, 1:400; ALK4,
1:400). Sections were rinsed twice for 5 min each time in wash buffers
and incubated with secondary antibodies [for phosphorylated Smad
2/3, ActRIIA, and ALK4, biotinylated goat-antirabbit IgG diluted 1:500
in NGS/TBS/BSA; for /3A, rabbit-antimouse diluted 1:25 in TBS (Dako
Corp., Cambridge, UK)].
Incubations lasted for 1 h and were followed by two washes for 5 min.
Thereafter, phosphorylated Smad 2/3, ActRIIA, and ALK4 sections were
incubated in avidin-biotin complex-horseradish peroxidase (Dako) for
1 h, and 0A sections were incubated in mouse peroxidase-antiperoxi-
dase (Dako) diluted 1:100 in PBS. Incubations were at room temperature
for 1 h, and all sections were washed in TBS (twice for 5 min each) and
bound antibodies visualized by incubation with liquid 3,3'-diamino-
benzidine tetrahydrochloride (Dako). Sections were counterstained
lightly with hematoxylin to enable cell identification. Negative controls
for each antibody examined were performed identically to the above
protocol with primary antibody incubations substituted with blocking
serum containing nonspecific Igs at the same concentration. Imageswere
captured using an Olympus Corp. Provis microscope (Olympus Corp.
Optical Co., London, UK) equipped with a Kodak DCS330 camera (East¬
man Kodak Co., Rochester, NY), stored on an HP computer and as¬
sembled using Photoshop 7.0.1 (Adobe Systems Inc., Mountain View,
CA).
Double-fluorescent immunohistochemistry
Sections were washed, subjected to antigen retrieval, and blocked as
described above. Negative controls were performed as above. Washes
detailed below were for 5 min each, and incubations were at room
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temperature unless otherwise specified. Rabbit anti-phosphorylated
Smad 2/3 was diluted 1:100 in NGS/TBS/BSA (see above) and incu¬
bated on sections overnight at4 C. Sectionswere washed, incubated with
goat antirabbit IgG 488 (Dako) diluted 1:200 in PBS for 1 h, and then
washed in PBS. Sections were reblocked with NGS/TBS/BSA for 1 h and
then incubated with mouse anti-CD31 or mouse anti-CD68 (Dako) di¬
luted 1:20 in NGS/TBS/BSA overnight at 4 C. Sections were washed,
incubated with biotinylated goat antimouse IgG (Dako) diluted 1 in 500
in NGS/TBS/BSA for 30 min, and then washed in TBS.
The fluorochrome streptavidin 546 Alexafluor (Molecular Probes,
Inc., Eugene, OR) diluted 1:200 in PBS was incubated on slides for 1 h.
For the labeling of nucleic acids, sections were counterstained with a
nuclear-specific blue fluorescent label (To-Pro 3; Molecular Probes) di¬
luted 1:2000 in PBS for 2 min. Sections were washed and mounted in
Permafluor (BeckmanCoulter,HighWycombe, UK). Fluorescent images
were captured using an LSM 510 Axiovert 100M confocal microscope
(Carl Zeiss Ltd.,WelwynGarden City,UK). Imageswere compiled using
Photoshop 7.0.1 (Adobe Systems).
Statistical analysis
Statistical analyses were carried out, after confirmation of normal
distributions for parametric analysis, using a paired f test when treat¬
ment and control samples were analyzed or with ANOVA when more
than two treatments were analyzed. Where significant differences were
observed (P < 0.05) using ANOVA, pairwise comparisons were carried
out using Bonferroni's multiple comparisons test. All statistical tests are
highlighted in the figure legends, and differences are given as either *,
P < 0.05; **, P < 0.01; or ***, P < 0.001. Differences were considered
significant at P < 0.05.
Results
MMP-2 and MMP-9 activity in primary cell culture
MMP activity was examined in primary cell cultures of
luteinized granulosa cells and fibroblast-like cells using gel¬
atin zymography (Fig. 1A). Primary cultures of luteinized
granulosa cells secreted MMP-9, whereas little MMP-2 ac¬
tivity was detected. Conversely, and as anticipated, fibro-
blast-like cells secreted large amounts ofMMP-2. Cocultures
of luteinized granulosa cells and fibroblast-like cells secreted
both zymogens.
The effect of activin-A on the expression ofMMP-2 in
fibroblast-like cells
MMP-2 activity in primary cell cultures was increased by
activin-A in a dose-dependent manner (10-100 ng/ml; P <
0.05; r2 = 0.55, by linear regression). Because intrafollicular
concentrations of activin-A have been reported to be in the
range of 0.42-26.3 ng/ml (18), we investigated the response
to physiological concentrations of activin-A (10 and 25 ng/
ml) in detail (Fig. IB). Both MMP-2 expression (P < 0.05, by
ANOVA) and activity (P < 0.05, by ANOVA) were increased
when compared with controls when fibroblast-like cells were
exposed to 25 ng/ml for 24 h (Fig. IB). Correspondingly, the
primary cultures of fibroblasts expressed activin receptors (I
and II) and Smad 2, 3, and 4 as well as MMP-2 (Fig. ID). We
believe that the effect of activin-A on fibroblast-like cells is
specific because cells exposed to inhibin-A show no change
in MMP-2 production (P > 0.05, paired t test, data not
shown). Furthermore, pilot studies (n = 2 corpora lutea) on
fibroblast-like cells obtained from prolonged cultures of dis¬
aggregated human corpora lutea exposed to 25 ng/ml ac¬
tivin-A also demonstrated the same effects on MMP-2 ex¬
pression (Fig. 1C). It is therefore likely that activin-A could
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Fig. 1. MMP-2 activity and expression in primary cell cultures. A,
Representative gelatin zymogram of primary and cocultures of lu¬
teinized granulosa cells and fibroblast-like cells. Luteinized granu¬
losa cells (LGC) secreted MMP-9 and very little MMP-2. Fibroblast-
like cells (Fib) secreted only MMP-2 whereas cocultures (Co-cult) of
the two cell types show activity for both zymogens. B, Activin-A
increases MMP-2 in primary cultures of fibroblast-like cells. Relative
MMP-2 mRNA expression, using real-time quantitative RT-PCR, is
shown in black bars, and MMP-2 activity, using gelatin zymography,
is shown in white bars. MMP-2 expression (P < 0.05, by ANOVA) and
activity (P < 0.05, by ANOVA) was significantly increased in fibro¬
blast-like cells exposed to 25 ng/ml activin-A in culture (n = 3-4
experiments). C, Pilot studies using fibroblast-like cells derived from
disaggregating human corpora lutea (n = 2) demonstrate the same
effect for MMP-2 expression to increase in the presence of 25 ng/ml
ofactivin-A. D, Fibroblast-like cells showmRNAexpression for house¬
keeping gene G6PDH (G6) and MMP-2; however, they do not express
the LH receptor (LHR), indicative that the activin action via hCG
mechanisms is under paracrine control. Furthermore, the expression
of activin receptors and signaling pathways can be confirmed in these
cells. Bands represent 200 and 500 bp as indicated. Bgly, /3-Glycan.
act as a regulator of luteal fibroblast MMP-2 production at
physiological concentrations.
Identification of activin synthesis and action in human
corpora lutea
Corpora lutea, at each stage of the luteal phase, have the
potential to synthesize activin-A, respond to activin-A, and
inhibit its action because they expressmRNA for J3A subunit,
activin receptors (I and II), Smad 2 and 3, and the common
Smad 4 aswell as inhibin a-subunit, /3-glycan, and follistatin.
The activin j3A subunit is localized to the LH-responsive
steroidogenic cells of corpora lutea at each stage of the luteal
phase (Fig. 2A). Although activin receptors can be found on
luteal steroidogenic cells, it is notable that luteal fibroblasts,
which secrete MMP-2, express both activin receptors I and II
(Fig. 2, B and C) and nuclear phosphorylated Smad 2/3 (Fig.
2D) at each stage of the luteal phase.
Change in Smad signaling across the luteal phase
We investigated phosphorylated Smad 2/3 across the
luteal phase by immunohistochemistry (Fig. 2, D-H). Nu¬
clear phosphorylated Smad 2/3 could be detected at all
stages of the luteal phase in both the steroidogenic (gran¬
ulosa lutein cells and theca lutein cells; Fig. 2D) and stro¬
mal cell compartments. Although it was detected in the
fibroblast layer, it was clear that not all cells in this layer
immunostained equally. We therefore colocalized phos¬
phorylated Smad 2/3 with other cell markers. Very little
phosphorylated Smad 2/3 immunostaining was noted in
endothelial cells (CD31-positive cells) when compared
with neighboring stromal cells (Fig. 2E) at any stage of the
luteal phase, although low-level staining could be noted in
some cells of vessels (Fig. 2F). In all sections examined, the
fibroblast layer contained macrophages (CD68-positive
cells). Dual immunostaining suggested that there was less
phospho-Smad 2/3 immunostaining in the macrophages
(Fig. 2, G and Fl) than the fibroblasts.
To investigate changes in Smad signaling across the luteal
phase, the expression of Smad 2 and Smad 3, in carefully
dated corpora lutea, was investigated using quantitative RT-
PCR (Fig. 3). Smad 3 expression increased to a maximum in
the late luteal phase (Fig. 3B) and was different between early
and mid (P < 0.05, by ANOVA) and early and late (P < 0.01,
by ANOVA) (Fig. 3B). The expression of Smad 2mRNA (Fig.
3A) was also assessed over the luteal phase, and although it
demonstrated a similar trend to that of Smad 3, the differ¬
ences did not reach significance.
Effect of hCG on activin-A and its inhibitors in primary cell
cultures of steroidogenic cells
To test our hypothesis that duringmaternal recognition of
pregnancy, the exposure of hCG to the corpus luteum results
in less activin-A signaling from the steroidogenic cells, we
assessed the effect of hCG in primary cultures of luteinized
granulosa cells. The secretion of both inhibin-A (range, 10—
500 pg/ml; P < 0.05, by t test) and activin-A (range, 1-5
ng/ml; P < 0.05 by t test) was increased by the addition of
hCG within 24 h (Fig. 4, A and B). Experimental results were
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Fig. 2. Immunolocalization of factors involved in activin/TGF-/3 signaling in human corpora lutea. A, Light-field microscopy of a late-luteal
human corpus luteum showing positive brown staining of the (3A-subunit in the granulosa-lutein cells (GLC) with little or none observed in
the surrounding fibroblast layer. Inset shows no staining in the negative control serial section. B and C, Positive staining for the activin receptors
ALK4 (B) and ActRIIA (C) in the surrounding fibroblast layer of a mid-luteal corpus luteum localized to cells that resemble fibroblast cells
(arrows). D, Phosphorylated Smad 2/3 is expressed during all stages of the luteal phase. Positive staining for this receptor-activated Smad is
evident in the nucleus ofgranulosa-lutein cells (GLC), thecal-lutein cells (TLC), and surrounding fibroblast layer (F) of the corpus luteum with
little staining around blood vessels (Bv). E, Double immunofluorescence of endothelial cells (CD 31) (arrow) in red colocalized with phosphor¬
ylated Smad 2/3 (green) in a mid-luteal corpus luteum. Nuclear phosphorylated Smad staining is clear in presumptive fibroblast cells (asterisk)
located in the stromal area of the corpus luteum and less marked in the endothelial cells (arrow). Nuclear staining is depicted in blue. F,
High-power images illustrate a low level of phosphorylated Smad 2/3 (green) in some endothelial cells (arrow) in red. G, Low-power image of
phosphorylated Smad 2/3 (green) and macrophages (CD 68-positive cells) (red) in a late-luteal corpus luteum. Phosphorylated Smad 2/3 is
localized to fibroblast cells (asterisk) and less so in the macrophages (arrow) stained in red. H, Higher-power view of an individual macrophage
(red) in the same tissue section (asterisk) showing low levels of phospho-Smad (green). Scale bars, 40 (im (A-D) and 20 pm (E-H).
standardized to their controls to consider variation within
individual experiments. Although exposure to hCG did not
change the inhibin:activin ratio, luteinized granulosa cells
markedly increased their expression of the activin-binding
protein follistatin (P < 0.01, by t test) in response to hCG
stimulation (Fig. 4C). In the presence of hCG, the up-regu-
lation of follistatin may therefore be able to reduce the local
actions of activin-A.
Evidence that luteal MMP-2 is under the paracrine control
ofactivin-A
To test our hypothesis that hCG could inhibit MMP-2
expression in a paracrine signaling fashion, we employed
a novel primary cell coculture system of luteinized gran¬
ulosa cells and fibroblast-like cells (3). In these cocultures,
the primary source of MMP-2 in the culture medium are
the fibroblast-like cells (Fig. 1A). The addition of hCG to
fibroblast-like cell cultures had no effect on the expression
of MMP-2 (P > 0.05, t test; Fig. 5A). However, cocultures
exposed to hCG demonstrated a significant reduction in
the expression of MMP-2 (P < 0.05, by t test; Fig. 5A),
suggestive that hCG is acting on luteinized granulosa cells
to influence fibroblast-like cell MMP-2 expression in a
paracrine manner.
To test our hypothesis that hCG is manipulating MMP-2
expression through a reduction in activin-A activity second¬
ary to an up-regulation of follistatin expression, we added
physiological concentrations of follistatin to our primary cell
cultures. The addition of follistatin to cultures of fibroblast-
like cells had no significant effect upon MMP-2 expression
(P > 0.05, t test; Fig. 5B). However, follistatin had the same
effect as hCG in reducing the expression of MMP-2 in co-
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Stage of the luteal cycle
Fig. 3. Expression ofthe receptor-activated Smads in human corpora
lutea over the luteal cycle. A, Real-time quantitative RT-PCR dem¬
onstrated that the mRNA expression of Smad 2 increased over the
luteal phase (n = 6 for each group); however, a nonsignificant trend
(P > 0.05, byANOVA) was observed. B, The expression ofSmad 3 was
significantly increased from the early luteal phase in both mid-luteal
(P < 0.05, byANOVA) and late-luteal (P < 0.01, byANOVA) samples.
cultures of luteinized granulosa cells and fibroblast-like cells
(Fig. 5B; P < 0.01, by t test).
Discussion
How luteolysis occurs in women and how it is inhibited
by hCG during maternal recognition of pregnancy is not yet
understood. What is clear, however, is that the inhibition of
luteolysis by hCG involves disparate effects on cell types in
the corpus luteum that do not express LH/hCG receptors.
We have previously shown that hCG regulates luteal fibro¬
blast (3,5), macrophage (4), and endothelial cell (19) function.
This means that paracrine signaling molecules from steroi¬
dogenic cells have key roles in the local regulation of luteal
cell function. To date, the identity of these molecules has
remained largely elusive. Here we have shown for the first
time, using a combination of observational studies on human
corpora lutea combined with interventional studies using
human primary cell culture and coculture models, that ac-
tivin-A is an excellent candidate molecule for a paracrine
regulator of luteal remodeling during luteolysis whose ac¬
tion can be inhibited by hCG during maternal recognition of
pregnancy.
It has to be highlighted that these studies used luteinized
granulosa cells and fibroblast-like cells from the luteinizing
follicle. We are using this coculture model to inform us about
the paracrine interactions that occur during luteolysis. It is
possible that dispersed cells from human corpora lutea may
respond differently at different stages of the luteal phase.
Unfortunately, such comprehensive studies using fresh hu¬
man luteal tissue are almost impossible, and it is likely that
Fig. 4. The effect of hCG on elements of the activin pathway in
primary cell cultures (n = 3). A and B, Luteinized granulosa cells show
an increase in inhibin-A (A) (P < 0.05, by t test) and activin-A (B) (P <
0.05, by t test) production when treated with hCG (100 ng/ml) for 24 h
relative to control samples. C, The expression of the activin binding
protein follistatin (P < 0.01, by t test) is up-regulated in the presence
of hCG (100 ng/ml); n = 3 separate experiments.
analysis of activin effects on remodeling of luteal cells will
need further assessment in subhuman species.
Activins belong to the structurally related TGF-/3 super-
family that includes inhibins and bone morphogenetic pro¬
teins. Members of this family have been shown to have
important paracrine regulatory roles in diverse physiological
processes (11). Indeed, activin signaling has been shown to
be essential in inflammation (20), cell proliferation and ap-
optosis (21), fetal development (22), and male reproduction
(23, 24). In particular, it has been established that activins
may have a paracrine role during the normal ovarian cycle
(24, 25). Activin can stimulate the proliferation of granulosa
cells in small follicles (26) and enhance their expression of
FSH receptors and aromatase (24, 27). It appears that one of
the roles of activin in the ovary is to stimulate smaller follicles
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Fig. 5. In vitromodel ofparacrine signaling in coculture experiments
of luteinized granulosa cells and luteal fibroblast-like cells. A, MMP-2
expression was significantly decreased (P < 0.05, by t test) in primary
cocultures exposed to hCG (100 ng/ml) for 24 h; B, similarly, the
expression of MMP-2 was significantly reduced (P < 0.01, by t test)
in cocultures treated with follistatin (FS) (500 ng/ml) for 24 h. Fi¬
broblast-like cell cultures in both treatment groups were unaffected
by either hCG or follistatin (P > 0.05, t test).
and inhibit luteinization of larger follicles to maintain the
follicle in an FSH-responsive state (24, 28).
There is evidence to support a paracrine role for activin in
the corpus luteum. In the first instance, the corpus luteum
has the mechanism to synthesize and secrete activin. Studies
in women (29) and primates (30) have localized inhibin a and
0A subunit mRNA and protein to the steroidogenic cells of
the corpus luteum. Dispersed luteal cells in vitro and the
intact corpus luteum in vivo secrete inhibin-A in a regulated
manner (31). The same is seen in cultures of human lutein¬
ized granulosa cells. In addition, these cells secrete activin-A,
and activin-A is found in the follicular fluid at the time of
ovulation (18). Indeed, circulating activin concentrations
change across the ovarian cycle, with an increase toward the
end of the luteal phase (10). As well as expressing the /3A
subunit mRNA and protein, it is likely that the granulosa-
lutein cells of the corpus luteum secrete activin-A during the
luteal phase.
In addition, we have shown that the corpus luteum has the
molecular mechanisms to respond to locally produced ac-
tivins. Activins signal through two types of transmembrane
serine/threonine kinase receptor interactions (32) and the
cytoplasmic to nuclear translocation of the intracellular
Smad proteins (33). Human corpora lutea express both the
type I (ALK 2/4) and type II (A) activin receptors as well as
components of the Smad (2,3, and 4) signaling pathway that
are induced by activin. Correspondingly, we have localized
the receptors and activated nuclear phosphorylated Smad
2/3 to both steroidogenic and stromal cells of the human
corpus luteum. Although the nature of the ligand signaling
through the Smad 2/3 pathway is not entirely clear, because
TGF-/3 signals through similar Smads (32,34), it is likely that
the activin signaling cascade is active and that activins do act
locally on different cells types in the corpus luteum.
Activin action, however, is highly controlled in physio¬
logical systems. It is tightly regulated by various inhibitors
at the ligand, receptor, and postreceptor levels (35). Follista¬
tin, a local regulator of activin, controls activin signaling by
forming biologically inactive complexes with the 0-subunits
of the activin glycoprotein. Suppression of activin-regulated
processes is also achieved by the activin antagonist inhibin
and its coreceptor 0-glycan. Inhibin opposes activin action by
competitively binding to the same site of the type II activin
receptor. Additionally, inhibins have also been thought to
have interactions with specific and high-affinity receptors
that may then activate signal transduction pathways, such as
the inhibitory Smads, that can oppose activin action (36).
0-Glycan on the other hand, has a high affinity for inhibin
and forms complexes with the type II activin receptor to
block the recruitment of the type I receptor (37) that is re¬
quired to activate the signaling cascade. As well as making
activin, the corpus luteum has at least some of the molecular
mechanisms required to inhibit activin.
It is not clear whether activin signaling changes across the
luteal phase. It is likely there is more activin available to act
in the late luteal phase because the increase in circulating
activin-A at the time of luteolysis (10) is not seen with regard
to its inhibitors, inhibin A (10, 31) and follistatin (38). We
were able to immunolocalize nuclear phosphorylated Smad
2/3, which would be detected in the presence of activin
signaling, throughout the luteal phase. Although most in¬
creases in Smad signaling are through phosphorylation of
the proteins, there are also increases in the expression of
Smad mRNA in response to ligand activation. We therefore
investigated the expression of Smad 2 and 3 mRNA across
the luteal phase. Expression of both Smads tended to be
maximal in the late-luteal phase. These results are compatible
with activin action increasing in the lead up to luteolysis.
The expression of both activin and its local inhibitors is
regulated in the corpus luteum. The addition of hCG up-
regulates the inhibin a-subunit and the secretion of inhibin-A
from steroidogenic cells in vitro and in vivo (31, 39). We
hypothesized that the inhibin:activin ratio would increase in
the presence of hCG and tested this using luteinized gran¬
ulosa cells in culture. We showed a similar stimulation of
both activin-A and inhibin-A and no change to the ratio.
However, other studies have shown that short-term gonad¬
otropin stimulation initially increased activin-A secretion,
but unlike inhibin-A, this diminishes later in a time- and
dose-dependent manner (40), and it is possible that hCG
increases the inhibinractivin ratio in the longer term. In ad-
Downloaded from endo.endojournals.org at Univ of Edinburgh FAST Er on December 4, 2007
Myers et al. • Activin-A as a Paracrine Regulator of Luteolysis
dition, both bound inactive activin and free active activin
were detected by the assay, and it is possible that the ratio
of inhibin to active activin changes. This is particularly im¬
portant because it is clear that follistatin is hormonally reg¬
ulated. hCG up-regulates follistatin from luteinized granu¬
losa cells in culture, and follistatin concentrations in follicular
fluid are hormonally regulated (38). For instance, follistatin
is up-regulated in the serum of pregnant women (15). Col¬
lectively, these data are suggestive that luteal activin action,
although not necessarily secretion, is inhibited by hCG dur¬
ing luteal rescue.
There appears to be a role for increased activin activity
during luteolysis. Previously, activin has been shown to in¬
hibit progesterone production by luteal cells in vitro (41), and
therefore it may have a role in the changes associated with
functional luteolysis. However, here we suggest that activin
has a role in the remodeling associated with structural lu¬
teolysis. One of the key features associated with luteolysis is
the up-regulation of MMP-2 in stromal cells (5, 6, 42). We
have shown for the first time that fibroblast-like cell MMP-2
is up-regulated by concentrations of activin (but not inhibin)
found inside the human ovary. For clarity, we use the term
fibroblast-like cells and stroma to represent the stromal cells
that are directly surrounding the steroidogenic cells and
invaginating in between them. Furthermore, stromalMMP-2
expression can be inhibited by hCG in a paracrine manner
both in vivo (5) and in coculture models in vitro. The effect of
hCG on MMP-2 in these cocultures can be replicated by the
addition of follistatin at concentrations found within the
human ovary. Because hCG up-regulates follistatin, these
results suggest that activin-A may be involved locally in the
physiological regulation of MMP-2 activity in the corpus
luteum.
MMP-2 is not known for being regulated at the level of its
expression. Indeed, an examination of the promoter region of
the MMP-2 gene shows fewer regulatory sequences than
other MMPs (42), consistent with a gene that is normally
constantly expressed. However, there are clearly certain cir¬
cumstances when its expression is regulated. It is increased
in fetalmembranes during labor (43) and in the endometrium
during menstruation (44), and more importantly, it is in¬
creased during natural and induced luteolysis in a wide
range of different species (5, 6, 42). The factors involved in
this regulation are not certain. There has been a suggestion
that steroids are involved in its regulation in the endome¬
trium (45) and cytokines such as TNF-a may be important in
the regulation of endometrial fibroblast (46) and bovine lu¬
teal (47) MMP-2 expression. Extravillous trophoblasts over-
expressing Smad 4 demonstrate a clear up-regulation of
MMP-2 production, mimicking the effect of TGF-/3 in this
particular system (48). The same theory may apply to ac¬
tivin-A in fibroblast cells of the corpus luteum because we
know they express the Smad proteins common to both TGF-J3
and activin signaling and that activin-A in fibroblast-like
cells increases MMP-2 production. Here, we demonstrate
that activin-A can up-regulate luteal MMP-2 expression and
activity in vitro at physiological concentrations.
There is some evidence, in other systems, that activin may
well regulate MMP-2 expression. Activin-A has been found
to regulate MMP-2 in both mouse peritoneal macrophages
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(49) and human decidua (50, 51). In addition, it has been
suggested that activin can up-regulate both MMP-9 and
MMP-2 expression in cultured human cytotrophoblast cells
(50). However, this was thought to be secondary to activin
affecting the differentiation status of these cells. Another
molecule from luteal fibroblasts with a role in tissue remod¬
eling during luteolysis is connective tissue growth factor (3).
We have shown that activin also up-regulates its expression
in luteal fibroblast-like cells (3), although this does not ap¬
pear to be the only regulating factor. It is not clear whether
other molecules as well as activin can regulate luteal MMP-2
expression during luteolysis.




Fig. 6. Schematic of the model we propose for the paracrine regula¬
tion of MMP-2 expression by hCG in human luteal cells. A, Steroi¬
dogenic cells (SC), but not fibroblast-like cells (FC), express the LH/
hCG receptor. The fibroblast cells secrete MMP-2 and express activin
receptors. B, During the late-luteal phase, increasing activin-A action
from the steroidogenic cells up-regulates the expression of MMP-2
from the fibroblast cells. C, In the presence of hCG during maternal
recognition of pregnancy, the increase of inhibin-A will block activin
binding to its receptors, whereas follistatin will bind and biologically
inactivate secreted activin-A, resulting in decreased activin signaling,
thus preventing the increased expression ofMMP-2. We suggest that
activin-A is a paracrine signaling molecule playing amajor role in the
regulation of luteolysis in women.
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during luteolysis, it is likely to be self-limiting in nature. This
is because the cellular source of activin is the steroidogenic
cells that undergo programmed cell death when the corpus
luteum is cleared from the ovary (1, 2). It is difficult to
determinewhether observations made in nonprimate species
are relevant to women because there are major species dif¬
ferences in the regulation of the corpus luteum. In themouse,
where ovarian activin /3A expression has been conditionally
knocked out (52), the ovary contains multiple corpora lutea
when examined. Although is it tempting to speculate that
luteolysis may be affected, it has to be remembered that
inhibin-A will also be knocked out, and this may well result
in higher FSH concentrations than would be expected to
cause more ovulations.
Observational studies on human corpora lutea inform us
that the steroidogenic cells expressing LH/hCG receptors
can secrete activin-A, and the stromal cells that express
MMP-2 have the molecular machinery to respond to locally
produced activin. Such observations, however, do not tell us
the roles of activin, and interventional studies are required.
It is now not practical to collect enough well characterized
human corpora lutea to disaggregate the cells and manipu¬
late these cells in culture, and other model systems have to
be used. The culture of luteinized granulosa cells and the
derivation of fibroblast-like cells have the potential to rep¬
licate the luteal steroidogenic cell/stromal cell interactions in
vitro. Although luteinized granulosa cells are LH/hCG re¬
sponsive and function in primary culture for 14 d, they may
differ from mature granulosa-lutein cells. In addition, al¬
though the phenotype of the fibroblast-like cells is identical
to luteal stromal cells in all the genes we have analyzed (3)
and expression patterns of MMP-2 from prolonged cultures
of fibroblasts obtained from corpora lutea, there may be
differences. Indeed, we have shown that there are at least two
types of fibroblast in the human corpus luteum (53). Fur¬
thermore, in culture, the cells do not have the local interac¬
tion with immune cells and endothelial cells seen in vivo.
Although we accept there are caveats to our model system
and indeed, our in vitro cell culture and coculture models
may not entirelymimic what is happening within the corpus
luteum, such model systems can give valuable insights into
mechanistic functions that otherwise may not be dissected.
Therefore, although care needs to be used in the interpreta¬
tion of their findings and used in conjunction with observa¬
tional studies, we believe we have the most appropriate
model to study and manipulate cell-cell interactions in the
human corpus luteum.
In conclusion, we suggest that activin-A may have a phys¬
iological role in luteolysis, and part of this role is to stimulate
luteal MMP-2 expression. We believe that hCG serves to
impede activin action (Fig. 6), and this will facilitate luteal
maintenance by inhibiting luteolysis and allowing the ma¬
ternal recognition of pregnancy.
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Role of Luteal Glucocorticoid Metabolism during
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The human corpus luteum (hCL) is an active, transient, and
dynamic endocrine gland. It will experience extensive tissue
and vascular remodeling followed by 1) demise of the whole
gland without any apparent scarring or 2) maintenance of
structural and functional integrity dependent on conceptus-
derived human chorionic gonadotropin (hCG). Because Cor¬
tisol has well-characterized roles in tissue remodeling and
repair, we hypothesized that itmay have a role in controlling
luteal dissolution during luteolysis and would be locally pro¬
duced toward the end of the luteal cycle. Glucocorticoid-me-
tabolizing enzymes [11/3-hydroxysteroid dehydrogenase
(11/1HSD) types 1 and 2] and the glucocorticoid receptor (GR)
were assessed in hCL and cultures of luteinized granulosa
cells (LGC) using immunofluorescence and quantitative RT-
PCR. Furthermore, the effect of Cortisol on steroidogenic cell
survival and fibroblast-like cell activity was explored in vitro.
The hCL expressed 110HSD isoenzymes in LGC and nuclear
GR in several cell types. hCG up-regulated the expression and
activity of 110HSD type 1 (P < 0.05) and down-regulated type
2 enzyme (P < 0.05) in vitro and tended to do the same in vivo.
Cortisol increased the survival of LGC treated with RU486
(P < 0.05) and suppressed the activity of a proteolytic enzyme
associated with luteolysis in fibroblast-like cells (P < 0.05).
Our results suggest that, rather than during luteolysis, it is
luteal rescuewith hCG that is associated with increased local
Cortisol generation by 11/3HSD type 1. Locally generated Cor¬
tisol may therefore act on the hCL through GR to have a
luteotropic role in the regulation of luteal tissue remodeling
during maternal recognition of pregnancy. (Endocrinology
148: 5769-5779, 2007)
THE HUMAN CORPUS LUTEUM develops from thepostovulatory follicle to become one of the most active
endocrine glands in the body. During the luteal life span, this
remarkable structure will experience very high cell turnover,
intense angiogenesis, and considerable steroid production
within a 14-d period. Such highly organized events rely upon
stringent paracrine interactions between neighboring and
surrounding cells. In a nonconception cycle, the corpus lu¬
teumwill undergo luteolysis, a complex process whereby the
tissue is subjected to a loss of structural and functional in¬
tegrity that is associated with an immune cell influx (1),
increase in matrix metalloproteinases (2), cell death (3), and
vascular regression (4). Remarkably, however, such dramatic
remodeling and rapid tissue removal occurs in an orderly
fashion without any evidence of permanent scar tissue.
Within the ovary, ovulation and the resulting folliculo-
luteal transition has been likened to an inflammatory re¬
sponse, as a result of the acute hemodynamic, cellular, and
biochemical changes that occur at the site of follicle rupture
(5, 6). Key studies have clearly shown that the repetitive
damage from consecutive ovulations must be quickly re¬
paired in anticipation for the next ovulatory cycle, and locally
First Published Online September 13, 2007
Abbreviations: CBP, Cortisol-binding protein; GR, glucocorticoid re¬
ceptor; hCG, human chorionic gonadotropin; 11/3HSD, 110-hydroxys-
teroid dehydrogenase; LDL, low-density lipoprotein; MMP-2, matrix
metalloproteinase 2; NGS, normal goat serum; TBS, Tris-buffered saline.
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produced glucocorticoids are involved (7-9). Cortisol, the
most important glucocorticoid, is well known to minimize
inflammatory damage to tissues by encouraging wound
healing and subsequent repair. Clear evidence of this phe¬
nomenon is apparent from the switch of 11/3-hydroxysteroid
dehydrogenase (11/3HSD) isoforms over the ovarian cycle,
complemented by the increased concentrations of Cortisol in
follicular fluid after the LH surge (10). At present, both
11/3HSD type 1 (that tends to generate Cortisol) and 11/3HSD
type 2 (that tends to inactivate Cortisol) isoforms, and their
activities, have been reported in the ovaries of several species
(11).
Throughout the human body, glucocorticoids are well
known to exhibit a plethora of physiological roles. Although
most of these actions have been best characterized in body
systems such as kidney, liver, adrenal, and local inflamma¬
tory responses, influences on human fertility, oocyte matu¬
ration, and the establishment of a functional corpus luteum
have been suggested (12-15). It has also been reported that
because glucocorticoids can inhibit endothelial cell prolifer¬
ation (16), they may have a role in the local regulation of
angiogenesis.
With the knowledge that glucocorticoids are involved in
inflammatory-associated events in the ovary and may ad¬
versely affect angiogenesis, we hypothesized that local Cor¬
tisol action may have a role in the luteolytic process. Al¬
though governed by different luteolytic mechanisms than in
women, elegant studies in the rat corpus luteum have iden¬
tified a potential role for 11/3HSD type 2 in the regressing
corpus luteum (17). Therefore, based upon the findings in the
5769
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rat study, coupled with much evidence for glucocorticoids in
tissue and scar regeneration, we hypothesized that glucocor¬
ticoids were involved across the luteal life span. Therefore,
the aims of the current study were to 1) investigate luteal
glucocorticoid metabolism, reception, and subsequent reg¬
ulation using carefully dated human corpora lutea and pri¬
mary cell cultures of luteinized granulosa cells and 2) estab¬
lish whether changes in Cortisol synthesis and metabolism
might be a key event in the regulation of the tissue remod¬
eling associated with luteolysis.
Materials and Methods
Collection of human corpora lutea
Tissue collection was approved by the local medical research ethics
committee, and all women gave informed consent. Human corpora lutea
(n = 18) were enucleated at the time of surgery fromwomenwith regular
menstrual cycles undergoing hysterectomy for benign conditions and
dated on the basis of the urinary LH surge as described previously (18,
19). In this study, six corpora lutea were classified as early luteal (LH+1
to LH+5), six as mid-luteal (LH+6 to LH+10), and six as late-luteal
(LH+11 to LH+14). At operation, the corpus luteum was quartered to
ensure that each quarter contained all cellular elements and fixed in 10%
neutral buffered formalin for subsequent immunohistochemistry. In
addition, archival corpora lutea that had been immediately frozen and
stored at - 70 C from previous studies (20,21) were also available. Frozen
tissue quarters for mRNA extraction were available from six late-luteal
corpora lutea and five corpora lutea that had been rescued (daily dou¬
bling doses of exogenous human chorionic gonadotropin (hCG) from
LH+7 for 5-8 d) as described previously (2, 19).
Isolation of human luteinized granulosa cells and
fibroblast-like cells
The medical ethics committee separately approved the collection of
cells from patients undergoing assisted conception. With patient con¬
sent, follicular fluid was collected fromwomen undergoing transvaginal
oocyte retrieval for in vitro fertilization after ovarian stimulation using
a standard procedure (22). Isolation of luteinized granulosa cells using
Percoll density gradient centrifugation was carried out as described
previously (20, 23). Fibroblast-like cells were obtained from prolonged
cultures of follicular aspirates as described previously (20).
Primary cell culture treatments
Pooled luteinized granulosa cells (100,000 per well of three to five
patients) were cultured in 24-well plates precoated with Matrigel (BD
Biosciences, Bedford, MA) in serum-free medium (supplemented
DMEM/Ham's F12 mixture), as described previously (20). Each pooled
experiment for the following treatments was carried out at least three
times to avoid biological bias.
Assessment of the acute effects of hCG and progesterone
Luteinized granulosa cells plated as above had fresh medium
changed every 2-3 d over the course of culture, and treatment was
carried out on d 6 or 7 of culture. The treatments groups were 1) controls
with low-density lipoprotein (LDL, 50 mg/liter; Sigma-Aldrich Corp.,
Dorset, UK), 2) hCG (10 ng/ml; Serono, Welwyn Garden City, UK) with
LDL (50 mg/liter), and 3) hCG (10 ng/ml) and LDL (50 mg/liter) in
conjunction with 100 pM aminoglutethimide (Sigma-Aldrich). After
24 h, medium and cells were stored for steroid analysis and mRNA
extractions, respectively. Progesterone concentrations in the culture me¬
dia were determined by an in-house RIA as described previously (20).
Manipulation ofhCG in prolonged cultures of luteinized
granulosa cells
To mimic the luteal phase in primary cell culture, luteinized gran¬
ulosa cells were plated as described above and grown for 12 d as
described previously (22). Briefly, cells were stimulated with low-dose
hCG (1 ng/ml) with LDL (50 mg/liter) beginning on d 2 and this was
repeated every second day until d 7when treatments were replaced with
maximal doses of 100 ng/ml hCG/LDL or LDL alone. Cells were an¬
alyzed after 7 d with hCG and on d 12 in the presence or absence of hCG
to mimic the progesterone secretion profile of late-luteal and luteal
rescue stages, respectively (22).
Relative cell counts for various steroid and steroid
inhibitor treatments
Pooled luteinized granulosa cells were cultured as above for 7 d in
the presence of the same carrier ethanol concentrations in each well. The
experiments were piloted to determine the appropriate concentrations
of reagents, and final experiments were repeated three times in triplicate.
The treatments were 1) control, 2) aminoglutethimide (100 p.m), 3) RU486
(100 p.M; Sigma), 4) RU486 (100 pin) with progesterone (500 pM; Sigma),
5) RU486 (100 pM) with Cortisol (500 pM; Sigma), and 6) RU486 (100 (im)
with hCG (100 ng/ml). After 7 d, the cells were removed by trypsiniza-
tion, resuspended, and counted using a hemocytometer. Values were
taken as the mean of at least four separate counts by an observer blinded
to the treatments and related to controls.
Treatment of cultured fibroblast-like cells with Cortisol
Cultures of fibroblast-like cells were derived as described above and
transferred to 24-well plates at a concentration of 60,000-80,000 cells per
well. After 6 h in serum-free culture, the medium was removed and
replaced with medium containing either Cortisol (100 nM) or an equiv¬
alent amount of the ethanol carrier as a control. After 24 h, the culture
medium was collected for subsequent zymography, and the cells were
used for mRNA extraction.
Preparation of cDNA from human corpora lutea and
cultured cells
Messenger RNA was batch extracted from frozen human corpora
lutea and reverse transcribed into cDNA using random hexamers as
described previously (20). Luteinized granulosa cell mRNA was ex¬
tracted using RNeasy mini-spin columns after lysis by the addition of
RNeasy lysis buffer (QIAGEN, Crawley, Sussex, UK). Lysates were
frozen until processed as per manufacturers' protocols and then DNase
treated with on-column DNase I (QIAGEN) and quantified using the
NanoDrop ND-1000 Spectrophometer (NanoDrop Technologies, Wil¬
mington, DE). mRNA was then reverse transcribed into cDNA using
random hexamers (Applied Biosystems, Foster City, CA).
Quantitative analysis ofgene expression by real-time PCR
Quantitative real-time PCR was carried out on the ABI PRISM 7700
sequence detection system (Applied Biosystems) using specific primers
and probes (Eurogentec, Southampton, UK) for each gene of interest
TABLE 1. List of all primer/probe sequences used for Taqman quantitative RT-PCR

















Sequences for 11/3HSD1, 11/3HSD2, and GRa were obtained from Rae et al. (8).
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(Table 1), and levels were related to a ribosomal 18S internal control
(Applied Biosystems). Quantitative real-time PCR was performed with
an extension temperature of 72 C and 30 cycles of amplification. All
samples were performed in duplicate, and a relative comparison was
made to an appropriate tissue control, either human placental or liver
cDNA.
Histology
Masson's modified trichrome staining was carried out on 5-/u,m par¬
affin sections of human corpora lutea. Briefly, sections were dewaxed,
rehydrated in alcohol, and washed in water. Sections were then placed
in Celestine blue for 3min, washed, placed in Mayer's acid hematoxylin
solution for 3 min, washed, and then counterstained with Biebrich scar¬
let-acid fuchsin solution for 15 min. After washing, the sections were
differentiated in 5% phosphotungstic acid for 15min before being placed
directly into aniline blue solution for 5-10min, washed, dehydrated, and
mounted for microscopy.
Immunohistochemistry
Immunolocalization of glucocorticoid receptor (GR) was carried out
using a rabbit polyclonal antibody (ABR; Cambridge Bioscience, Cam¬
bridge, UK) in 5-jttm paraffin tissue sections of human corpora lutea
prepared on poly-l-lysine-coated microscope slides. These sections were
dewaxed, rehydrated, washed in PBS, subjected to microwave antigen
retrieval in 0.01 m citric acid (pH 6.0) for 10 min, and left to cool to room
temperature. All sections were washed and placed in 3% H202/meth-
anol for 30min, followed by an avidin and biotin block and another block
using normal goat serum (NGS; Diagnostics Scotland, Edinburgh, UK)
diluted 1:4 in PBS containing 5% BSA [NGS/Tris-buffered saline (TBS)/
BSA] for 1 h at room temperature.
GR antibody was diluted 1:2000 in blocking solution and incubated
on sections overnight at 4 C. After rinsing, sections were incubated with
the biotinylated goat antirabbit IgG (diluted 1:500 in NGS/TBS/BSA)
secondary antibody (Dako Corp., Cambridge, UK) for 1 h. After wash¬
ing, the sections were incubated in avidin-biotin complex-horseradish
peroxidase (Dako), and binding was visualized by incubation with liq¬
uid 3,3'-diaminobenzidine tetrahydrochloride (Dako). Sections were
counterstained lightly with hematoxylin to enable cell identification.
Negative controls were performed identically to the above protocol with
primary antibody incubations substituted with blocking serum contain¬
ing nonspecific Igs at the same concentration. Images were captured
using an Olympus Provis microscope (Olympus Corp. Optical Co.,
London, UK) equipped with a Kodak DCS330 camera (Eastman Kodak
Co., Rochester, NY), stored on an HP computer and assembled using
Photoshop 7.0.1 (Adobe, Mountain View, CA).
Fluorescent immunohistochemistry
Sections were washed, subjected to antigen retrieval, and blocked as
described above, and negative controls were performed as above. Rabbit
anti-GR and rabbit anti-ll/3HSD type 1 (Cayman/IDS Ltd., Bolton UK)
diluted 1:100 in NGS/TBS/BSA were incubated on sections overnight
at 4 C. Sections were washed, and slides were incubated with goat
antirabbit IgG 488 (Dako) diluted 1:200 in PBS for 1 h.
Sections that were labeled with anti-GR were subjected to further
colocalization experiments. Sections were reblocked with NGS/PBS/
BSA for 1 h and then incubated with mouse monoclonal antibodies
anti-CD31 (Dako; 1:20 in block), anti-CD68 (Dako; 1:20 in block), or
anti-a-smooth muscle actin (a-SMA, Dako; 1:500 in block) overnight at
4 C. Sections were washed and incubated with the fluorochrome strepta-
vidin 546 Alexafluor (Molecular Probes, Eugene, OR) diluted 1:200 in
PBS for 1 h.
Sections that were labeled with anti-ll/3HSD type 1 were reblocked
with normal donkey serum/PBS/BSA for 1 h and then incubated with
sheep anti-ll/3HSD type 2 (kind gift from Prof. Ian Mason, The Uni¬
versity of Edinburgh, Edinburgh, UK) diluted 1:50 in donkey serum.
Sections were washed and incubated with donkey antisheep peroxidase
(Dako) 1:200 in normal donkey serum/PBS/BSA for 30 min before
washing and incubating for 10minwith tyramideCy3 (TSA plus cyanine
3 system; PerkinElmer Life Sciences, Boston, MA) diluted 1:50 in the
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supplied buffer to amplify the 11/3HSD type 2 immunostaining with red
fluorescence.
Nucleic acids were labeled with To-Pro 3 and washed and mounted
in Permafluor (Beckman Coulter, High Wycombe, UK). Fluorescent
images were captured using an LSM 510 Axiovert 100M confocal mi¬
croscope (Carl Zeiss Ltd., Welwyn GardenCity, UK). Images of 11/3HSD
type 1 and 11/3HSD type 2 were analyzed comparatively by standard¬
izing the computer settings for each isoform. Therefore, the relative
intensity of staining for each isoform corresponds to abundance of
protein levels. All images were compiled using Photoshop 7.0.1 (Adobe
Systems Inc., San Jose, CA).
Measurement of net llfiHSD oxidoreductase activity
Interconversion of cortisone to Cortisol via 11-oxoreductase activity
was assessed in the presence and absence of hCG. Pooled luteinized
granulosa cells were stimulated with either 100 ng/ml hCG in serum-
free medium or serum-free medium alone for 24 h. Controls included
incubations containing no cells with only Matrigel. After hCG stimu¬
lation, culture medium was discarded from wells and replaced with
culture medium containing 100 nM cortisone substrate and 0.1 /xCi
[3H]cortisone to give a final volume of 500 /xl/well. All incubations were
in triplicate for 4 h at 37 C with 95% air-5% C02 After incubation,
medium was added to glass tubes containing 5-ml aliquots of dichlo-
romethane and vortexed thoroughly. To separate the aqueous and or¬
ganic phases, tubes were centrifuged at 12,000 rpm for 10 min. After the
aqueous phase was removed, samples were evaporated to dryness un¬
der nitrogen gas at 45 C. Steroid residues were resuspended in 100 /u.1
dichloromethane and samples along with one [3H]cortisol and one
[3H]cortisone blot were transferred to silica gel-precoated plastic sheets
for thin-layer chromatographic separation of precursor and product in
the solvent system of chloroform-ethanol (92:8 by volume) (Merck, Had-
deson, Hertfordshire, UK). Thin-layer chromatography plates were then
scanned using a Bioscan System 200 detector (Lablogic Systems, Shef¬
field, UK), and corresponding peaks were analyzed for enzymatic ac¬
tivity in each sample and consequently each treatment group. Results are
expressed as amount of cortisone converted to Cortisol (picomoles) per
hour.
Gelatin zymography
Cell culture medium was collected from serum-free cultures and
subsequently frozen at -20 C. Aliquots of 200 p.1were subjected to freeze
drying for 2-3 h until they resembled a powder and then reconstituted
in 20 fjd sterile dH20. One microliter of the reconstituted sample was
added to sample buffer [10% (vol/vol) glycerol, 1% (wt/vol) SDS, and
0.04% (vol/vol) bromophenol blue] and applied to an 11% (wt/vol)
polyacrylamide gel containing 1 mg/ml gelatin and 0.1% (wt/vol) SDS.
Gels were incubated in 2.5% Triton X-100 for 45 min after electrophoretic
separation of proteins and then incubated at 37 C overnight in digestion
buffer [50 mmol/liter Tris-HCl (pH 7.6) containing 0.2 mol/liter NaCl,
5 mmol/liter CaCl2, and 0.02% (wt/vol) Brij 35] as described previously
(2). Gels were stained in staining solution [30% (vol/vol) methanol, 10%
glacial acetic acid, and 0.5% (wt/vol) Coomassie brilliant blue G250] and
then destained in the same solution minus the Coomassie staining dye.
The bands on the zymography gels reflect the activity of matrix met-
alloproteinase 2 (MMP-2) and were analyzed by transmission densi¬
tometry (G-700 densitometer; Bio-Rad, Hemel Hempstead, Hertford¬
shire, UK), and integrated software (Quantity One, Bio-Rad). All
densitometry measurements were made between samples on the same
gel or between gels run under identical conditions with a common
control sample on each gel to ensure comparability.
Statistical analysis
Parametric statistics were used when the data were distributed nor¬
mally, with appropriate tests highlighted in the figure legends. Differ¬
ences were considered significant at P < 0.05 level.
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Results
Expression and localization of llpHSDs in the human
corpus luteum
The granulosa-lutein cells of the corpus luteum can easily
be identified by their localization and morphological char¬
acteristics (Fig. 1A). Both isoforms of the cortisol-metaboliz-
ing enzyme 11/3HSD (type 1 and type 2) could be immuno-
localized to the cytoplasm of granulosa-lutein cells in human
corpora lutea (Fig. 1, B and C), although the staining intensity
of 11J3HSD type 1 was much greater than that of 11/3HSD
type 2. Specific immunostaining for each isoform could be
detected in each corpus luteum analyzed from each stage of
the functional luteal phase. No staining could be detected in
negative control sections (Fig. IB, inset). The corpus luteum
of women therefore has the capacity for the local production
and metabolism of Cortisol.
Expression and localization ofgenomic GR in the human
corpus luteum
Nuclear GR immunostaining could also be detected in
human corpora lutea. GR were also localized to the nuclei of
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granulosa-lutein cells (Fig. ID), but unlike the 11/3HSD iso¬
forms, GR could be localized to nonsteroidogenic cell types.
Dual-staining immunohistochemistry with a-SMA demon¬
strated GR expression in stromal myofibroblasts and peri¬
cytes (Fig. 1, E and F). Dual immunostaining with CD68 and
CD31 demonstrated specific nuclear GR expression in mac¬
rophages (Fig. 1G) and endothelial cells (Fig. 1TI) in each
corpus luteum examined. This pattern of GR immunostain¬
ing was detected in corpora lutea from each stage of the luteal
phase. Various different cells in the human corpus luteum
therefore have the capacity to respond to both systemic and
locally produced Cortisol in an autocrine, paracrine, or en¬
docrine manner.
The effect of hCG on llfiHSD and GR expression in
primary cultures of luteinized granulosa cells
To determine whether the expression of GR and cortisol-
metabolizing enzymes in steroidogenic cells could be acutely
regulated, the effect of hCG was examined in primary cell
cultures of human luteinized granulosa cells. The addition of
hCG for 24 h resulted in a 30-fold up-regulation of 11/LFISD
Fig. 1. Immunolocalization of cortisol-metabolizing enzymes and the GR in the human corpus luteum. A, A midluteal human corpus luteum
(stained with Masson's trichrome) is a heterogeneous tissue composed of the steroidogenic granulosa-lutein cells (GLC) and theca-lutein cells
(TLC), an inner and outer supportive stromal layer that consists of predominantly fibroblast (F) layers and blood vessels (BV), and the central
clot (CC) that once comprised the antral cavity of the follicle; B and C, immunofluorescence staining demonstrates that the GLC of the corpus
luteum express the cortisol-metabolizing enzymes 11/3HSD type 1 (green with blue nuclear stain) (B) and llfiHSD type 2 (red with blue nuclear
stain) (C); inset in B, negative control for llfiHSD type 1 and 2; D, the GR protein is ubiquitously expressed in the corpus luteum as seen by
the positive brown DAB staining; E, immunofluorescence, however, further confirms that GR can be colocalizedwith other cell types; for example,
nuclear GR (green) is present in the GLC, whereas a-SMA-positive cells represent stromal myofibroblasts and pericytes (red); F, high-power
images reveal that GR (green) is localized to the presumptive fibroblast cells (red); G and H, macrophages (red, CD68) (G) and endothelial cells
(red, CD31) (H) of the corpus luteum. Nuclear staining is depicted in blue. Scale bars, 200 pm (A), 40 jim (B, C, and E), 100 pm (D), 10 pm
(F and H), and 20 pm (G).
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type 1 expression (P < 0.05, Kruskal-Wallis) (Fig. 2A). At the
same time, 11/3HSD type 2 was down-regulated (P < 0.05,
Kruskal-Wallis) (Fig. 2B), whereas GR expression was also
up-regulated (P < 0.05, ANOVA) (Fig. 2C). To determine the
functionality of the enzyme and the direction of 11/3FISD
activity, 11-oxoreductase activity was assessed in the pres¬
ence and absence of hCG. This confirmed that hCG stimu¬
lated reductase activity and acted to generate Cortisol (P <
0.05, t test) (Fig. 2E).
Because luteinized granulosa cells have genomic pro¬
gesterone receptors, and hCG stimulates progesterone se¬
cretion (range, 460-890 ng/ml), cells were cultured with
the progesterone synthesis inhibitor aminoglutethimide to
separate hCG effects from progesterone effects (20) (P <
0.0001, ANOVA) (Fig. 2D). Aminoglutethimide reduced
progesterone (range 160-400 ng/ml) secretion to control
levels (170-200 ng/ml) in the presence of hCG (Fig. 2D).
Although aminoglutethimide had no effect on hCG-stim-
ulated up-regulation of 11/3FISD type 1 and GR, it inhib¬
ited the hCG-induced down-regulation of 11/3HSD type 2
(Fig. 2B). This suggests that progesterone may be involved
in the local regulation of 11/3HSD isoform expression.
Overall, these data suggest that Cortisol metabolism and
reception may be hormonally regulated in luteal steroi¬
dogenic cells.
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The effect of chronic manipulation of hCG in cultures of
human luteinized granulosa cells
To determine whether hCG could regulate the expression
of ll/3HSDs and GR in more physiologically relevant pro¬
longed culture conditions, 12-d cultures of luteinized gran¬
ulosa cells, designed to mimic the luteal phase (20), were
examined. Withdrawal of hCG in culture down-regulated
llj3FfSD type 1 (P < 0.05, Kruskal-Wallis), whereas its ex¬
pression was maintained in the presence of hCG (Fig. 3A).
Conversely, hCG withdrawal had no effect on llj3HSD type
2 expression, whereas maintenance of hCG did not alter its
expression because the trend toward reduction did not reach
significance (P > 0.05, Kruskal-Wallis) (Fig. 3B). The expres¬
sion of GR showed a similar pattern to that of 11/3HSD type
1, but there were no significant changes detected (Fig. 3C)
(P > 0.05, ANOVA). These data suggest that cortisol-metab-
olizing enzymes may continue to be differentially regulated
by hCG under chronic conditions.
The effect of hCG on the expression of 11 fiHSDs in human
corpora lutea in vivo
To determine the effect of hCG of luteal 11/3FISD expres¬
sion in women, we examined archival tissues collected in the
late luteal phase in the absence or presence of exogenous
hCG to rescue the corpus luteum and mimic the changes of
Fig. 2. hCG modulates the 11/3HSD
enzymes and GR in luteinized granu¬
losa cells in primary culture. A, The
expression of 11/3HSD type 1 is up-
regulated by hCG independently of
progesterone as evident by the addi¬
tion of progesterone synthesis inhibi¬
tor aminoglutethimide (P < 0.05,
Kruskal-Wallis); B, hCG, however, de¬
creased the expression of 11/3HSD
type 2 (P < 0.05, Kruskal-Wallis),
whereas in the presence of aminoglu¬
tethimide inhibition of type 2 was pre¬
vented; C, similar to that of 11/3HSD
type 1, hCG increased GR expression
in luteinized granulosa cells (P <
0.0001, ANOVA), whereas the addi¬
tion of aminoglutethimide had no ef¬
fect; D, hCG stimulated an increase of
progesterone (P < 0.0001, ANOVA),
and this increase was blocked by the
addition of aminoglutethimide; E,
hCG increases 11-oxoreductase activ¬
ity, which acts to generate Cortisol
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Fig. 3. Chronic manipulation with hCG in cultures of luteinized
granulosa cells designed to mimic the luteal phase involved low-dose
hCG stimulation until d 7, which was either replaced by maximal-
dose hCG on d 12 (+) or removal of hCG on d 12 (-). A, Withdrawal
ofhCG on d 12 down-regulated the expression of 11/3HSD type 1 (P <
0.05, Kruskal-Wallis), whereas expression was maintained in the
presence of hCG; B, expression levels of 11/3HSD type 2 remained
unchanged (P > 0.05, Kruskal-Wallis) by hCG withdrawal or main¬
tenance; C, the expression ofGR demonstrated a tendency to decrease
with hCG withdrawal and maintain levels with hCG (P < 0.05,
ANOVA). n.s., No significant difference.
early pregnancy (2). In vivo, the effects of hCG did not quite
reach significance (P > 0.05, t test), although there was a clear
differential effect on the expression of 11/3HSD type 1 and
11/3HSD type 2 (Fig. 4). Exogenous hCG tended to up-reg-
ulate 11/3HSD type 1 (Fig. 4A) but tended to down-regulate
11/3HSD type 2 (Fig. 4B). There were no specific effects of
hCG on the expression of GR in the corpus luteum of women
(Fig. 4C). These data suggest that the differential regulation
of Cortisol metabolism in luteinized granulosa cells in vitro
may also occur in the human corpus luteum in vivo.
The effect ofRU486 on primary cultures of luteinized
granulosa cells
Because hCG seems to promote the generation and action
of Cortisol, we hypothesized that Cortisol may function as a
local luteotropic factor during luteal rescue and that Cortisol
withdrawal may have a role during luteolysis. We therefore
investigated whether Cortisol could function as a survival
Late Resc
Fig. 4. Modulation of ll/3HSDs and GR in human corpora lutea in
vivo suggests a tendency for Cortisol regeneration during hCG rescue.
A, The relative expression levels of 11/3HSD type 1 tended toward an
increase during hCG-induced luteal rescue compared with that of the
late luteal phase; B, conversely, the opposite was true for 11/3HSD
type 2, whereby expression levels tended toward a decline during
hCG-induced luteal rescue compared with the late luteal phase; C,
expression of GR remained relatively unchanged in the presence or
absence of hCG. n.s., No significant difference.
factor in cultures of luteinized granulosa cells. The Cortisol
and progesterone antagonist RU486 reduced the number of
luteinized granulosa cells in culture (P < 0.001, ANOVA)
after 7 d treatment (Fig. 5). This effect was not seen when
progesterone synthesis was inhibited by aminoglutethimide
(Fig. 5). This decrease in cell number in the presence ofRU486
could be prevented by the addition of Cortisol (P > 0.05,
ANOVA) so that cell numbers were no different from con¬
trols (Fig. 5). Conversely, the addition of saturating concen¬
trations of progesterone or hCG in the presence of RU486 did
not increase the cell number beyond that ofRU486 alone (P >
0.05, ANOVA) (Fig. 5). These data crudely suggest that Cor¬
tisol may have direct actions on luteinized granulosa cells in
vitro.
The effect of Cortisol on nonsteroidogenic cells
As well as the steroidogenic cells of the corpus luteum, GR
can be localized to nonsteroidogenic cells. This suggests that
Cortisol has the potential to function as a paracrine regulatory
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Fig. 5. The effect of RU486 and steroids on luteinized granulosa cell
survival after 7 d in culture. Culturing the cells with aminoglute-
thimide had no effect on the number of cells remaining after 7 d (P >
0.05, ANOVA), whereas RU486 reduced cell numbers by 50% (P <
0.001, ANOVA). The addition ofprogesterone to RU486 did not return
cell numbers to control levels (P < 0.05, ANOVA), whereas the ad¬
dition ofCortisol increased cell numbers (P < 0.05, ANOVA) to control
levels (P > 0.05, ANOVA). The addition ofhCG to RU486 had no effect
(P > 0.05, ANOVA) with numbers less than controls (P < 0.01,
ANOVA) and RU486 with Cortisol (P < 0.01,ANOVA). Different letters
represent significant differences.
factor. We therefore investigated the effect of Cortisol on our
novel primary cultures of ovarian fibroblast-like cells de¬
rived from the luteinizing follicle (20,23). These cells secrete
MMP-2 that is regulated in a paracrine manner by hCG
through intermediary molecules (18). In vivo, hCG inhibits
the expression of luteal fibroblast MMP-2 (P < 0.05, t test)
(Fig. 6A). In vitro, our fibroblast-like cells express MMP-2
mRNA and proteolytic activity. The addition of exogenous
Cortisol inhibited both the expression (P < 0.001, t test) and
activity (P < 0.0001, t test) of MMP-2 (Fig. 6, B and C). This
suggests that Cortisol may have the potential to have relevant
effects on neighboring nonsteroidogenic cells.
Discussion
We hypothesized that locally produced Cortisol may be
involved in regulating tissue remodeling during luteolysis.
We have shown that the human corpus luteum expresses the
enzymes required to increase or decrease the local availabil¬
ity of Cortisol and the receptor pathways to respond to glu¬
cocorticoids. We have combined studies in human corpora
lutea with primary human cell culture models to show that
the expression of the 11/3HSD enzymes that control the local
availability of Cortisol is hormonally regulated. Although, as
discussed previously, luteinized granulosa cells in vitro are
not a perfect representation of granulosa-lutein cells in vivo
(23), we believe that the in vitro and in vivo paradigms are
complementary. Both paradigms suggest that in women,
there is a change in 11/3HSD isoforms across the luteal phase
that is associated with the functional state of the gland. This
is complementary to the only other study investigating
11 )31 ISP) in the corpus luteum that suggested there may be
more 11 j3HSD type 2 in the regressing rat corpus luteum (17).
It is uncertain what role Cortisol has in the human corpus
luteum. Roles for active glucocorticoids in the ovary have




Fig. 6. MMP-2 expression and activity appear to be modulated by
glucocorticoids in primary cell cultures of fibroblast-like cells. A, The
expression ofMMP-2 was down-regulated during hCG-induced luteal
rescue in human corpora lutea (P < 0.05, t test); B, primary cell
cultures of fibroblast-like cells treated with Cortisol mirror the effect
of hCG during luteal rescue because Cortisol inhibits MMP-2 expres¬
sion (P < 0.001, t test); C, gelatin zymography further confirms that
Cortisol reduces MMP-2 activity (P < 0.0001, t test) in these fibroblast-
like cells from the luteinizing follicle.
esis and ovulation (11). Previous experiments in our labo¬
ratory demonstrated that hCG has the ability to regulate
many different cell types and their molecular functions
within the corpus luteum and highlighted the important role
for locally produced intermediate regulatory molecules (18,
20, 21, 23). Herein, we propose that glucocorticoids may be
regulatory molecules with signaling roles within the corpus
luteum. We believe that hCG promotes the generation of
active glucocorticoids that have a luteotropic role in the
human corpus luteum such that the structural remodeling
associated with luteolysis is inhibited and maintenance of
early pregnancy is facilitated. Similarly, removal of local
Cortisolmay facilitate luteal regression in the absence of hCG.
The ll/3HSDs catalyze the interconversion of active (Cor¬
tisol) and inactive (cortisone) glucocorticoids by isoforms
type 1 and 2, respectively. The temporal and spatial expres-
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sions of both isoforms have been documented in the ovary
of other species (24-27). It is well established that 11/3HSD
type 2 is the predominant isoform during the follicular phase
of the ovarian cycle, localized to the nonluteinized granulosa
cells before the LH surge (26). This is an important concept
because too much Cortisol during the follicular phase is re¬
ported to disrupt FSH-stimulated granulosa cell develop¬
ment/ function (and presumably estradiol production) (28),
which would consequently inhibit successful folliculogen-
esis. In addition, during folliculogenesis, the predominant
steroid is estradiol, and unlike progesterone (as discussed
below), estradiol has a very low affinity for cortisol-binding
protein (CBP) (29) and thus will not displace Cortisol. Because
it has also been reported that estradiol can increase the he¬
patic production of CBP (30), another mechanism may exist
during the follicular phase to lower free Cortisol. It seems that
in the follicular phase, local Cortisol generation and action
tends to be inhibited.
This is not the case, however, in the periovulatory period.
Once the dominant follicle is exposed to the midcycle pre¬
ovulatory gonadotropin surge, the predominant isoform
switches from type 2 to type 1 11/3HSD (26, 27). This phe¬
nomenon can also be seen by a rise of free Cortisol that is 50
times higher in follicular fluid after the LH surge (10, 31),
indicative that expression levels of the 11/3HSD enzymes in
the ovary are an accurate measure for the direction of glu¬
cocorticoid biosynthesis. Indeed, it has been suggested that
this process is involved in facilitating fertility. Some studies
report that IVF patients with a higher Cortisol to cortisone
ratio in their follicular fluid have greater pregnancy success
rates (32,33), although others do not agree (31,34). It is likely,
however, that the switch in isoforms around ovulation has
effects on the oocyte as well as regulating the inflammatory
reaction associated with follicular rupture and its resolution
(6). Such findings further support the hypothesis that
11(11 ISD enzyme activities in the human ovary are develop-
mentally and hormonally regulated (27).
The expression of 11 (31 ISD type 1 in luteinizing granulosa
cells is maintained in the granulosa lutein cells of the corpus
luteum. We also detected 11/3HSD type 2 in the corpus lu-
teum. Type 2 11/3HSD mRNA expression and protein has
previously been reported to be very low or undetectable in
freshly isolated luteinized granulosa cells of both rats and
humans (26, 35-37). This suggests that as the corpus luteum
is formed there may be a recovery of lljSHSD type 2 ex¬
pression. Indeed, all our cultures of luteinized granulosa cells
expressed 11/3HSD type 2, and they had been cultured for at
least 7 d before analysis. Although 11/31 ISD type 1 remains
the most abundant isoform in luteinized granulosa cells in
culture and in the corpus luteum, both isoforms are ex¬
pressed. hCG inhibited the expression of 11/3HSD type 2 in
vitro and tended to do the same in vivo. In contrast, hCG
stimulated 11J3HSD type 1 expression acutely and in pro¬
longed cultures and tended to do the same in vivo. The
regulation of 11/3HSD type 1, like in the periovulatory pe¬
riod, seems to a direct effect of hCG signaling. However, as
the inhibition of 11/3HSD type 2 by hCG was blocked when
progesterone synthesis was inhibited, progesterone rather
than hCG may be involved in the inhibition of 11/3HSD type
2 expression. This finding supports a similar experiment in
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granulosa cells by Thurston et al. (37) and demonstrates the
same principles of progesterone actions observed in the kid¬
ney and placenta (38-40) whereby progesterone inhibits
11/3HSD type 2. Indeed, because progesterone receptor ex¬
pression is down-regulated as the corpus luteum matures,
this may be a mechanism for the reemergence of steroido¬
genic cell 11/3HSD type 2 expression in the corpus luteum
(22).
The effect of hCG on 11J3HSD type 1 expression was mir¬
rored by 11-oxoreductase activity levels and the generation
of Cortisol from cortisone. We are unable, however, to assess
Cortisol metabolism in the late luteal and rescued corpus
luteum to confirm this in vivo. Although we believe that
changes in the expression of different 11J3HSD isoforms in
tissues informs the direction of Cortisol/cortisone metabo¬
lism (27), it is clear that 11/3HSD type 1 has the potential to
act as a bidirectional enzyme (given the appropriate coen¬
zyme environment) (41). However, previous detailed studies
on the direction of metabolism in luteinized granulosa cells
(27, 37), ovarian surface epithelial cells (8, 9, 42), and other
tissues (43-45) aswell as the phenotype of 11/3HSD knockout
mice (46) have suggested that in vivo 11/3HSD type 1 pref¬
erentially generates Cortisol. However, as pointed out by
Jonas et al. (47), recent studies have established that the net
direction of 11/3HSD type 1 is dependant upon the cell avail¬
ability of hexose-6-phosphase-dependent NADPH, which
may be different in highly steroidogenically active tissues
and the direction of Cortisol metabolism in vivo remains to be
studied.
The human corpus luteum has the potential to respond to
locally generated Cortisol because it expresses nuclear GR.
Indeed, GR has been localized previously to many cell com¬
partments in the ovary (36). Although the primary receptor
for Cortisol is GR, Cortisol also has a high affinity for the
mineralocorticoid receptor. We did not analyze the expres¬
sion of mineralocorticoid receptor, but it has been reported
to be expressed in the ovary (36). We have localized the
expression of GR to the nuclei of steroidogenic cells. These
cells of the human corpus luteum are also reported to express
other important nuclear steroid receptors such as estrogen
and progesterone receptors (48-50). It is unclear whether
other steroids can influence glucocorticoid signaling by re¬
ceptor-dependent mechanisms, but it is likely that Cortisol
has direct effects on the cells expressing the 11/3HSD en¬
zymes involved in its synthesis and metabolism.
It is not clear whether the expression of GR in the corpus
luteum is regulated. We have shown that steroidogenic cell
progesterone receptors are differentially regulated in the cor¬
pus luteum across the luteal phase (22), although their role
has not yet been elucidated (51). In contrast, we could see no
obvious changes in steroidogenic cell GR immunostaining
across the luteal phase. Indeed, in the endometrium, where
glandular progesterone receptor expression in the secretory
phase shows changes similar to that in luteal steroidogenic
cells (22,52), there was no change in GR expression across the
functional menstrual cycle (53). However, in vitro hCG
tended to up-regulate GR expression similar to its effects on
11/3HSD type 1. Whether GR expression in corpora lutea is
hormonally regulated but masked by detection methods is
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not entirely clear. What is clear is that multiple cell types in
each corpus luteum express nuclear GR.
Luteal endothelial cells and macrophages express nuclear
GR. Protein colocalization of GR with CD31 demonstrates
specific nuclear staining of endothelial cells. The effect of
Cortisol on luteal endothelial cells is not clear, but glucocor¬
ticoids have been shown to suppress angiogenesis (54), and
this is most notably due to the suppression of vascular en¬
dothelial growth factor action (54, 55). In the human corpus
luteum, however, there continues to be some angiogenesis
stimulated by hCG during luteal rescue (56) in response to
the marked up-regulation of vascular endothelial growth
factor after exogenous hCG (57). Immune cells, most notably
macrophages (CD68-positive cells), which also express GR,
accumulate in the corpus luteum during luteolysis and show
a marked reduction in number during hCG-induced luteal
rescue (1). The role of Cortisol in luteal macrophage accu¬
mulation and action is not clear, but because glucocorticoids
are known to regulate cytokine signaling and macrophages
in both health and disease (58), it may affect the immune
cell-mediated processes during luteolysis. Luteal myofibro¬
blasts are known to express macrophage chemoattractant
protein-1 (59), and these cells also express nuclear GR.
When considering a role for glucocorticoids in the corpus
luteum, it is very important to establish the relationship
between Cortisol and the marked excess of structurally re¬
lated progesterone. Cortisol exists in one of two forms,
bound and free, that regulate its bioavailability. In most
systems, the majority of the steroid is bound to plasma pro¬
teins (notably CBP) with only a fraction free and unbound
(12). Although CBP has the highest affinity for Cortisol of all
the binding globulins, other steroids such as progesterone
and particularly 170H-progesterone have high binding af¬
finities to CBP (12, 29). Therefore, very high concentrations
of progesterone and progesterone metabolites (such as in the
corpus luteum) will displace Cortisol from CBP, that acts as
a buffer reservoir, resulting in the environment becoming
enriched with free Cortisol. This scenario is known as the free
hormone hypothesis (12,29) and predicts that the bioactivity
of Cortisol is proportional to free hormone concentrations
and not total concentration, which includes the protein-
bound fraction. This is an important paradigm to consider
because the concentration of free biologically active Cortisol
in preovulatory follicular fluid is 10 times greater than that
of serum (31). It is likely that, because of high local proges¬
terone concentrations, rather than being mainly bound to
CBP in the corpus luteum, locally generated Cortisol is more
likely to be free and functional at lower concentrations.
It is still not clear what effects Cortisol has on luteal cells.
We hypothesized that it may affect the survival of luteinized
granulosa cells. Our observations and those of others (60)
suggested that RU486 reduced survival of these cells in cul¬
ture. We used simple cell counting to document the effect on
RU486 on cell survival. Because cells treated with the pro¬
gesterone synthesis disruptor aminoglutethimide, which
blocks P450 side-chain cleavage, showed no change in their
morphology or viability, we tested whether the effect of
RU486 could be reversed by hCG or exogenous progesterone.
Unlike a previous study using human luteinized granulosa
cells, under slightly different conditions (60), we could not
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fully reverse the RU486 effects using progesterone. However,
we were able to do so using Cortisol. It is not clear whether
this effect is at the level of the receptor because the concen¬
tration of Cortisol would not be expected to fully displace
the RU486. It may be that Cortisol affects the cell suscep¬
tibility to RU486 in different ways. There may be specific
effects of RU486 not mediated by hormone antagonism.
Direct actions of RU486 have been reported in ovarian
epithelial cancer cells and human endometrium, whereby
it down-regulated molecules involved in signal transduc¬
tion pathways by cytokines, growth factors, and other
physiological stimuli that control cell functions (61). In¬
deed, in cultured luteinized granulosa cells, Cortisol and
dexamethasone offer protection against serum depriva¬
tion and induced apoptosis by bcl-2 and TNF-a (62, 63)
through mechanisms that include stabilization of the actin
cytoskeleton (64). Whatever the mechanism of action, our
results crudely suggest that Cortisol may have direct ef¬
fects on luteal steroidogenic cells. Indeed, if Cortisol has
any direct genomic effects in vivo, they are more likely to
promote, rather than inhibit, steroidogenic cell survival
and function.
If Cortisol does have luteotropic actions, it may also have
specific actions on the nonsteroidogenic cells of the corpus
luteum that are key regulators of tissue remodeling during
luteolysis. Luteal fibroblasts are the main source of MMP-2,
a key proteolytic enzyme involved in tissue remodeling as¬
sociated with luteolysis in women (2) and in many other
species (65-67). Both primates (67) and women (2) show
maximal MMP-2 expression in the late luteal phase. How¬
ever, duringmaternal recognition of pregnancy,MMP-2 pro¬
duction is considerably reduced (2), suggestive that hCG is
regulating the enzymatic expression through intermediate
molecules (18). Furthermore, it is tempting to speculate that
active glucocorticoids may also prevent luteolysis by inhi¬
bition of intraluteal prostaglandin synthesis (68). Although
this is an attractive suggestion, the actual role of prostaglan¬
dins in the human corpus luteum remains elusive.
In the present study, our novel findings suggest that Cor¬
tisol may be involved in paracrine interactions that control
tissue remodeling. Recently, an in vitro study from our lab¬
oratory modeling the human corpus luteum has shown that
activin A is a paracrine factor secreted from luteinized gran¬
ulosa cells that may up-regulate fibroblast MMP-2 secretion
(23) in the absence of hCG. In contrast to activin A (23),
Cortisol treatment of luteal fibroblast-like cells in culture re¬
sulted in a reduction in the production of MMP-2, a pattern
reflecting MMP-2 expression in exogenous hCG-rescued lu¬
teal tissue (2). Indeed, glucocorticoids decreased MMP-2 ac¬
tivity in rat aortic smooth muscle cells (69) and in a fibro¬
sarcoma cell line (70). It seems that the nonsteroidogenic cells
forming the corpus luteum have the ability to directly re¬
spond to Cortisol. If these effects do occur in vivo, it is likely
that Cortisol tends to inhibit rather than stimulate the re¬
modeling associated with luteolysis and may therefore be
considered to be luteotropic in nature.
We hypothesized that during luteolysis, more Cortisol is
generated in the local environment, consequently preventing
aberrant scarring to the tissue. It is clear, however, from the
present study that luteolysis is not associated with an in-
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crease in Cortisol, and the opposite is true. We have shown
that hCG tends to generateCortisol by up-regulating 11 /3HSD
type 1 and down-regulating 11/3HSD type 2. We have shown
that the corpus luteum has the potential to react to this
Cortisol and that the effect on steroidogenic and neighboring
cells tends to be luteotropic rather than luteolytic. In sum¬
mary, our observational and interventional in vivo and in
vitro models have generated results that suggest that Cortisol
tends to be withdrawn during luteolysis and maintained
during luteal rescue. Glucocorticoids may have a role in the
local luteal regulation of maternal recognition of pregnancy
in women.
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